<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>CN109862919A - The therapeutic agent that antibody-drug conjugates combined immunization mediates 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/CN109862919A/en">
    <meta name="description" content="
     The present invention relates to the antibody-drug conjugates (ADC) for cancer immunotherapy.The present invention provides the use for cancer treatment and united ADC of immunization therapy (IMT) agent.Such as: the present invention provides the ADC used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and IMT agent in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the IMT agent and ADC in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and the IMT agent in patient.The present invention provides the ADC used in cancer immunotherapy is used for, wherein this is using including combining with IMT agent the ADC simultaneously, individually or sequential application is in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with ADC the IMT agent simultaneously, individually or sequential application is in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with the IMT agent ADC simultaneously, individually or sequential application is in patient.The present invention provides a kind of cancer immunotherapy method, this method includes that ADC and IMT agent is applied to patient.The present invention provides a kind of cancer immunotherapy method, this method include by ADC and IMT agent simultaneously, individually or sequential application is in patient. 
     
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="The therapeutic agent that antibody-drug conjugates combined immunization mediates 
       ">
    <meta name="DC.date" content="2017-10-10" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The present invention relates to the antibody-drug conjugates (ADC) for cancer immunotherapy.The present invention provides the use for cancer treatment and united ADC of immunization therapy (IMT) agent.Such as: the present invention provides the ADC used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and IMT agent in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the IMT agent and ADC in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and the IMT agent in patient.The present invention provides the ADC used in cancer immunotherapy is used for, wherein this is using including combining with IMT agent the ADC simultaneously, individually or sequential application is in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with ADC the IMT agent simultaneously, individually or sequential application is in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with the IMT agent ADC simultaneously, individually or sequential application is in patient.The present invention provides a kind of cancer immunotherapy method, this method includes that ADC and IMT agent is applied to patient.The present invention provides a kind of cancer immunotherapy method, this method include by ADC and IMT agent simultaneously, individually or sequential application is in patient. 
     
   
   ">
    <meta name="citation_patent_application_number" content="CN:201780062150.7A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/ed/55/c0/6351d6727d6fb5/CN109862919A.pdf">
    <meta name="citation_patent_publication_number" content="CN:109862919:A">
    <meta name="DC.date" content="2019-06-07">
    <meta name="DC.contributor" content="R.E." scheme="inventor">
    <meta name="DC.contributor" content="J.W." scheme="inventor">
    <meta name="DC.contributor" content="E." scheme="inventor">
    <meta name="DC.contributor" content="R." scheme="inventor">
    <meta name="DC.contributor" content="J.-" scheme="inventor">
    <meta name="DC.contributor" content="MedImmune Ltd" scheme="assignee">
    <meta name="DC.relation" content="EP:2301570:A1" scheme="references">
    <meta name="DC.relation" content="CN:108136015:A" scheme="references">
    <meta name="DC.relation" content="CN:108884161:A" scheme="references">
    <meta name="citation_reference" content="CATHERINE S. DIEFENBACH ET AL.: &quot;Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)&quot;, BLOOD, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 585, XP086650487, DOI: 10.1182/blood.V126.23.585.585" scheme="references">
    <meta name="citation_reference" content="DAVID M GOLDENBERG ET AL.: &quot;Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb&quot;, BLOOD, vol. 116, no. 21, 19 November 2010 (2010-11-19), pages 3941, XP086608310, DOI: 10.1182/blood.V116.21.3941.3941" scheme="references">
    <meta name="citation_reference" content="PHILIPP MLLER ET AL.: &quot;Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade&quot;, SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 315, 25 November 2015 (2015-11-25), pages 1 - 14, XP055437353, DOI: 10.1126/scitranslmed.aac4925" scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            The therapeutic agent that antibody-drug conjugates combined immunization mediates 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA298354426" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div num="0001" class="abstract style-scope patent-text">The present invention relates to the antibody-drug conjugates (ADC) for cancer immunotherapy.The present invention provides the use for cancer treatment and united ADC of immunization therapy (IMT) agent.Such as: the present invention provides the ADC used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and IMT agent in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the IMT agent and ADC in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is used including being administered in combination the ADC and the IMT agent in patient.The present invention provides the ADC used in cancer immunotherapy is used for, wherein this is using including combining with IMT agent the ADC simultaneously, individually or sequential application is in patient.The present invention also provides the IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with ADC the IMT agent simultaneously, individually or sequential application is in patient.The present invention provides ADC the and IMT agent used in cancer immunotherapy is used for, wherein this is using including combining with the IMT agent ADC simultaneously, individually or sequential application is in patient.The present invention provides a kind of cancer immunotherapy method, this method includes that ADC and IMT agent is applied to patient.The present invention provides a kind of cancer immunotherapy method, this method include by ADC and IMT agent simultaneously, individually or sequential application is in patient.</div>
    </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6801"><a id="link" href="#" class="style-scope state-modifier">A61K47/6801</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6803"><a id="link" href="#" class="style-scope state-modifier">A61K47/6803</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0012"><a id="link" href="#" class="style-scope state-modifier">A61K9/0012</a></state-modifier>
                  <span class="description style-scope classification-tree">Galenical forms characterised by the site of application</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0019"><a id="link" href="#" class="style-scope state-modifier">A61K9/0019</a></state-modifier>
                  <span class="description style-scope classification-tree">Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2803"><a id="link" href="#" class="style-scope state-modifier">C07K16/2803</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2818"><a id="link" href="#" class="style-scope state-modifier">C07K16/2818</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2803"><a id="link" href="#" class="style-scope state-modifier">C07K16/2803</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2827"><a id="link" href="#" class="style-scope state-modifier">C07K16/2827</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 6 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">CN109862919A</h2>
                  <p class="tagline style-scope patent-result">China</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Unexaminded application</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/ed/55/c0/6351d6727d6fb5/CN109862919A.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;adc&quot;,&quot;imt&quot;,&quot;agent&quot;,&quot;antibody&quot;,&quot;genbank&quot;]" data-before="20161011"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/CN109862919A"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN109862919A/zh"><a id="link" href="#" class="style-scope state-modifier">Chinese</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="R.E."><a id="link" href="#" class="style-scope state-modifier">R.E.</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="J.W."><a id="link" href="#" class="style-scope state-modifier">J.W.</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="E."><a id="link" href="#" class="style-scope state-modifier">E.</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="R."><a id="link" href="#" class="style-scope state-modifier">R.</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="J.-"><a id="link" href="#" class="style-scope state-modifier">J.-</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    MedImmune Ltd
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2017</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2019534882A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2019518979A</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-10</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2018069289A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2017/075766</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-10</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN109862919A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201780062150.7A</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-10</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20200023072A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US16/341,194</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-10</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3525829A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP17788161.2A</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-10</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW201827084A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW106134797A</div>
                <div class="style-scope application-timeline">Filing date: 2017-10-11</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2021</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20220211864A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/524,139</div>
                <div class="style-scope application-timeline">Filing date: 2021-11-11</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application CN201780062150.7A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2017-10-10</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="MedImmune Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by MedImmune Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2019-06-07</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN109862919A/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of CN109862919A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Pending</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (113)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (3)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (1)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=CN&amp;NR=109862919A&amp;KC=A&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/CN/109862919/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/CN109862919A">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES192836232" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    <invention-title lang="EN" id="title1" class="style-scope patent-text">The therapeutic agent that antibody-drug conjugates combined immunization mediates</invention-title>
    <background-art class="style-scope patent-text">
      <div id="p0001" num="0001" class="description-paragraph style-scope patent-text">Background technique</div>
      <div id="p0002" num="0002" class="description-paragraph style-scope patent-text">The present invention relates to the treatment or prevention for cancer, are conjugated in particular for the antibody-drug of cancer immunotherapy
Object and application thereof.</div>
      <div id="p0003" num="0003" class="description-paragraph style-scope patent-text">Cancer immunotherapy changes the therapeutic modality of cancer patient thoroughly.Interfere immunologic test point (such as CTLA-4
And PD-1) monoclonal antibody have shown that in kinds of tumors type have clinical efficacy (Wolchok et al., 2013
Callahan and Wolchok, 2013).Other than these antibody, it also developed and adjust a variety of of adaptability and congenital immunity
Other drugs (Khalil et al., 2016Smyth et al., 2016).</div>
      <div id="p0004" num="0004" class="description-paragraph style-scope patent-text">In view of the drug resistance generally produced after single therapy, it is assumed that conjoint therapy will improve clinical benefit.In fact,
The joint study of panimmunity treatment has led to improved reactivity and survival rate (Larkin et al., 2015).</div>
      <div id="p0005" num="0005" class="description-paragraph style-scope patent-text">Other than the therapeutic agent of selectively targeted immune system, also show that have to immune system according to other medicaments are described
There are some effects.It has been shown that some chemotherapy (such as anthracycline and oxaliplatin) inducing immunogenic cell deaths (ICD)
And increase antitumor response (Rios-Doria et al., 2015Galluzzi et al., 2012Tesniere et al., 2010
Obeid et al., 2007), every document, which all passes through to quote, to be incorporated herein.ICD is certain cytotoxic drugs to cause immunogene
Property molecule release mode induce tumour cell apoptosis process.</div>
      <div id="p0006" num="0006" class="description-paragraph style-scope patent-text">Targeted therapies (such as MEK and BRAF inhibitor) also have shown that with some immunoregulation effects (Liu et al. people,
2015Hu-Lieskovan et al., 2015Vanneman and Dranoff, 2012, every document, which all passes through to quote, is incorporated to this
Text), however these therapeutic agents whether cause ICD by other certain mechanism or influence immune system is unclear.</div>
      <div id="p0007" num="0007" class="description-paragraph style-scope patent-text">Chemotherapy or targeted therapies need systemic administration drug, therefore two kinds of therapies not target tumors itself.?
Antibody-drug conjugates (ADC) classification, which is developed, by the way that cytotoxicity payload is directly conjugated to antibody overcomes the limit
System, the antibody is close and is specifically bound to the antigen being overexpressed on tumour cell.It is effectively negative that ADC can provide cytotoxicity
It is loaded onto the positioning delivery of tumour, and has shown that the accumulation intracellular for promoting drug in tumour cell.It is this to be located in tumour
Inside provide relatively high drug concentration, and the systemic administration of unconjugated (that is, not targeting) drug to realize it is identical swollen
Tumor concentration then may generate unacceptable toxic level to normal cell.</div>
      <div id="p0008" num="0008" class="description-paragraph style-scope patent-text">Have studied the immunoregulatory activity of some ADC payloads.M  ller et al. has shown that, hinders when with checkpoint
When disconnected joint, Ansamitocins P3 and the direct dendritic cell maturation of aplysiatoxin induction and increase antitumor efficacy (Muller et al.,
2014bMuller et al., 2014a, this two documents are incorporated herein by quoting).From the viewpoint of mechanism, by ADC with exempt from
The method (Gerber et al., 2016) for having been considered as increasing antitumor response is combined in epidemic disease treatment.In fact, a nearest Xiang Yan
Study carefully and show when combining with anti-CTLA-4 and PD-1, T-DM1 (ADC of targeting Her2 receptor) generates antitumor in Mice Body
Synergistic effect, provide ADC and immunization therapy is combined can produce the initial concept verifying of powerful antitumor effect (Muller et al.,
2015)</div>
      <div id="p0009" num="0009" class="description-paragraph style-scope patent-text">Most of ADC and following microtubule inhibitors payload are conjugated in clinical development at present: statin class in difficult to understand
(auristatins) or class CHROMATOGRAPHIC FRACTIONATION AND MASS (maytansinoids).(Sievers and Senter, 2013, the document is by quoting
It is incorporated herein).In this report, the immunoregulatory activity of other two kinds of ADC payloads: PBD (pyrrolo- benzo two is had studied
Azepine<span class="patent-image-not-available style-scope patent-text"></span>Class) and tubulysin class (tubulysins) (Hartley, 2011Li et al. people, 2016).The effect of tubulysin class
Mechanism is that tubulin polymerization object is made to go to stablize, and the G2/M in mitosis is caused to stagnate, so as to cause Apoptosis, and PBD
Interchain linkage is formed in DNA, leads to mitotic arrest and subsequent Apoptosis during the S phase.With PBD payload
ADC be highly effective, external EC50 typically in low picomolar range (Saunders et al., 2015).Although more
Effectively, but the micro-pipe destabilization mechanism of tubulysin is similar to statin class and class CHROMATOGRAPHIC FRACTIONATION AND MASS in Austria.Nevertheless,
But have shown that such compound (micro-pipe goes to stablize) can induce immunogenicity effect, and microtubule stabilization chemical combination object then cannot
(Martin et al., 2014).Although exempting from document evidence suggests certain DNA targets can induce to agent (such as radiation and adriamycin)
Epidemic focus cell death, but there are no the open source literatures that display PBD is capable of inducing immunogenic cell death, and in view of
DNA alkylating agent mitomycin C does not induce ICD, though can induce nor obvious (Kroemer et al., 2013Obeid
Et al., 2007).</div>
      <div id="p0010" num="0010" class="description-paragraph style-scope patent-text">Therefore, it is necessary to novel immune modulability fluorescent dye with tumour-specific targeting therapy, these therapies, which have to treat to suffer from, works as front
The potentiality of the patient for the illness that method does not meet sufficiently.</div>
    </background-art>
    <disclosure class="style-scope patent-text">
      <div id="p0011" num="0011" class="description-paragraph style-scope patent-text">Summary of the invention</div>
      <div id="p0012" num="0012" class="description-paragraph style-scope patent-text">The present invention relates to the antibody-drug conjugates (ADC) for cancer immunotherapy.The present invention provides be used for cancer
Treatment with the united ADC of immunization therapy (IMT) agent.Such as:</div>
      <div id="p0013" num="0013" class="description-paragraph style-scope patent-text">The present invention provides for used in the cancer immunotherapy as herein Anywhere defined in ADC, wherein
The use includes that ADC and IMT agent are administered in combination in patient.The present invention also provides for used in the cancer immunotherapy
Such as Anywhere defined IMT agent herein, wherein the use includes that IMT agent and ADC are administered in combination in patient.</div>
      <div id="p0014" num="0014" class="description-paragraph style-scope patent-text">The present invention provides for used in the cancer immunotherapy as herein Anywhere defined in ADC and such as this
Text Anywhere defined IMT agent, wherein the use includes that ADC and IMT agent are administered in combination in patient.</div>
      <div id="p0015" num="0015" class="description-paragraph style-scope patent-text">The present invention provides for used in the cancer immunotherapy as herein Anywhere defined in ADC, wherein
The use includes combining ADC with IMT agent simultaneously, individually or sequential application is in patient.The present invention also provides in cancer
Such as Anywhere defined IMT agent herein used in immunization therapy, wherein the use includes combining IMT agent together with ADC
When, individually or sequential application in patient.</div>
      <div id="p0016" num="0016" class="description-paragraph style-scope patent-text">The present invention provides for used in the cancer immunotherapy as herein Anywhere defined in ADC and such as this
Text Anywhere defined in IMT agent, wherein the use includes combining ADC with IMT agent simultaneously, individually or sequential application is in trouble
Person.</div>
      <div id="p0017" num="0017" class="description-paragraph style-scope patent-text">The present invention provides cancer immunotherapy method, this method include will as herein Anywhere defined in ADC with
As Anywhere defined IMT agent is applied to patient herein.</div>
      <div id="p0018" num="0018" class="description-paragraph style-scope patent-text">The present invention provides cancer immunotherapy method, this method include will as herein Anywhere defined in ADC with
As herein Anywhere defined in IMT agent simultaneously, individually or sequential application is in patient.</div>
      <div id="p0019" num="0019" class="description-paragraph style-scope patent-text">In one embodiment, IMT agent and ADC agent sequential application.IMT agent can ADC application after at least 1 hour, extremely
Few 2 hours, at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least
It applies within 96 hours, at least 120 hours.IMT agent can ADC application after most 15 days, it is 20 days most, most 25 days or most 30
Its application.</div>
      <div id="p0020" num="0020" class="description-paragraph style-scope patent-text">In one embodiment, compared with dosage needed for treatment validity is reached when single therapy, as this paper is any
ADC defined in side is applied with lower dosage.Reach needed for treatment validity when in another embodiment, with single therapy
Dosage compare, the IMT agent as defined in Anywhere reagent herein is applied with lower dosage.In yet another embodiment,
Compared with the corresponding dosage of IMT agent needed for reaching treatment validity when single therapy or ADC, as Anywhere defined herein
ADC and as herein Anywhere defined in IMT agent with the application of lower dosage.</div>
      <div id="p0021" num="0021" class="description-paragraph style-scope patent-text">In one embodiment, as herein Anywhere defined in ADC than reaching treatment validity when single therapy
Required dosage is low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, extremely
Few 20%, at least 10%, at least 5%, at least 1% dosage application.In another embodiment, as Anywhere determined herein
The IMT agent of justice with it is lower at least 90% than dosage needed for reaching treatment validity when single therapy, at least 80%, at least 70%,
At least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1% dosage is applied
With.In yet another embodiment, as herein Anywhere defined in ADC and as herein Anywhere defined in IMT agent it is equal
It is low at least 90% with corresponding dosage than IMT agent or ADC needed for reaching treatment validity when single therapy, at least 80%, extremely
Few 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1%
Dosage application.Appropriate model for observing tumour growth is well-known to those having ordinary skill in the art, and can be according to institute
The indication of research and change.</div>
      <div id="p0022" num="0022" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined ADC drug is Pyrrolobenzodiazepines herein<span class="patent-image-not-available style-scope patent-text"></span>
(PBD).In another embodiment, as Anywhere defined ADC drug is tubulysin herein.</div>
      <div id="p0023" num="0023" class="description-paragraph style-scope patent-text">In one embodiment, intravenous application as herein Anywhere defined in ADC.In one embodiment, it swells
In tumor application as herein Anywhere defined in ADC.In one embodiment, intravenous application as Anywhere determined herein
The IMT agent of justice.In one embodiment, application such as Anywhere defined IMT agent herein in peritonaeum.In one embodiment
In, application such as Anywhere defined IMT agent herein in tumour.</div>
      <div id="p0024" num="0024" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined IMT agent is checkpoint inhibitor herein.In another implementation
Example in, such as herein Anywhere defined in IMT agent be tumor necrosis factor (TNF) receptor superfamily agonist.At one
In embodiment, such as Anywhere defined IMT agent is selected from the group being made up of: apoptosis albumen -1 herein
(PD-1) TNFR of inhibitor, programmed death-ligand -1 (PD-L1) inhibitor, OX40 agonist and glucocorticoid inducible
GAP-associated protein GAP (GITR) agonist.In yet another embodiment, as Anywhere defined IMT agent is selected from by with the following group herein
At group: anti-PD-1 antibody, anti-PD-L1 antibody, anti-OX40 antibody, OX40 ligand fusion protein and GITRL fusion protein.</div>
      <div id="p0025" num="0025" class="description-paragraph style-scope patent-text">In one embodiment, as above Anywhere defined in antibody be identify tumor associated antigen antibody or its
Antigen-binding fragment.Exemplary oncologic related antigen is listed below, can produce for the embodiment of the present invention for this
The antibody of a little antigens.Hereafter also list for the embodiment of the present invention for the exemplary antibodies of tumor associated antigen or its
Antigen-binding fragment.</div>
      <div id="p0026" num="0026" class="description-paragraph style-scope patent-text">Tumor associated antigen and isoantibody</div>
      <div id="p0027" num="0027" class="description-paragraph style-scope patent-text">(1) BMPR1B (bone morphogenetic protein receptor-IB type)</div>
      <div id="p0028" num="0028" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0029" num="0029" class="description-paragraph style-scope patent-text">Genbank accession number NM_001203</div>
      <div id="p0030" num="0030" class="description-paragraph style-scope patent-text">Genbank version number NM_001203.2 GI:169790809</div>
      <div id="p0031" num="0031" class="description-paragraph style-scope patent-text">Genbank records update date: 02:06 afternoon on the 23rd of September in 2012</div>
      <div id="p0032" num="0032" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0033" num="0033" class="description-paragraph style-scope patent-text">Genbank accession number NP_001194</div>
      <div id="p0034" num="0034" class="description-paragraph style-scope patent-text">Genbank version number NP_001194.1 GI:4502431</div>
      <div id="p0035" num="0035" class="description-paragraph style-scope patent-text">Genbank records update date: 02:06 afternoon on the 23rd of September in 2012</div>
      <div id="p0036" num="0036" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0037" num="0037" class="description-paragraph style-scope patent-text">Ten Dijke, P. et al., Science [science] 264 (5155): 101-104 (1994), Oncogene [cancer base
Cause] 14 (11): 1377-1382 (1997))WO 2004/063362 (claim 2)2003/042661 (claim of WO
12)US 2003/134790-A1 (the 38-39 pages)2002/102235 (claim 13 of WOPage 296)WO 2003/
055443 (the 91-92 pages)(the example 2 of WO 2002/99122The 528-530 pages)WO 2003/029421 (claim 6)
2003/024392 (claim 2 of WOFigure 112)2002/98358 (claim 1 of WOPage 183)WO 2002/
54940 (the 100-101 pages)WO 2002/59377 (the 349-350 pages)2002/30268 (claim 27 of WO376th
Page)2001/48204 (example of WOFig. 4)NP_001194 bone morphogenetic protein receptor, IB type/pid=NP_
001194.1.MIM:603248AY065994.</div>
      <div id="p0038" num="0038" class="description-paragraph style-scope patent-text">(2)E16(LAT1SLC7A5)</div>
      <div id="p0039" num="0039" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0040" num="0040" class="description-paragraph style-scope patent-text">Genbank accession number NM_003486</div>
      <div id="p0041" num="0041" class="description-paragraph style-scope patent-text">Genbank version number NM_003486.5 GI:71979931</div>
      <div id="p0042" num="0042" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 27th, 2012 12:06</div>
      <div id="p0043" num="0043" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0044" num="0044" class="description-paragraph style-scope patent-text">Genbank accession number NP_003477</div>
      <div id="p0045" num="0045" class="description-paragraph style-scope patent-text">Genbank version number NP_003477.4 GI:71979932</div>
      <div id="p0046" num="0046" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 27th, 2012 12:06</div>
      <div id="p0047" num="0047" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0048" num="0048" class="description-paragraph style-scope patent-text">Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication] 255 (2), 283-288
(1999), [nature] 395 (6699) Nature: 288-291 (1998), Gaugitsch, H.W. et al., (1992)
J.Biol.Chem. [journal of biological chemistry] 267 (16): 11267-11273)WO 2004/048938 (example 2)WO 2004/
032842 (example IV)WO 2003/042661 (claim 12)WO 2003/016475 (claim 1)WO 2002/
78524 (examples 2)2002/99074 (claim 19 of WOThe 127-129 pages)2002/86443 (claim 27 of WO
Page 222,393)2003/003906 (claim 10 of WOPage 293)2002/64798 (claim 33 of WOThe
93-95 pages)2000/14228 (claim 5 of WOThe 133-136 pages)US 2003/224454 (Fig. 3)WO 2003/
025138 (claim 12Page 150)NP_003477 sapiens's Solute Carrier family 7 (cationic amino acid transporter albumen, y+ system
System) member 5/pid=NP_003477.3- homo sapiens (Homo sapiens)MIM:600182NM_015923.</div>
      <div id="p0049" num="0049" class="description-paragraph style-scope patent-text">(3) STEAP1 (six cross-film epithelium antigens of prostate)</div>
      <div id="p0050" num="0050" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0051" num="0051" class="description-paragraph style-scope patent-text">Genbank accession number NM_012449</div>
      <div id="p0052" num="0052" class="description-paragraph style-scope patent-text">Genbank version number NM_012449.2 GI:22027487</div>
      <div id="p0053" num="0053" class="description-paragraph style-scope patent-text">Genbank records update date: 02:57 afternoon on the 9th of September in 2012</div>
      <div id="p0054" num="0054" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0055" num="0055" class="description-paragraph style-scope patent-text">Genbank accession number NP_036581</div>
      <div id="p0056" num="0056" class="description-paragraph style-scope patent-text">Genbank version number NP_036581.1 GI:9558759</div>
      <div id="p0057" num="0057" class="description-paragraph style-scope patent-text">Genbank records update date: 02:57 afternoon on the 9th of September in 2012</div>
      <div id="p0058" num="0058" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0059" num="0059" class="description-paragraph style-scope patent-text">CancerRes. [cancer research] 61 (15), 5857-5860 (2001), Hubert, R.S. et al., (1999)
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 96 (25): 14523-14528)WO 2004/
065577 (claim 6)WO 2004/027049 (Fig. 1 L)EP 1394274 (example 11)2004/016225 (right of WO
It is required that 2)WO 2003/042661 (claim 12)US 2003/157089 (example 5)2003/185830 (example of US
5)US 2003/064397 (Fig. 2)(the example 5 of WO 2002/89747The 618-619 pages)(the example 9 of WO 2003/022995
Figure 13 A, example 53Page 173, example 2Fig. 2A)Six cross-film epithelium antigens of prostateMIM:604415.</div>
      <div id="p0060" num="0060" class="description-paragraph style-scope patent-text">(4)0772P(CA125MUC16)</div>
      <div id="p0061" num="0061" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0062" num="0062" class="description-paragraph style-scope patent-text">Genbank accession number AF361486</div>
      <div id="p0063" num="0063" class="description-paragraph style-scope patent-text">Genbank version number AF361486.3 GI:34501466</div>
      <div id="p0064" num="0064" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 07:56</div>
      <div id="p0065" num="0065" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0066" num="0066" class="description-paragraph style-scope patent-text">Genbank accession number AAK74120</div>
      <div id="p0067" num="0067" class="description-paragraph style-scope patent-text">Genbank version number AAK74120.3 GI:34501467</div>
      <div id="p0068" num="0068" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 07:56</div>
      <div id="p0069" num="0069" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0070" num="0070" class="description-paragraph style-scope patent-text">J.Biol.Chem. [journal of biological chemistry] 276 (29): 27371-27375 (2001))WO 2004/045553
(claim 14)2002/92836 (claim 6 of WOFigure 12)2002/83866 (claim 15 of WO116-121
Page)US 2003/124140 (example 16)GI:34501467.</div>
      <div id="p0071" num="0071" class="description-paragraph style-scope patent-text">(5) MPF (MPF, MSLN, SMR, megakaryocyte-potentiating factor, mesothelin)</div>
      <div id="p0072" num="0072" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0073" num="0073" class="description-paragraph style-scope patent-text">Genbank accession number NM_005823</div>
      <div id="p0074" num="0074" class="description-paragraph style-scope patent-text">Genbank version number NM_005823.5 GI:293651528</div>
      <div id="p0075" num="0075" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 2nd of September in 2012</div>
      <div id="p0076" num="0076" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0077" num="0077" class="description-paragraph style-scope patent-text">Genbank accession number NP_005814</div>
      <div id="p0078" num="0078" class="description-paragraph style-scope patent-text">Genbank version number NP_005814.2 GI:53988378</div>
      <div id="p0079" num="0079" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 2nd of September in 2012</div>
      <div id="p0080" num="0080" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0081" num="0081" class="description-paragraph style-scope patent-text">Yamaguchi, N. et al., Biol.Chem. [biochemistry] 269 (2), 805-808 (1994),
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 96 (20): 11531-11536 (1999),
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 93 (1): 136-140 (1996), J.Biol.Chem.
[journal of biological chemistry] 270 (37): 21984-21990 (1995))WO 2003/101283 (claim 14)(WO 2002/
102235 (claims 13The 287-288 pages)2002/101075 (claim 4 of WOThe 308-309 pages)WO 2002/
71928 (the 320-321 pages)WO 94/10312 (the 52-57 pages)IM:601051.</div>
      <div id="p0082" num="0082" class="description-paragraph style-scope patent-text">(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, sapiens's Solute Carrier family 34 (sodium phosphate) member 2, II type sodium according to
Rely property phosphate transporter 3b)</div>
      <div id="p0083" num="0083" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0084" num="0084" class="description-paragraph style-scope patent-text">Genbank accession number NM_006424</div>
      <div id="p0085" num="0085" class="description-paragraph style-scope patent-text">Genbank version number NM_006424.2 GI:110611905</div>
      <div id="p0086" num="0086" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 22nd, 2012 03:39</div>
      <div id="p0087" num="0087" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0088" num="0088" class="description-paragraph style-scope patent-text">Genbank accession number NP_006415</div>
      <div id="p0089" num="0089" class="description-paragraph style-scope patent-text">Genbank version number NP_006415.2 GI:110611906</div>
      <div id="p0090" num="0090" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 22nd, 2012 03:39</div>
      <div id="p0091" num="0091" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0092" num="0092" class="description-paragraph style-scope patent-text">J.Biol.Chem. [journal of biological chemistry] 277 (22): 19665-19672 (2002), Genomics [genome
Learn] 62 (2): 281-284 (1999), Feild, J.A. et al., (1999) Biochem.Biophys.Res.Commun. [biology
Chemistry and biophysical research communication] 258 (3): 578-582)WO 2004/022778 (claim 2)EP 1394274
(example 11)2002/102235 (claim 13 of WOPage 326)0875569 (claim 1 of EPThe 17-19 pages)
2001/57188 (claim 20 of WOPage 329)WO 2004/032842 (example IV)WO 2001/75177 (want by right
Ask 24The 139-140 pages)MIM:604217.</div>
      <div id="p0093" num="0093" class="description-paragraph style-scope patent-text">(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, brain signal albumen
(Semaphorin) 5b Hlog, the domain sema, seven thrombospondin repetitive sequence (1 type and 1 pattern) transmembrane domains (TM) and
Short cytoplasm domain, (semaphorin) 5B)</div>
      <div id="p0094" num="0094" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0095" num="0095" class="description-paragraph style-scope patent-text">Genbank accession number AB040878</div>
      <div id="p0096" num="0096" class="description-paragraph style-scope patent-text">Genbank version number AB040878.1 GI:7959148</div>
      <div id="p0097" num="0097" class="description-paragraph style-scope patent-text">Genbank records update date: 05:40 afternoon on the 2nd of August in 2006</div>
      <div id="p0098" num="0098" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0099" num="0099" class="description-paragraph style-scope patent-text">Genbank accession number BAA95969</div>
      <div id="p0100" num="0100" class="description-paragraph style-scope patent-text">Genbank version number BAA95969.1 GI:7959149</div>
      <div id="p0101" num="0101" class="description-paragraph style-scope patent-text">Genbank records update date: 05:40 afternoon on the 2nd of August in 2006</div>
      <div id="p0102" num="0102" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0103" num="0103" class="description-paragraph style-scope patent-text">Nagase T. et al., (2000) DNA Res. [DNA research] 7 (2): 143-150)(the power of WO 2004/000997
1) benefit requiresWO 2003/003984 (claim 1)2002/06339 (claim 1 of WOPage 50)WO 2001/
88133 (claims 141-43,48-58 page)WO 2003/054152 (claim 20)(the power of WO 2003/101400
11) benefit requiresIt logs in: 30Q9P283GenewHGNC:10737.</div>
      <div id="p0104" num="0104" class="description-paragraph style-scope patent-text">(8)PSCA hlg(2700050C12RikC530008O16RikRIKEN cDNA 2700050C12RIKEN
CDNA 2700050C12 gene)</div>
      <div id="p0105" num="0105" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0106" num="0106" class="description-paragraph style-scope patent-text">Genbank accession number AY358628</div>
      <div id="p0107" num="0107" class="description-paragraph style-scope patent-text">Genbank version number AY358628.1 GI:37182377</div>
      <div id="p0108" num="0108" class="description-paragraph style-scope patent-text">Genbank record update date: on December 1st, 2009 morning 04:15</div>
      <div id="p0109" num="0109" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0110" num="0110" class="description-paragraph style-scope patent-text">Genbank accession number AAQ88991</div>
      <div id="p0111" num="0111" class="description-paragraph style-scope patent-text">Genbank version number AAQ88991.1 GI:37182378</div>
      <div id="p0112" num="0112" class="description-paragraph style-scope patent-text">Genbank record update date: on December 1st, 2009 morning 04:15</div>
      <div id="p0113" num="0113" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0114" num="0114" class="description-paragraph style-scope patent-text">Ross et al., (2002) CancerRes. [cancer research] 62:2546-2553US 2003/129192 (want by right
It asks 2)US 2004/044180 (claim 12)US 2004/044179 (claim 11)(the power of US 2003/096961
11) benefit requiresUS 2003/232056 (example 5)WO 2003/10575816 (claim 12)US 2003/206918
(example 5)EP 1347046 (claim 1)WO 2003/025148 (claim 20)GI:37182378.</div>
      <div id="p0115" num="0115" class="description-paragraph style-scope patent-text">(9) ETBR (endothelin receptor B)</div>
      <div id="p0116" num="0116" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0117" num="0117" class="description-paragraph style-scope patent-text">Genbank accession number AY275463</div>
      <div id="p0118" num="0118" class="description-paragraph style-scope patent-text">Genbank version number AY275463.1 GI:30526094</div>
      <div id="p0119" num="0119" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 02:26</div>
      <div id="p0120" num="0120" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0121" num="0121" class="description-paragraph style-scope patent-text">Genbank accession number AAP32295</div>
      <div id="p0122" num="0122" class="description-paragraph style-scope patent-text">Genbank version number AAP32295.1 GI:30526095</div>
      <div id="p0123" num="0123" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 02:26</div>
      <div id="p0124" num="0124" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0125" num="0125" class="description-paragraph style-scope patent-text">[biochemistry and biophysics research are logical by Nakamuta M. et al., Biochem.Biophys.Res.Commun.
News] 177,34-39,1991OgawaY. et al., Biochem.Biophys.Res.Commun. [biochemistry and biophysics
Research Notes] 178,248-255,1991Arai H. et al., Jpn.Circ.J. [Japanese blood circulation magazine] 56,1303-
1307,1992Arai H. et al., J.Biol.Chem. [journal of biological chemistry] 268,3463-3470,1993Sakamoto
A., Yanagisawa M. et al., Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication]
178,656-663,1991Elshourbagy N.A. et al., J.Biol.Chem. [journal of biological chemistry] 268,3873-
3879,1993Haendler B. et al., J.Cardiovasc.Pharmacol. [cardiovascular pharmacology magazine] 20, s1-S4,
1992Tsutsumi M. et al., Gene [gene] 228,43-49,1999Strausberg R.L. et al.,
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 99,16899-16903,2002Bourgeois C.
Et al., J.Clin.Endocrinol.Metab. [Clinical Endocrinology and metabolism magazine] 82,3116-3123,1997Okamoto
Y. et al., Biol.Chem. [biochemistry] 272,21589-21596,1997Verheij J.B. et al.,
Am.J.Med.Genet. [United States Medicine science of heredity magazine] 108,223-225,2002Hofstra R.M.W. et al.,
Eur.J.Hum.Genet. [European human genetics magazine] 5,180-185,1997Puffenberger E.G. et al., Cell
[cell] 79,1257-1266,1994Attie T. et al., Hum.Mol.Genet. [human molecular genetics] 4,2407-
2409,1995Auricchio A. et al., Hum.Mol.Genet. [human molecular genetics] 5:351-354,1996)
Amiel J. et al., Hum.Mol.Genet. [human molecular genetics] 5,355-357,1996Hofstra R.M.W. et al.,
Nat.Genet. [natural genetics] 12,445-447,1996SvenssonP.J. et al., Hum.Genet. [human genetics
Magazine] 103,145-148,1998Fuchs S. et al., Mol.Med. [molecular medicine] 7,115-124,2001Pingault
V. et al., (2002) Hum.Genet. [human genetics magazine] 111,198-206WO 2004/045516 (claim 1)
WO 2004/048938 (example 2)WO 2004/040000 (claim 151)WO 2003/087768 (claim 1)
WO 2003/016475 (claim 1)WO 2003/016475 (claim 1)WO 2002/61087 (Fig. 1)WO
2003/016494 (Fig. 6)2003/025138 (claim 12 of WOPage 144)2001/98351 (claim 1 of WO
The 124-125 pages)0522868 (claim 8 of EPFig. 2)2001/77172 (claim 1 of WOThe 297-299 pages)
US 2003/109676US 6518404 (Fig. 3)(the claim 1a of US 5773223The column 31-34)WO 2004/
001004</div>
      <div id="p0126" num="0126" class="description-paragraph style-scope patent-text">(10) MSG783 (RNF124, imagination protein FLJ20315)</div>
      <div id="p0127" num="0127" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0128" num="0128" class="description-paragraph style-scope patent-text">Genbank accession number NM_017763</div>
      <div id="p0129" num="0129" class="description-paragraph style-scope patent-text">Genbank version number NM_017763.4 GI:167830482</div>
      <div id="p0130" num="0130" class="description-paragraph style-scope patent-text">Genbank record update date: on July 22nd, 2012 morning 12:34</div>
      <div id="p0131" num="0131" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0132" num="0132" class="description-paragraph style-scope patent-text">Genbank accession number NP_060233</div>
      <div id="p0133" num="0133" class="description-paragraph style-scope patent-text">Genbank version number NP_060233.3 GI:56711322</div>
      <div id="p0134" num="0134" class="description-paragraph style-scope patent-text">Genbank record update date: on July 22nd, 2012 morning 12:34</div>
      <div id="p0135" num="0135" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0136" num="0136" class="description-paragraph style-scope patent-text">WO 2003/104275 (claim 1)WO 2004/046342 (example 2)WO 2003/042661 (want by right
It asks 12)2003/083074 (claim 14 of WOPage 61)WO 2003/018621 (claim 1)WO 2003/
024392 (claim 2Figure 93)WO 2001/66689 (example 6)Locus ID:54894.</div>
      <div id="p0137" num="0137" class="description-paragraph style-scope patent-text">(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, relating to prostate cancers
Because of 1, prostate cancer associated protein 1, six cross-film epithelium antigens of prostate, 2, six cross-film prostateins)</div>
      <div id="p0138" num="0138" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0139" num="0139" class="description-paragraph style-scope patent-text">Genbank accession number AF455138</div>
      <div id="p0140" num="0140" class="description-paragraph style-scope patent-text">Genbank version number AF455138.1 GI:22655487</div>
      <div id="p0141" num="0141" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:54</div>
      <div id="p0142" num="0142" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0143" num="0143" class="description-paragraph style-scope patent-text">Genbank accession number AAN04080</div>
      <div id="p0144" num="0144" class="description-paragraph style-scope patent-text">Genbank version number AAN04080.1 GI:22655488</div>
      <div id="p0145" num="0145" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:54</div>
      <div id="p0146" num="0146" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0147" num="0147" class="description-paragraph style-scope patent-text">Lab.Invest. [laboratory research] 82 (11): 1573-1582 (2002))WO 2003/087306US
2003/064397 (claim 1Fig. 1)2002/72596 (claim 13 of WOThe 54-55 pages)WO 2001/72962
(claim 1Fig. 4 B)WO 2003/104270 (claim 11)WO 2003/104270 (claim 16)US
2004/005598 (claim 22)WO 2003/042661 (claim 12)2003/060612 (claim 12 of US
Figure 10)2002/26822 (claim 23 of WOFig. 2)2002/16429 (claim 12 of WOFigure 10)GI:
22655488</div>
      <div id="p0148" num="0148" class="description-paragraph style-scope patent-text">(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cationic channel subfamily M
Member 4)</div>
      <div id="p0149" num="0149" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0150" num="0150" class="description-paragraph style-scope patent-text">Genbank accession number NM_017636</div>
      <div id="p0151" num="0151" class="description-paragraph style-scope patent-text">Genbank version number NM_017636.3 GI:304766649</div>
      <div id="p0152" num="0152" class="description-paragraph style-scope patent-text">Genbank record update date: on June 29th, 2012 morning 11:27</div>
      <div id="p0153" num="0153" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0154" num="0154" class="description-paragraph style-scope patent-text">Genbank accession number NP_060106</div>
      <div id="p0155" num="0155" class="description-paragraph style-scope patent-text">Genbank version number NP_060106.2 GI:21314671</div>
      <div id="p0156" num="0156" class="description-paragraph style-scope patent-text">Genbank record update date: on June 29th, 2012 morning 11:27</div>
      <div id="p0157" num="0157" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0158" num="0158" class="description-paragraph style-scope patent-text">Xu, X.Z. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 98 (19):
10692-10697 (2001), Cell [cell] 109 (3): 397-407 (2002), J.Biol.Chem. [journal of biological chemistry]
278(33):30813-30820(2003))US 2003/143557 (claim 4)2000/40614 (claim of WO
14The 100-103 pages)2002/10382 (claim 1 of WOFig. 9 A)WO 2003/042661 (claim 12)WO
2002/30268 (claim 27Page 391)US 2003/219806 (claim 4)WO 2001/62794 (want by right
Ask 14Figure 1A-D)MIM:606936.</div>
      <div id="p0159" num="0159" class="description-paragraph style-scope patent-text">(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratoma derivative growth factor)</div>
      <div id="p0160" num="0160" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0161" num="0161" class="description-paragraph style-scope patent-text">Genbank accession number NM_003212</div>
      <div id="p0162" num="0162" class="description-paragraph style-scope patent-text">Genbank version number NM_003212.3 GI:292494881</div>
      <div id="p0163" num="0163" class="description-paragraph style-scope patent-text">Genbank records update date: 02:27 afternoon on the 23rd of September in 2012</div>
      <div id="p0164" num="0164" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0165" num="0165" class="description-paragraph style-scope patent-text">Genbank accession number NP_003203</div>
      <div id="p0166" num="0166" class="description-paragraph style-scope patent-text">Genbank version number NP_003203.1 GI:4507425</div>
      <div id="p0167" num="0167" class="description-paragraph style-scope patent-text">Genbank records update date: 02:27 afternoon on the 23rd of September in 2012</div>
      <div id="p0168" num="0168" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0169" num="0169" class="description-paragraph style-scope patent-text">Ciccodicola, A. et al., EMBO J. [European Molecular Bioglogy Organization's proceedings] 8 (7): 1987-1991
(1989), [American Journal of Human Genetics] 49 (3) Am.J.Hum.Genet.: 555-565 (1991))US 2003/224411
(claim 1)WO 2003/083041 (example 1)WO 2003/034984 (claim 12)(the power of WO 2002/88170
Benefit requires 2The 52-53 pages)2003/024392 (claim 2 of WOFigure 58)2002/16413 (claim 1 of WOThe
94-95, page 105)2002/22808 (claim 2 of WOFig. 1)(the example 2 of US 5854399The column 17-18)US
5792616 (Fig. 2)MIM:187395.</div>
      <div id="p0170" num="0170" class="description-paragraph style-scope patent-text">(14) CD21 (CR2 (complement receptor 2) or C3DR (C3d/ Epstein-Ba Er Er Shi (Epstein Barr) virus
Receptor) or Hs.73792)</div>
      <div id="p0171" num="0171" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0172" num="0172" class="description-paragraph style-scope patent-text">Genbank accession number M26004</div>
      <div id="p0173" num="0173" class="description-paragraph style-scope patent-text">Genbank version number M26004.1 GI:181939</div>
      <div id="p0174" num="0174" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0175" num="0175" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0176" num="0176" class="description-paragraph style-scope patent-text">Genbank accession number AAA35786</div>
      <div id="p0177" num="0177" class="description-paragraph style-scope patent-text">Genbank version number AAA35786.1 GI:181940</div>
      <div id="p0178" num="0178" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0179" num="0179" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0180" num="0180" class="description-paragraph style-scope patent-text">Fujisaku et al., (1989) J.Biol.Chem. [journal of biological chemistry] 264 (4): 2118-2125)Weis
J.J. et al., J.Exp.Med. [The Journal of Experimental Medicine] 167,1047-1066,1988Moore M. et al.,
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 84,9194-9198,1987Barel M. et al.,
Mol.Immunol. [molecular immunology] 35,1025-1031,1998Weis J.J. et al.,
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 83,5639-5643,1986Sinha S.K. etc.
People, (1993) J.Immunol. [Journal of Immunology] 150,5311-5320WO 2004/045520 (example 4)US 2004/
005538 (example 1)WO 2003/062401 (claim 9)WO 2004/045520 (example 4)(the figure of WO 91/02536
9.1-9.9)WO 2004/020595 (claim 1)It logs in: P20023Q13866Q14212EMBLM26004
AAA35786.1</div>
      <div id="p0181" num="0181" class="description-paragraph style-scope patent-text">(15) CD79b (CD79B, CD79 , IGb (immunoglobulin correlation ), B29)</div>
      <div id="p0182" num="0182" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0183" num="0183" class="description-paragraph style-scope patent-text">Genbank accession number NM_000626</div>
      <div id="p0184" num="0184" class="description-paragraph style-scope patent-text">Genbank version number NM_000626.2 GI:90193589</div>
      <div id="p0185" num="0185" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:53</div>
      <div id="p0186" num="0186" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0187" num="0187" class="description-paragraph style-scope patent-text">Genbank accession number NP_000617</div>
      <div id="p0188" num="0188" class="description-paragraph style-scope patent-text">Genbank version number NP_000617.1 GI:11038674</div>
      <div id="p0189" num="0189" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:53</div>
      <div id="p0190" num="0190" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0191" num="0191" class="description-paragraph style-scope patent-text">Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] (2003) 100 (7): 4126-4131,
Blood [blood] (2002) 100 (9): 3068-3076, Muller et al., (1992) Eur.J.Immunol. [European immunology
Magazine] 22 (6): 1621-1625)WO 2004/016225 (claim 2, Figure 140)WO 2003/087768,US 2004/
101874 (claims 1, page 102)WO 2003/062401 (claim 9)WO 2002/78524 (example 2)US
2002/150573 (claim 5, page 15)US 5644033WO 2003/048202 (claim 1, the 306th and 309
Page)WO 99/58658, US 6534482 (claim 13, Figure 17 A/B)WO 2000/55351 (claim 11, the
1145-1146 pages)MIM:147245</div>
      <div id="p0192" num="0192" class="description-paragraph style-scope patent-text">(16) FcRH2 (IFGP4, IRTA4, SPAP1A (the phosphatase anchorin 1a containing the domain SH2), SPAP1B,
SPAP1C)</div>
      <div id="p0193" num="0193" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0194" num="0194" class="description-paragraph style-scope patent-text">Genbank accession number NM_030764</div>
      <div id="p0195" num="0195" class="description-paragraph style-scope patent-text">Genbank version number NM_030764.3 GI:227430280</div>
      <div id="p0196" num="0196" class="description-paragraph style-scope patent-text">Genbank record update date: on June 30th, 2012 morning 12:30</div>
      <div id="p0197" num="0197" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0198" num="0198" class="description-paragraph style-scope patent-text">Genbank accession number NP_110391</div>
      <div id="p0199" num="0199" class="description-paragraph style-scope patent-text">Genbank version number NP_110391.2 GI:19923629</div>
      <div id="p0200" num="0200" class="description-paragraph style-scope patent-text">Genbank record update date: on June 30th, 2012 morning 12:30</div>
      <div id="p0201" num="0201" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0202" num="0202" class="description-paragraph style-scope patent-text">AY358130)Genome Res. [genome research] 13 (10): 2265-2270 (2003),
Immunogenetics [immunogenetics] 54 (2): 87-95 (2002), Blood [blood] 99 (8): 2662-2669 (2002),
Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 98 (17): 9772-9777 (2001), Xu, M.J. etc.
People, (2001) Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication] 280 (3): 768-
775WO 2004/016225 (claim 2)WO 2003/0778362001/38490 (claim 5 of WOFigure 18 D-1-
18D-2)WO 2003/097803 (claim 12)WO 2003/089624 (claim 25)MIM:606509.</div>
      <div id="p0203" num="0203" class="description-paragraph style-scope patent-text">(17)HER2(ErbB2)</div>
      <div id="p0204" num="0204" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0205" num="0205" class="description-paragraph style-scope patent-text">Genbank accession number M11730</div>
      <div id="p0206" num="0206" class="description-paragraph style-scope patent-text">Genbank version number M11730.1 GI:183986</div>
      <div id="p0207" num="0207" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0208" num="0208" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0209" num="0209" class="description-paragraph style-scope patent-text">Genbank accession number AAA75493</div>
      <div id="p0210" num="0210" class="description-paragraph style-scope patent-text">Genbank version number AAA75493.1 GI:306840</div>
      <div id="p0211" num="0211" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0212" num="0212" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0213" num="0213" class="description-paragraph style-scope patent-text">Coussens L. et al., Science [science] (1985) 230 (4730): 1132-1139)Yamamoto T. etc.
People, Nature [nature] 319,230-234,1986Semba K. et al., Proc.Natl.Acad.Sci.U.S.A. [state, the U.S.
The academy of sciences, family proceeding] 82,6497-6501,1985Swiercz J.M. et al., J.Cell Biol. [cell biology magazine]
165,869-880,2004Kuhns J.J. et al., J.Biol.Chem. [journal of biological chemistry] 274,36422-36427,
1999Cho H.-S. et al., Nature [nature] 421,756-760,2003Ehsani A. et al., (1993) Genomics
[genomics] 15,426-429WO 2004/048938 (example 2)WO 2004/027049 (Fig. 1 I)WO 2004/
009622WO 2003/081210WO 2003/089904 (claim 9)WO 2003/016475 (claim 1)US
2003/118592WO 2003/008537 (claim 1)2003/055439 (claim 29 of WOFigure 1A-B)WO
2003/025228 (claim 37Fig. 5 C)(the example 13 of WO 2002/22636The 95-107 pages)WO 2002/12341
(claim 68Fig. 7)WO 2002/13847 (the 71-74 pages)WO 2002/14503 (the 114-117 pages)WO 2001/
53463 (claims 2The 41-46 pages)WO 2001/41787 (page 15)2000/44899 (claim 52 of WOFigure
7)2000/20579 (claim 3 of WOFig. 2)5869445 (claim 3 of USThe column 31-38)(the power of WO 9630514
Benefit requires 2The 56-61 pages)EP 1439393 (claim 7)WO 2004/043361 (claim 7)WO 2004/
022709(the example 3 of WO 2001/00244Fig. 4)It logs in: P04626EMBLM11767AAA35808.1.EMBL
M11761AAA35808.1</div>
      <div id="p0214" num="0214" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0215" num="0215" class="description-paragraph style-scope patent-text">Abbott (Abbott): US 20110177095</div>
      <div id="p0216" num="0216" class="description-paragraph style-scope patent-text">For example, comprising with SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5
(CDR-H3), SEQ ID NO:104 and/or SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2) and SEQ ID
The CDR of the amino acid sequence of NO:8 (CDR-L3) has in total at least antibody of the CDR of 80% sequence identity, wherein with having
The antibody of the VL of VH with the SEQ ID NO:2 of SEQ ID NO:1 is compared, the immunogene of Anti-HER 2 or anti-HER2 binding fragment
Property reduce.</div>
      <div id="p0217" num="0217" class="description-paragraph style-scope patent-text">Hundred strong companies (Biogen): US 20100119511</div>
      <div id="p0218" num="0218" class="description-paragraph style-scope patent-text">For example, ATCC accession number: PTA-10355, PTA-10356, PTA-10357, PTA 10358</div>
      <div id="p0219" num="0219" class="description-paragraph style-scope patent-text">For example, be bound to the purified antibody molecule of HER2, which includes from selected from being made up of
All six CDR:BIIB71F10 (SEQ ID NO:11,13), the BIIB69A09 (SEQ ID NO:15,17) of the antibody of group
BIIB67F10(SEQ ID NO:19,21)BIIB67F11(SEQ ID NO:23,25),BIIB66A12(SEQ ID NO:27,
29)BIIB66C01(SEQ ID NO:3133)BIIB65C10(SEQ ID NO:3537)BIIB65H09(SEQ ID
And BIIB65B03 (SEQ ID NO:43,45) NO:39,41), or change that is identical with the CDR or having compared with the CDR
Change the CDR being no more than at two.</div>
      <div id="p0220" num="0220" class="description-paragraph style-scope patent-text">Trastuzumab (Herceptin) (genentech corp (Genentech))-US 6,054,297ATCC accession number
CRL-10463 (genentech corp)</div>
      <div id="p0221" num="0221" class="description-paragraph style-scope patent-text">Handkerchief trastuzumab (Pertuzumab) (genentech corp) US 20110117097</div>
      <div id="p0222" num="0222" class="description-paragraph style-scope patent-text">It is stepped on for example, see SEQ ID No.15 and 16, SEQ ID No.17 and 18, SEQ ID No.23 and 24 and ATCC
Record HB-12215, HB-12216, CRL 10463, HB-12697.</div>
      <div id="p0223" num="0223" class="description-paragraph style-scope patent-text">US 20090285837</div>
      <div id="p0224" num="0224" class="description-paragraph style-scope patent-text">US 20090202546</div>
      <div id="p0225" num="0225" class="description-paragraph style-scope patent-text">For example, ATCC accession number: HB-12215, HB-12216, CRL 10463, HB-12698.</div>
      <div id="p0226" num="0226" class="description-paragraph style-scope patent-text">US 20060088523</div>
      <div id="p0227" num="0227" class="description-paragraph style-scope patent-text">For example, ATCC accession number: HB-12215, HB-12216</div>
      <div id="p0228" num="0228" class="description-paragraph style-scope patent-text">For example, comprising the variable light shown in SEQ ID No.3 and 4 respectively and variable heavy chain amino acid sequence
Antibody.</div>
      <div id="p0229" num="0229" class="description-paragraph style-scope patent-text">For example, comprising the light-chain amino acid sequence selected from SEQ ID No.15 and 23 and being selected from SEQ ID No.16 and 24
Heavy chain amino acid sequence antibody.</div>
      <div id="p0230" num="0230" class="description-paragraph style-scope patent-text">US 20060018899</div>
      <div id="p0231" num="0231" class="description-paragraph style-scope patent-text">For example, ATCC accession number: (7C2) HB-12215, (7F3) HB-12216, (4D5) CRL-10463, (2C4) HB-
12697</div>
      <div id="p0232" num="0232" class="description-paragraph style-scope patent-text">For example, antibody or its desamidization and/or oxidation comprising amino acid sequence shown in SEQ ID No.23
Variant.</div>
      <div id="p0233" num="0233" class="description-paragraph style-scope patent-text">US 2011/0159014</div>
      <div id="p0234" num="0234" class="description-paragraph style-scope patent-text">For example, the antibody of the light-chain variable domain with the hypervariable region comprising SEQ ID NO:1.</div>
      <div id="p0235" num="0235" class="description-paragraph style-scope patent-text">For example, the antibody of the heavy chain variable domain with the hypervariable region comprising SEQ ID NO:2.</div>
      <div id="p0236" num="0236" class="description-paragraph style-scope patent-text">US 20090187007</div>
      <div id="p0237" num="0237" class="description-paragraph style-scope patent-text">Glycotope company: TrasGEX antibody http://www.glycotope.com/pipeline</div>
      <div id="p0238" num="0238" class="description-paragraph style-scope patent-text">For example, see international arthrocarcinoma research institute (International Joint Cancer Institute) and Changhai
Cancer center, hospital (Changhai Hospital Cancer Cent): HMTI-Fc Ab-Gao J. et al., BMB
Rep.2009 October 3142(10):636-41.</div>
      <div id="p0239" num="0239" class="description-paragraph style-scope patent-text">Symphogen company: US 20110217305</div>
      <div id="p0240" num="0240" class="description-paragraph style-scope patent-text">China consonance stem cell and genetic engineering Co., Ltd (Union Stem Cell&amp;Gene Engineering,
China)-Liu HQ. et al., Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. [cell and molecular immunology magazine]
In May, 201026(5):456-8.</div>
      <div id="p0241" num="0241" class="description-paragraph style-scope patent-text">(18)NCA(CEACAM6)</div>
      <div id="p0242" num="0242" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0243" num="0243" class="description-paragraph style-scope patent-text">Genbank accession number M18728</div>
      <div id="p0244" num="0244" class="description-paragraph style-scope patent-text">Genbank version number M18728.1 GI:189084</div>
      <div id="p0245" num="0245" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0246" num="0246" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0247" num="0247" class="description-paragraph style-scope patent-text">Genbank accession number AAA59907</div>
      <div id="p0248" num="0248" class="description-paragraph style-scope patent-text">Genbank version number AAA59907.1 GI:189085</div>
      <div id="p0249" num="0249" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0250" num="0250" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0251" num="0251" class="description-paragraph style-scope patent-text">Barnett T. et al., Genomics [genomics] 3,59-66,1988Tawaragi Y. et al.,
Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication] 150,89-96,1988
Strausberg R.L. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 99:16899-
16903,2002WO 2004/063709EP 1439393 (claim 7)WO 2004/044178 (example 4)WO
2004/031238WO 2003/042661 (claim 12)WO 2002/78524 (example 2)(the power of WO 2002/86443
Benefit requires 27Page 427)WO 2002/60317 (claim 2)It logs in: P40199Q14920EMBLM29541
AAA59915.1.EMBLM18728.</div>
      <div id="p0252" num="0252" class="description-paragraph style-scope patent-text">(19)MDP(DPEP1)</div>
      <div id="p0253" num="0253" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0254" num="0254" class="description-paragraph style-scope patent-text">Genbank accession number BC017023</div>
      <div id="p0255" num="0255" class="description-paragraph style-scope patent-text">Genbank version number BC017023.1 GI:16877538</div>
      <div id="p0256" num="0256" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 6th, 2012 01:00</div>
      <div id="p0257" num="0257" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0258" num="0258" class="description-paragraph style-scope patent-text">Genbank accession number AAH17023</div>
      <div id="p0259" num="0259" class="description-paragraph style-scope patent-text">Genbank version number AAH17023.1 GI:16877539</div>
      <div id="p0260" num="0260" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 6th, 2012 01:00</div>
      <div id="p0261" num="0261" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0262" num="0262" class="description-paragraph style-scope patent-text">Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 99 (26): 16899-16903
(2002))WO 2003/016475 (claim 1)2002/64798 (claim 33 of WOThe 85-87 pages)JP
05003790 (Fig. 6-8)WO 99/46284 (Fig. 9)MIM:179780.</div>
      <div id="p0263" num="0263" class="description-paragraph style-scope patent-text">(20)IL20R-(IL20RaZCYTOR7)</div>
      <div id="p0264" num="0264" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0265" num="0265" class="description-paragraph style-scope patent-text">Genbank accession number AF184971</div>
      <div id="p0266" num="0266" class="description-paragraph style-scope patent-text">Genbank version number AF184971.1 GI:6013324</div>
      <div id="p0267" num="0267" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 10:00</div>
      <div id="p0268" num="0268" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0269" num="0269" class="description-paragraph style-scope patent-text">Genbank accession number AAF01320</div>
      <div id="p0270" num="0270" class="description-paragraph style-scope patent-text">Genbank version number AAF01320.1 GI:6013325</div>
      <div id="p0271" num="0271" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 10:00</div>
      <div id="p0272" num="0272" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0273" num="0273" class="description-paragraph style-scope patent-text">Clark H.F. et al., Genome Res. [genome research] 13,2265-2270,2003Mungall A.J.
Et al., Nature [nature] 425,805-811,2003Blumberg H. et al., Cell [cell] 104,9-19,2001
Dumoutier L. et al., J.Immunol. [Journal of Immunology] 167,3545-3549,2001Parrish-Novak J. etc.
People, J.Biol.Chem. [journal of biological chemistry] 277,47517-47523,2002Pletnev S. et al., (2003)
Biochemistry [biochemistry] 42:12617-12624Sheikh F. et al., [immunology is miscellaneous by (2004) J.Immunol.
Will] 172,2006-2010EP 1394274 (example 11)US 2004/005320 (example 5)WO 2003/029262 (the
74-75 pages)2003/002717 (claim 2 of WOPage 63)WO 2002/22153 (the 45-47 pages)US 2002/
042366 (the 20-21 pages)WO 2001/46261 (the 57-59 pages)WO 2001/46232 (the 63-65 pages)WO 98/
37193 (claims 1The 55-59 pages)It logs in: Q9UHF4Q6UWA9Q96SH8EMBLAF184971
AAF01320.1</div>
      <div id="p0274" num="0274" class="description-paragraph style-scope patent-text">(21) shortening (Brevican) (BCAN, BEHAB)</div>
      <div id="p0275" num="0275" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0276" num="0276" class="description-paragraph style-scope patent-text">Genbank accession number AF229053</div>
      <div id="p0277" num="0277" class="description-paragraph style-scope patent-text">Genbank version number AF229053.1 GI:10798902</div>
      <div id="p0278" num="0278" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 12:58</div>
      <div id="p0279" num="0279" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0280" num="0280" class="description-paragraph style-scope patent-text">Genbank accession number AAG23135</div>
      <div id="p0281" num="0281" class="description-paragraph style-scope patent-text">Genbank version number AAG23135.1 GI:10798903</div>
      <div id="p0282" num="0282" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 12:58</div>
      <div id="p0283" num="0283" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0284" num="0284" class="description-paragraph style-scope patent-text">Gary S.C. et al., Gene [gene] 256,139-147,2000Clark H.F. et al., Genome Res.
[genome research] 13,2265-2270,2003Strausberg R.L. et al., Proc.Natl.Acad.Sci.U.S.A.
[National Academy of Sciences proceeding] 99,16899-16903,2002US 2003/186372 (claim 11)US 2003/
186373 (claims 11)2003/119131 (claim 1 of USFigure 52)2003/119122 (claim 1 of USFigure
52)US 2003/119126 (claim 1)2003/119121 (claim 1 of USFigure 52)US 2003/119129
(claim 1)US 2003/119130 (claim 1)2003/119128 (claim 1 of USFigure 52)US 2003/
119125 (claims 1)WO 2003/016475 (claim 1)WO 2002/02634 (claim 1)</div>
      <div id="p0285" num="0285" class="description-paragraph style-scope patent-text">(22)EphB2R(DRTERKHek5EPHT3Tyro5)</div>
      <div id="p0286" num="0286" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0287" num="0287" class="description-paragraph style-scope patent-text">Genbank accession number NM_004442</div>
      <div id="p0288" num="0288" class="description-paragraph style-scope patent-text">Genbank version number NM_004442.6 GI:111118979</div>
      <div id="p0289" num="0289" class="description-paragraph style-scope patent-text">Genbank records update date: 04:43 afternoon on the 8th of September in 2012</div>
      <div id="p0290" num="0290" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0291" num="0291" class="description-paragraph style-scope patent-text">Genbank accession number NP_004433</div>
      <div id="p0292" num="0292" class="description-paragraph style-scope patent-text">Genbank version number NP_004433.2 GI:21396504</div>
      <div id="p0293" num="0293" class="description-paragraph style-scope patent-text">Genbank records update date: 04:43 afternoon on the 8th of September in 2012</div>
      <div id="p0294" num="0294" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0295" num="0295" class="description-paragraph style-scope patent-text">Chan, J. and Watt, V.M., Oncogene [oncogene] 6 (6), 1057-1061 (1991) Oncogene [cancer base
Cause] 10 (5): 897-905 (1995), Annu.Rev.Neurosci. [neurology department is commented academic year] 21:309-345 (1998),
Int.Rev.Cytol. [international cytology comment] 196:177-244 (2000))WO 2003042661 (claim 12)WO
200053216 (claims 1Page 41)WO 2004065576 (claim 1)2004020583 (claim of WO
9)WO 2003004529 (the 128-132 pages)200053216 (claim 1 of WOPage 42)MIM:600997.</div>
      <div id="p0296" num="0296" class="description-paragraph style-scope patent-text">(23)ASLG659(B7h)</div>
      <div id="p0297" num="0297" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0298" num="0298" class="description-paragraph style-scope patent-text">Genbank accession number AX092328</div>
      <div id="p0299" num="0299" class="description-paragraph style-scope patent-text">Genbank version number AX092328.1 GI:13444478</div>
      <div id="p0300" num="0300" class="description-paragraph style-scope patent-text">Genbank record update date: on January 26th, 2011 morning 07:37</div>
      <div id="p0301" num="0301" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0302" num="0302" class="description-paragraph style-scope patent-text">US 2004/0101899 (claim 2)WO 2003104399 (claim 11)(the figure of WO 2004000221
3)US 2003/165504 (claim 1)US 2003/124140 (example 2)US 2003/065143 (Figure 60)WO
2002/102235 (claim 13Page 299)US 2003/091580 (example 2)2002/10187 (claim of WO
6Figure 10)2001/94641 (claim 12 of WOFig. 7 b)2002/02624 (claim 13 of WOFigure 1A -1B)US
2002/034749 (claim 54The 45-46 pages)(the example 2 of WO 2002/06317The 320-321 pages, claim 34
The 321-322 pages)WO 2002/71928 (the 468-469 pages)(the example 1 of WO 2002/02587Fig. 1)WO 2001/
40269 (examples 3The 190-192 pages)(the example 2 of WO 2000/36107The 205-207 pages)2004/053079 (right of WO
It is required that 12)WO 2003/004989 (claim 1)WO 2002/71928 (233-234,452-453 page)WO 01/
16318</div>
      <div id="p0303" num="0303" class="description-paragraph style-scope patent-text">(24) PSCA (prostate stem cell antigen precursor)</div>
      <div id="p0304" num="0304" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0305" num="0305" class="description-paragraph style-scope patent-text">Genbank accession number AJ297436</div>
      <div id="p0306" num="0306" class="description-paragraph style-scope patent-text">Genbank version number AJ297436.1 GI:9367211</div>
      <div id="p0307" num="0307" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 1st, 2011 morning 11:25</div>
      <div id="p0308" num="0308" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0309" num="0309" class="description-paragraph style-scope patent-text">Genbank accession number CAB97347</div>
      <div id="p0310" num="0310" class="description-paragraph style-scope patent-text">Genbank version number CAB97347.1 GI:9367212</div>
      <div id="p0311" num="0311" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 1st, 2011 morning 11:25</div>
      <div id="p0312" num="0312" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0313" num="0313" class="description-paragraph style-scope patent-text">Reiter R.E. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 95,1735-
1740,1998Gu Z. et al., Oncogene [oncogene] 19,1288-1296,2000
Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication] (2000) 275 (3): 783-788
WO 2004/022709EP 1394274 (example 11)US 2004/018553 (claim 17)WO 2003/008537
(claim 1)2002/81646 (claim 1 of WOPage 164)2003/003906 (claim 10 of WO288th
Page)(the example 1 of WO 2001/40309Figure 17)(the example 1 of US 2001/055751Fig. 1 b)WO 2000/32752 (want by right
Ask 18Fig. 1)98/51805 (claim 17 of WOPage 97)98/51824 (claim 10 of WOPage 94)WO
98/40403 (claim 2Figure 1B)It logs in: O43653EMBLAF043498AAC39607.1</div>
      <div id="p0314" num="0314" class="description-paragraph style-scope patent-text">(25)GEDA</div>
      <div id="p0315" num="0315" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0316" num="0316" class="description-paragraph style-scope patent-text">Genbank accession number AY260763</div>
      <div id="p0317" num="0317" class="description-paragraph style-scope patent-text">Genbank version number AY260763.1 GI:30102448</div>
      <div id="p0318" num="0318" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 02:24</div>
      <div id="p0319" num="0319" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0320" num="0320" class="description-paragraph style-scope patent-text">Genbank accession number AAP14954</div>
      <div id="p0321" num="0321" class="description-paragraph style-scope patent-text">Genbank version number AAP14954.1 GI:30102449</div>
      <div id="p0322" num="0322" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 02:24</div>
      <div id="p0323" num="0323" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0324" num="0324" class="description-paragraph style-scope patent-text">AP14954 lipoma HMGIC fusion partner sample albumen/pid=AAP14954.1- homo sapiens (mankind)WO 2003/
054152 (claim 20)WO 2003/000842 (claim 1)WO 2003/023013 (example 3, claim
20)US 2003/194704 (claim 45)GI:30102449.</div>
      <div id="p0325" num="0325" class="description-paragraph style-scope patent-text">(26) BAFF-R (B cell activating factor receptor, BLyS receptor 3, BR3)</div>
      <div id="p0326" num="0326" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0327" num="0327" class="description-paragraph style-scope patent-text">Genbank accession number AF116456</div>
      <div id="p0328" num="0328" class="description-paragraph style-scope patent-text">Genbank version number AF116456.1 GI:4585274</div>
      <div id="p0329" num="0329" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 09:44</div>
      <div id="p0330" num="0330" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0331" num="0331" class="description-paragraph style-scope patent-text">Genbank accession number AAD25356</div>
      <div id="p0332" num="0332" class="description-paragraph style-scope patent-text">Genbank version number AAD25356.1 GI:4585275</div>
      <div id="p0333" num="0333" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 09:44</div>
      <div id="p0334" num="0334" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0335" num="0335" class="description-paragraph style-scope patent-text">BAFF receptor/pid=NP_443177.1- homo sapiens: Thompson, J.S. et al., Science [science] 293
(5537),2108-2111(2001)WO 2004/058309WO 2004/0116112003/045422 (example of WOThe
32-33 pages)2003/014294 (claim 35 of WOFig. 6 B)2003/035846 (claim 70 of WO615-616
Page)WO 2002/94852 (column 136-137)2002/38766 (claim 3 of WOPage 133)WO 2002/24909
(example 3Fig. 3)MIM:606269NP_443177.1NM_052945_1AF132600</div>
      <div id="p0336" num="0336" class="description-paragraph style-scope patent-text">(27) CD22 (B-cell receptor CD22-B isotype, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814)</div>
      <div id="p0337" num="0337" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0338" num="0338" class="description-paragraph style-scope patent-text">Genbank accession number AK026467</div>
      <div id="p0339" num="0339" class="description-paragraph style-scope patent-text">Genbank version number AK026467.1 GI:10439337</div>
      <div id="p0340" num="0340" class="description-paragraph style-scope patent-text">Genbank records update date: 11:24 afternoon on the 11st of September in 2006</div>
      <div id="p0341" num="0341" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0342" num="0342" class="description-paragraph style-scope patent-text">Genbank accession number BAB15489</div>
      <div id="p0343" num="0343" class="description-paragraph style-scope patent-text">Genbank version number BAB15489.1 GI:10439338</div>
      <div id="p0344" num="0344" class="description-paragraph style-scope patent-text">Genbank records update date: 11:24 afternoon on the 11st of September in 2006</div>
      <div id="p0345" num="0345" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0346" num="0346" class="description-paragraph style-scope patent-text">Wilson et al., (1991) J.Exp.Med. [The Journal of Experimental Medicine] 173:137-146WO 2003/072036
(claim 1Fig. 1)IM:107266NP_001762.1NM_001771_1.</div>
      <div id="p0347" num="0347" class="description-paragraph style-scope patent-text">(27a) CD22 (CD22 molecule)</div>
      <div id="p0348" num="0348" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0349" num="0349" class="description-paragraph style-scope patent-text">Genbank accession number X52785</div>
      <div id="p0350" num="0350" class="description-paragraph style-scope patent-text">Genbank version number X52785.1 GI:29778</div>
      <div id="p0351" num="0351" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:09</div>
      <div id="p0352" num="0352" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0353" num="0353" class="description-paragraph style-scope patent-text">Genbank accession number CAA36988</div>
      <div id="p0354" num="0354" class="description-paragraph style-scope patent-text">Genbank version number CAA36988.1 GI:29779</div>
      <div id="p0355" num="0355" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:09</div>
      <div id="p0356" num="0356" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0357" num="0357" class="description-paragraph style-scope patent-text">Stamenkovic I. et al., Nature [nature] 345 (6270), 74-77 (1990)?</div>
      <div id="p0358" num="0358" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0359" num="0359" class="description-paragraph style-scope patent-text">Official signs: CD22</div>
      <div id="p0360" num="0360" class="description-paragraph style-scope patent-text">Other alias: SIGLEC-2, SIGLEC2</div>
      <div id="p0361" num="0361" class="description-paragraph style-scope patent-text">Other titles: B-cell receptor CD22Bone-marrow-derived lymphocyte adhesion moleculeBL-CAMCD22 antigenT cell surface is anti-
Former Leu-14Sialic acid combination Ig sample agglutinin 2Sialic acid combination Ig sample agglutinin 2</div>
      <div id="p0362" num="0362" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0363" num="0363" class="description-paragraph style-scope patent-text">G5/44 (English trastuzumab (Inotuzumab) difficult to understand): DiJoseph JF. et al., Cancer Immunol
Immunother. [Cancer Immunol and immunization therapy] in January, 200554(1):11-24.</div>
      <div id="p0364" num="0364" class="description-paragraph style-scope patent-text">Epratuzumab (Epratuzumab)-Goldenberg DM. et al., Expert Rev Anticancer
Ther. [anticancer therapy comment of experts] 6 (10): 1341-53,2006.</div>
      <div id="p0365" num="0365" class="description-paragraph style-scope patent-text">(28) CD79a (CD79A, CD79 ), immunoglobulin correlation , with Ig  (CD79B) covalent interaction and in table
It is related to the B cell specific proteins of the signal of B cell differentiation on face with Ig M molecule forming composite, transduction), pI:4.84, point
Son amount: 25028TM:2 [P] gene chromosome: 19q13.2).</div>
      <div id="p0366" num="0366" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0367" num="0367" class="description-paragraph style-scope patent-text">Genbank accession number NM_001783</div>
      <div id="p0368" num="0368" class="description-paragraph style-scope patent-text">Genbank version number NM_001783.3 GI:90193587</div>
      <div id="p0369" num="0369" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:48</div>
      <div id="p0370" num="0370" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0371" num="0371" class="description-paragraph style-scope patent-text">Genbank accession number NP_001774</div>
      <div id="p0372" num="0372" class="description-paragraph style-scope patent-text">Genbank version number NP_001774.1 GI:4502685</div>
      <div id="p0373" num="0373" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:48</div>
      <div id="p0374" num="0374" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0375" num="0375" class="description-paragraph style-scope patent-text">WO 2003/088808,US 2003/0228319WO 2003/062401 (claim 9)US 2002/
150573 (claims 4, the 13-14 pages)WO 99/58658 (claim 13, Figure 16)WO 92/07574 (Fig. 1)US
5644033Ha et al., (1992) J.Immunol. [Journal of Immunology] 148 (5): 1526-1531M  ller et al., (1992)
Eur.J.Immunol. [European Journal of Immunology] 22:1621-1625</div>
      <div id="p0376" num="0376" class="description-paragraph style-scope patent-text">Hashimoto et al., (1994) Immunogenetics [immunogenetics] 40 (4): 287-295Preud'
Homme et al., (1992) Clin.Exp.Immunol. [clinical trial immunology] 90 (1): 141-146Yu et al., (1992)
J.Immunol. [Journal of Immunology] 148 (2) 633-637Sakaguchi et al., (1988) EMBO J. [European molecular biosciences
Learn association journal] 7 (11): 3457-3464</div>
      <div id="p0377" num="0377" class="description-paragraph style-scope patent-text">(29) CXCR5 (Hugh Burkitt (Burkitt) lymthoma receptor 1, by the activation of CXCL13 chemotactic factor (CF), in lymphocyte
It is functioned in migration and humoral defense, in HIV-2 infection and the development of possible AIDS, lymthoma, myeloma and leukaemia
In the g protein coupled receptor that plays a role)372aa, pI:8.54, molecular weight: 41959TM:7 [P] gene chromosome:
11q23.3</div>
      <div id="p0378" num="0378" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0379" num="0379" class="description-paragraph style-scope patent-text">Genbank accession number NM_001716</div>
      <div id="p0380" num="0380" class="description-paragraph style-scope patent-text">Genbank version number NM_001716.4 GI:342307092</div>
      <div id="p0381" num="0381" class="description-paragraph style-scope patent-text">Genbank records update date: 01:49 afternoon on the 30th of September in 2012</div>
      <div id="p0382" num="0382" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0383" num="0383" class="description-paragraph style-scope patent-text">Genbank accession number NP_001707</div>
      <div id="p0384" num="0384" class="description-paragraph style-scope patent-text">Genbank version number NP_001707.1 GI:4502415</div>
      <div id="p0385" num="0385" class="description-paragraph style-scope patent-text">Genbank records update date: 01:49 afternoon on the 30th of September in 2012</div>
      <div id="p0386" num="0386" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0387" num="0387" class="description-paragraph style-scope patent-text">WO 2004/040000WO 2004/015426US 2003/105292 (example 2)6555339 (example of US
2)WO 2002/61087 (Fig. 1)WO 2001/57188 (claim 20, page 269)2001/72830 (12-13 of WO
Page)WO 2000/22129 (example 1, the 152-153 pages, example 2, the 254-256 pages)WO 99/28468 (claim 1,
Page 38)US 5440021 (example 2, the column 49-52)WO 94/28931 (the 56-58 pages)WO 92/17497 (want by right
Ask 7, Fig. 5)Dobner et al., (1992) Eur.J.Immunol. [European Journal of Immunology] 22:2795-2799Barella
Et al., (1995) Biochem.J. [journal of biological chemistry] 309:773-779</div>
      <div id="p0388" num="0388" class="description-paragraph style-scope patent-text">(30) (they are simultaneously presented to the MHC II class molecule (Ia antigen) of CD4+T lymphocyte to HLA-DOB by binding peptide
 subunit)273aa, pI:6.56, molecular weight: 30820.TM:1 [P] gene chromosome: 6p21.3)</div>
      <div id="p0389" num="0389" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0390" num="0390" class="description-paragraph style-scope patent-text">Genbank accession number NM_002120</div>
      <div id="p0391" num="0391" class="description-paragraph style-scope patent-text">Genbank version number NM_002120.3 GI:118402587</div>
      <div id="p0392" num="0392" class="description-paragraph style-scope patent-text">Genbank records update date: 04:46 afternoon on the 8th of September in 2012</div>
      <div id="p0393" num="0393" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0394" num="0394" class="description-paragraph style-scope patent-text">Genbank accession number NP_002111</div>
      <div id="p0395" num="0395" class="description-paragraph style-scope patent-text">Genbank version number NP_002111.1 GI:4504403</div>
      <div id="p0396" num="0396" class="description-paragraph style-scope patent-text">Genbank records update date: 04:46 afternoon on the 8th of September in 2012</div>
      <div id="p0397" num="0397" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0398" num="0398" class="description-paragraph style-scope patent-text">Tonnelle et al., (1985) EMBO J. [European Molecular Bioglogy Organization's proceedings] 4 (11): 2839-2847
Jonsson et al., (1989) Immunogenetics [immunogenetics] 29 (6): 411-413Beck et al., (1992)
J.Mol.Biol. [J. Mol. BioL] 228:433-441Strausberg et al., (2002)
Proc.Natl.Acad.Sci USA [National Academy of Sciences proceeding] 99:16899-16903Servenius et al., (1987)
J.Biol.Chem. [journal of biological chemistry] 262:8759-8766Beck et al., (1996) J.Mol.Biol. [molecular biology
Magazine] 255:1-13Naruse et al., (2002) Tissue Antigens [tissue antigen] 59:512-519WO 99/
58658 (claim 13, Figure 15)US 6153408 (column 35-38)US 5976551 (column 168-170)US
6011146 (columns 145-146)Kasahara et al., (1989) Immunogenetics [immunogenetics] 30 (1): 66-
68Larhammar et al., (1985) J.Biol.Chem. [journal of biological chemistry] 260 (26): 14111-14119</div>
      <div id="p0399" num="0399" class="description-paragraph style-scope patent-text">(31) (purinoceptor P2X ligand-gated ion channel 5 (ion channel gated by Extracellular ATP) may relate to P2X5
And cynapse transmitting and nerve to occur, defect may cause the Pathological Physiology of idiopathic detrusor instability)422aa), pI:
7.63, molecular weight: 47206TM:1 [P] gene chromosome: 17p13.3).</div>
      <div id="p0400" num="0400" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0401" num="0401" class="description-paragraph style-scope patent-text">Genbank accession number NM_002561</div>
      <div id="p0402" num="0402" class="description-paragraph style-scope patent-text">Genbank version number NM_002561.3 GI:325197202</div>
      <div id="p0403" num="0403" class="description-paragraph style-scope patent-text">Genbank record update date: on June 27th, 2012 morning 12:41</div>
      <div id="p0404" num="0404" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0405" num="0405" class="description-paragraph style-scope patent-text">Genbank accession number NP_002552</div>
      <div id="p0406" num="0406" class="description-paragraph style-scope patent-text">Genbank version number NP_002552.2 GI:28416933</div>
      <div id="p0407" num="0407" class="description-paragraph style-scope patent-text">Genbank record update date: on June 27th, 2012 morning 12:41</div>
      <div id="p0408" num="0408" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0409" num="0409" class="description-paragraph style-scope patent-text">Le et al., (1997) FEBS Lett. [communication of federation, European biochemistry association] 418 (1-2): 195-199
WO 2004/047749WO 2003/072035 (claim 10)Touchman et al., (2000) Genome Res. [gene
Group research] 10:165-173WO 2002/22660 (claim 20)WO 2003/093444 (claim 1)WO
2003/087768 (claim 1)WO 2003/029277 (page 82)</div>
      <div id="p0410" num="0410" class="description-paragraph style-scope patent-text">(32) CD72 (B cell differentiation antigen CD72, Lyb-2)359aa, pI:8.66, molecular weight: 40225, TM:1 [P]
Gene chromosome: 9p13.3).</div>
      <div id="p0411" num="0411" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0412" num="0412" class="description-paragraph style-scope patent-text">Genbank accession number NM_001782</div>
      <div id="p0413" num="0413" class="description-paragraph style-scope patent-text">Genbank version number NM_001782.2 GI:194018444</div>
      <div id="p0414" num="0414" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:43</div>
      <div id="p0415" num="0415" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0416" num="0416" class="description-paragraph style-scope patent-text">Genbank accession number NP_001773</div>
      <div id="p0417" num="0417" class="description-paragraph style-scope patent-text">Genbank version number NP_001773.1 GI:4502683</div>
      <div id="p0418" num="0418" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 01:43</div>
      <div id="p0419" num="0419" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0420" num="0420" class="description-paragraph style-scope patent-text">WO 2004042346 (claim 65)WO 2003/026493 (51-52,57-58 page)WO 2000/
75655 (the 105-106 pages)Von Hoegen et al., (1990) J.Immunol. [Journal of Immunology] 144 (12): 4870-
4877Strausberg et al., (2002) Proc.Natl.Acad.Sci USA [National Academy of Sciences proceeding] 99:16899-
16903</div>
      <div id="p0421" num="0421" class="description-paragraph style-scope patent-text">(33) LY64 (lymphocyte antigen 64 (RP105) (the I type film egg of repetitive sequence (LRR) family rich in leucine
It is white) regulation B cell activates and Apoptosis, and function is lost related to the increase of the disease activity of Patients with SLE
Connection)661aa, pI:6.20, molecular weight: 74147TM:1 [P] gene chromosome: 5q12).</div>
      <div id="p0422" num="0422" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0423" num="0423" class="description-paragraph style-scope patent-text">Genbank accession number NM_005582</div>
      <div id="p0424" num="0424" class="description-paragraph style-scope patent-text">Genbank version number NM_005582.2 GI:167555126</div>
      <div id="p0425" num="0425" class="description-paragraph style-scope patent-text">Genbank records update date: 01:50 afternoon on the 2nd of September in 2012</div>
      <div id="p0426" num="0426" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0427" num="0427" class="description-paragraph style-scope patent-text">Genbank accession number NP_005573</div>
      <div id="p0428" num="0428" class="description-paragraph style-scope patent-text">Genbank version number NP_005573.2 GI:167555127</div>
      <div id="p0429" num="0429" class="description-paragraph style-scope patent-text">Genbank records update date: 01:50 afternoon on the 2nd of September in 2012</div>
      <div id="p0430" num="0430" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0431" num="0431" class="description-paragraph style-scope patent-text">US 2002/193567WO 97/07198 (claim 11, the 39-42 pages)Miura et al., (1996)
Genomics [genomics] 38 (3): 299-304Miura et al., (1998) Blood [blood] 92:2815-2822WO
2003/083047WO 97/44452 (claim 8, the 57-61 pages)WO 2000/12130 (the 24-26 pages).</div>
      <div id="p0432" num="0432" class="description-paragraph style-scope patent-text">(34) ((the presumption receptor in immunoglobulin Fc domain contains C2 type Ig sample domain and ITAM to Fc receptor-like protein 1 to FcRH1
Domain) may play a role in bone-marrow-derived lymphocyte differentiation)429aa, pI:5.28, molecular weight: 46925TM:1 [P] gene dyeing
Body: 1q21-1q22)</div>
      <div id="p0433" num="0433" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0434" num="0434" class="description-paragraph style-scope patent-text">Genbank accession number NM_052938</div>
      <div id="p0435" num="0435" class="description-paragraph style-scope patent-text">Genbank version number NM_052938.4 GI:226958543</div>
      <div id="p0436" num="0436" class="description-paragraph style-scope patent-text">Genbank records update date: 01:43 afternoon on the 2nd of September in 2012</div>
      <div id="p0437" num="0437" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0438" num="0438" class="description-paragraph style-scope patent-text">Genbank accession number NP_443170</div>
      <div id="p0439" num="0439" class="description-paragraph style-scope patent-text">Genbank version number NP_443170.1 GI:16418419</div>
      <div id="p0440" num="0440" class="description-paragraph style-scope patent-text">Genbank records update date: 01:43 afternoon on the 2nd of September in 2012</div>
      <div id="p0441" num="0441" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0442" num="0442" class="description-paragraph style-scope patent-text">WO 2003/077836WO 2001/38490 (claim 6, Figure 18 E-1-18-E-2)Davis et al.,
(2001) Proc.Natl.Acad.Sci USA [National Academy of Sciences proceeding] 98 (17): 9772-9777WO 2003/
089624 (claim 8)EP 1347046 (claim 1)WO 2003/089624 (claim 7).</div>
      <div id="p0443" num="0443" class="description-paragraph style-scope patent-text">(35) (immunoglobulin superfamily receptor transposition correlation 2, may be in B cell development and lymthoma occur IRTA2
The presumption immunity receptor to play a roleThe imbalance of the gene as caused by transposition control occurs in some B cell malignant tumours)
977aa, pI:6.88, molecular weight: 106468, TM:1 [P] gene chromosomes: 1q21)</div>
      <div id="p0444" num="0444" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0445" num="0445" class="description-paragraph style-scope patent-text">Genbank accession number AF343662</div>
      <div id="p0446" num="0446" class="description-paragraph style-scope patent-text">Genbank version number AF343662.1 GI:13591709</div>
      <div id="p0447" num="0447" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:16</div>
      <div id="p0448" num="0448" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0449" num="0449" class="description-paragraph style-scope patent-text">Genbank accession number AAK31325</div>
      <div id="p0450" num="0450" class="description-paragraph style-scope patent-text">Genbank version number AAK31325.1 GI:13591710</div>
      <div id="p0451" num="0451" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:16</div>
      <div id="p0452" num="0452" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0453" num="0453" class="description-paragraph style-scope patent-text">AF343663AF343664AF343665AF369794AF397453AK090423AK090475
AL834187,AY358085Mouse: AK089756, AY158090, AY506558NP_112571.1WO 2003/024392
(claim 2, Figure 97)Nakayama et al., (2000) Biochem.Biophys.Res.Commun. [biochemistry and life
The communication of object physical study] 277 (1): 124-127WO 2003/077836WO 2001/38490 (claim 3, Figure 18 B-1-
18B-2)</div>
      <div id="p0454" num="0454" class="description-paragraph style-scope patent-text">(36) TENB2 (TMEFF2, brain tumor cancer suppressor protein (tomoregulin), TPEF, HPP1, TR, presumption cross-film
Proteoglycans, related with EGF/ heregulin (heregulin) family's growth factor and follistatin)374aa)</div>
      <div id="p0455" num="0455" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0456" num="0456" class="description-paragraph style-scope patent-text">Genbank accession number AF179274</div>
      <div id="p0457" num="0457" class="description-paragraph style-scope patent-text">Genbank version number AF179274.2 GI:12280939</div>
      <div id="p0458" num="0458" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:05</div>
      <div id="p0459" num="0459" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0460" num="0460" class="description-paragraph style-scope patent-text">Genbank accession number AAD55776</div>
      <div id="p0461" num="0461" class="description-paragraph style-scope patent-text">Genbank version number AAD55776.2 GI:12280940</div>
      <div id="p0462" num="0462" class="description-paragraph style-scope patent-text">Genbank record update date: on March 11st, 2010 morning 01:05</div>
      <div id="p0463" num="0463" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0464" num="0464" class="description-paragraph style-scope patent-text">NCBI is logged in: AAD55776, AAF91397, AAG49451, NCBI RefSeq:NP_057276NCBI gene:
23671OMIM:605734SwissProt Q9UIK5AY358907,CAF85723,CQ782436WO 2004/074320
JP 2004113151WO 2003/042661WO 2003/009814EP 1295944 (the 69-70 pages)WO 2002/
30268 (pages 329)WO 2001/90304US 2004/249130US 2004/022727WO 2004/063355US
2004/197325US 2003/232350US 2004/005563US 2003/124579Horie et al., (2000)
Genomics [genomics] 67:146-152Uchida et al., (1999) Biochem.Biophys.Res.Commun. are [raw
Object chemistry and biophysical research communication] 266:593-602Liang et al., (2000) Cancer Res. [cancer research] 60:
4907-12Glynne-Jones et al., (2001) Int J Cancer. [international journal of cancer] October 1594(2):178-
84</div>
      <div id="p0465" num="0465" class="description-paragraph style-scope patent-text">(37) PSMA-FOLH1 (folic acid hydrolase (prostate-specific membrane antigen) 1)</div>
      <div id="p0466" num="0466" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0467" num="0467" class="description-paragraph style-scope patent-text">Genbank accession number M99487</div>
      <div id="p0468" num="0468" class="description-paragraph style-scope patent-text">Genbank version number M99487.1 GI:190663</div>
      <div id="p0469" num="0469" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0470" num="0470" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0471" num="0471" class="description-paragraph style-scope patent-text">Genbank accession number AAA60209</div>
      <div id="p0472" num="0472" class="description-paragraph style-scope patent-text">Genbank version number AAA60209.1 GI:190664</div>
      <div id="p0473" num="0473" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0474" num="0474" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0475" num="0475" class="description-paragraph style-scope patent-text">Israeli R.S. et al., CancerRes. [cancer research] 53 (2), 227-230 (1993)</div>
      <div id="p0476" num="0476" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0477" num="0477" class="description-paragraph style-scope patent-text">Official signs: FOLH1</div>
      <div id="p0478" num="0478" class="description-paragraph style-scope patent-text">Other alias: GIG27, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAD enzyme, PSM, PSMA, mGCP</div>
      <div id="p0479" num="0479" class="description-paragraph style-scope patent-text">Other titles: N- acetylation -connection acidic dipeptidase 1N- acetylation--connection acidic dipeptidase INAALAD
Enzyme I27 albumen of cell growth suppressor geneLeaf acyl poly-gamma-glutamic acid carboxypeptidaseGlutamic acid carboxylase IIGlutamate carboxypeptidase
2Glutamate carboxypeptidase IIFilm glutamate carboxypeptidaseProstate-specific membrane antigen variant FPteroyl poly-gamma-glutamic acid carboxylic peptide
Enzyme</div>
      <div id="p0480" num="0480" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0481" num="0481" class="description-paragraph style-scope patent-text">US 7,666,425: the antibody generated by the hybridoma with following ATCC reference number: ATCC accession number HB-
12101, ATCC accession number HB-12109, ATCC accession number HB-12127 and ATCC accession number HB-12126.</div>
      <div id="p0482" num="0482" class="description-paragraph style-scope patent-text">Proscan: the monoclonal antibody (US selected from the group being made of 8H12,3E11,17G1,29B4,30C1 and 20F2
7,811,564Moffett S. et al., Hybridoma (Larchmt) [hybridoma] .2007 December26(6):363-72).</div>
      <div id="p0483" num="0483" class="description-paragraph style-scope patent-text">Sai Tuogen company (Cytogen): monoclonal antibody 7E11-C5 (ATCC accession number HB 10494) and 9H10-A4
(ATCC accession number HB11430)-US 5,763,202</div>
      <div id="p0484" num="0484" class="description-paragraph style-scope patent-text">GlycoMimetics:NUH2-ATCC accession number HB 9762 (US 7,135,301)</div>
      <div id="p0485" num="0485" class="description-paragraph style-scope patent-text">Human Genome Sciences (Human Genome Science): 97131 (US of HPRAJ70-ATCC accession number
6,824,993)With American type culture collection (American Type Culture Collection, " ATCC ")
The amino acid sequence of cDNA clone (HPRAJ70) coding of 97131 preservation of deposit number</div>
      <div id="p0486" num="0486" class="description-paragraph style-scope patent-text">Plum Drakens company (Medarex): lack the anti-PSMA antibody-US 7,875,278 of fucosyl residues</div>
      <div id="p0487" num="0487" class="description-paragraph style-scope patent-text">The anti-PSMA antibody of mouse include 3F5.4G6,3D7.1.1,4E10-1.14,3E11,4D8,3E6,3C9,2C7,1G3,
3C4,3C6,4D4,1G9,5C8B9,3G6,4C8B9 and monoclonal antibody.Secrete 3F5.4G6,3D7.1.1,4E10-1.14,
The hybridoma of 3E11,4D8,3E6,3C9,2C7,1G3,3C4,3C6,4D4,1G9,5C8B9,3G6 or 4C8B9 disclose preservation,
And it is described in United States Patent (USP) No.6,159,508.Relevant hybridoma discloses preservation and in United States Patent (USP)
It is described in No.6,107,090.In addition, the anti-PSMA antibody of humanization (the humanization pattern including J591) is in PCT Publication WO
It is described in further detail in 02/098897.</div>
      <div id="p0488" num="0488" class="description-paragraph style-scope patent-text">Other mouse anti humans PSMA antibody has been described in the art, such as mAb 107-1A4 (Wang, S. et al.
(2001) Int.J.Cancer [international journal of cancer] 92:871-876) and mAb 2C9 (Kato, K. et al. (2003)
Int.J.Urol. [international urology magazine] 10:439-444).</div>
      <div id="p0489" num="0489" class="description-paragraph style-scope patent-text">The example of the anti-PSMA monoclonal antibody of the mankind include 4A3,7F12,8C12,8A11,16F9,2A10,2C6,2F5 and
1C3 antibody, such as initially in PCT Publication WO 01/09192 and WO 03/064606 and on 2 18th, 2005 titles submitted
In U.S.Provisional Serial 60/654,125 for " human monoclonal antibody of prostate-specific membrane antigen (PSMA) "
Description carry out separation and structural characterization.The V of 4A3,7F12,8C12,8A11,16F9,2A10,2C6,2F5 and 1C3<sub class="style-scope patent-text">H</sub>Amino acid
Sequence is respectively as shown in SEQ ID NO:1-9.The V of 4A3,7F12,8C12,8A11,16F9,2A10,2C6,2F5 and 1C3<sub class="style-scope patent-text">L</sub>Amino
Acid sequence is respectively as shown in SEQ ID NO:10-18.</div>
      <div id="p0490" num="0490" class="description-paragraph style-scope patent-text">The anti-PSMA antibody of other mankind includes PCT Publication WO 03/034903 and U.S. Patent application No.2004/
The antibody disclosed in 0033229.</div>
      <div id="p0491" num="0491" class="description-paragraph style-scope patent-text">Northwest biological therapy company (NW Biotherapeutics): selected from by with ATCC accession number HB12060's
3F5.4G6, the 3D7-1.I. with ATCC accession number HB12309,4E10-1.14,3E11 with ATCC accession number HB12310
(ATCC HB12488)4D8(ATCC HB12487)3E6(ATCC HB12486)3C9(ATCC HB12484)2C7(ATCC
HB12490)1G3(ATCC HB12489)3C4(ATCC HB12494)3C6(ATCC HB12491)4D4(ATCC
HB12493), the group of 1G9 (ATCC HB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485) composition is miscellaneous
Hand over oncocyte system-referring to US 6,150,508</div>
      <div id="p0492" num="0492" class="description-paragraph style-scope patent-text">PSMA development company (PSMA Development Company)/Pu Luo Geordie Ces Co., Ltd (Progenics)/match
Tuo Gen company-Seattle Genetics Inc. (Seattle Genetics): with the hybridoma of ATCC accession number PTA-3258 preservation
The mAb 3.9 of the generation or mAb 10.3-US 7,850,971 generated with the hybridoma of ATCC accession number PTA-3347 preservation</div>
      <div id="p0493" num="0493" class="description-paragraph style-scope patent-text">PSMA development company (PSMA Development Company)-PSMA antibody compositions (US 20080286284,
Table 1)</div>
      <div id="p0494" num="0494" class="description-paragraph style-scope patent-text">This application is the U.S. Patent Application Serial Number 10/395,894 (US 7,850,971) submitted on March 21st, 2003
Divisional application</div>
      <div id="p0495" num="0495" class="description-paragraph style-scope patent-text">Freiburg, Germany university hospital (University Hospital Freiburg, Germany)-mAb 3/A12,3/
E7 and 3/F11 (WolfP. et al., Prostate [prostate] .2010 April 170(5):562-9).</div>
      <div id="p0496" num="0496" class="description-paragraph style-scope patent-text">(38) SST (somatostatin receptorPay attention to there are 5 kinds of hypotypes)</div>
      <div id="p0497" num="0497" class="description-paragraph style-scope patent-text">(38.1) SSTR2 (somatostatin receptor 2)</div>
      <div id="p0498" num="0498" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0499" num="0499" class="description-paragraph style-scope patent-text">Genbank accession number NM_001050</div>
      <div id="p0500" num="0500" class="description-paragraph style-scope patent-text">Genbank version number NM_001050.2 GI:44890054</div>
      <div id="p0501" num="0501" class="description-paragraph style-scope patent-text">Genbank records update date: 01:37 afternoon on the 19th of August in 2012</div>
      <div id="p0502" num="0502" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0503" num="0503" class="description-paragraph style-scope patent-text">Genbank accession number NP_001041</div>
      <div id="p0504" num="0504" class="description-paragraph style-scope patent-text">Genbank version number NP_001041.1 GI:4557859</div>
      <div id="p0505" num="0505" class="description-paragraph style-scope patent-text">Genbank records update date: 01:37 afternoon on the 19th of August in 2012</div>
      <div id="p0506" num="0506" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0507" num="0507" class="description-paragraph style-scope patent-text">Yamada Y. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 89 (1), 251-
255(1992)Susini C. et al., Ann Oncol. [Ann.Oncol] in December, 200617(12):1733-42</div>
      <div id="p0508" num="0508" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0509" num="0509" class="description-paragraph style-scope patent-text">Official signs: SSTR2</div>
      <div id="p0510" num="0510" class="description-paragraph style-scope patent-text">Other titles: SRIF-1SS2R2 type of somatostatin receptor</div>
      <div id="p0511" num="0511" class="description-paragraph style-scope patent-text">(38.2) SSTR5 (somatostatin receptor 5)</div>
      <div id="p0512" num="0512" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0513" num="0513" class="description-paragraph style-scope patent-text">Genbank accession number D16827</div>
      <div id="p0514" num="0514" class="description-paragraph style-scope patent-text">Genbank version number D16827.1 GI:487683</div>
      <div id="p0515" num="0515" class="description-paragraph style-scope patent-text">Genbank records update date: 12:45 afternoon on the 1st of August in 2006</div>
      <div id="p0516" num="0516" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0517" num="0517" class="description-paragraph style-scope patent-text">Genbank accession number BAA04107</div>
      <div id="p0518" num="0518" class="description-paragraph style-scope patent-text">Genbank version number BAA04107.1 GI:487684</div>
      <div id="p0519" num="0519" class="description-paragraph style-scope patent-text">Genbank records update date: 12:45 afternoon on the 1st of August in 2006</div>
      <div id="p0520" num="0520" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0521" num="0521" class="description-paragraph style-scope patent-text">Yamada, Y. et al., Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication]
195(2),844-852(1993)</div>
      <div id="p0522" num="0522" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0523" num="0523" class="description-paragraph style-scope patent-text">Official signs: SSTR5</div>
      <div id="p0524" num="0524" class="description-paragraph style-scope patent-text">Other alias: SS-5-R</div>
      <div id="p0525" num="0525" class="description-paragraph style-scope patent-text">Other titles: somatostatin receptor subtype 55 type of somatostatin receptor</div>
      <div id="p0526" num="0526" class="description-paragraph style-scope patent-text">(38.3)SSTR1</div>
      <div id="p0527" num="0527" class="description-paragraph style-scope patent-text">(38.4)SSTR3</div>
      <div id="p0528" num="0528" class="description-paragraph style-scope patent-text">(38.5)SSTR4</div>
      <div id="p0529" num="0529" class="description-paragraph style-scope patent-text">Two subunits (39+40) of AvB6-</div>
      <div id="p0530" num="0530" class="description-paragraph style-scope patent-text">(39) ITGAV (integrin,  V)</div>
      <div id="p0531" num="0531" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0532" num="0532" class="description-paragraph style-scope patent-text">Genbank accession number M14648J02826M18365</div>
      <div id="p0533" num="0533" class="description-paragraph style-scope patent-text">Genbank version number M14648.1 GI:340306</div>
      <div id="p0534" num="0534" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:56</div>
      <div id="p0535" num="0535" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0536" num="0536" class="description-paragraph style-scope patent-text">Genbank accession number AAA36808</div>
      <div id="p0537" num="0537" class="description-paragraph style-scope patent-text">Genbank version number AAA36808.1 GI:340307</div>
      <div id="p0538" num="0538" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:56</div>
      <div id="p0539" num="0539" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0540" num="0540" class="description-paragraph style-scope patent-text">Suzuki S. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 83 (22),
8614-8618(1986)</div>
      <div id="p0541" num="0541" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0542" num="0542" class="description-paragraph style-scope patent-text">Official signs: ITGAV</div>
      <div id="p0543" num="0543" class="description-paragraph style-scope patent-text">Other alias: CD51, MSK8, VNRA, VTNR</div>
      <div id="p0544" num="0544" class="description-paragraph style-scope patent-text">Other titles: the antigen identified by monoclonal antibody L230Beta 2 integrin alpha-VBeta 2 integrin alpha V  3Integrin egg
It is white,  V (Vitronectic receptor,  polypeptide, antigens c D51)Vitronectic receptor subunit </div>
      <div id="p0545" num="0545" class="description-paragraph style-scope patent-text">(40) ITGB6 (integrin,  6)</div>
      <div id="p0546" num="0546" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0547" num="0547" class="description-paragraph style-scope patent-text">Genbank accession number NM_000888</div>
      <div id="p0548" num="0548" class="description-paragraph style-scope patent-text">Genbank version number NM_000888.3 GI:9966771</div>
      <div id="p0549" num="0549" class="description-paragraph style-scope patent-text">Genbank record update date: on June 27th, 2012 morning 12:46</div>
      <div id="p0550" num="0550" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0551" num="0551" class="description-paragraph style-scope patent-text">Genbank accession number NP_000879</div>
      <div id="p0552" num="0552" class="description-paragraph style-scope patent-text">Genbank version number NP_000879.2 GI:9625002</div>
      <div id="p0553" num="0553" class="description-paragraph style-scope patent-text">Genbank record update date: on June 27th, 2012 morning 12:46</div>
      <div id="p0554" num="0554" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0555" num="0555" class="description-paragraph style-scope patent-text">Sheppard D.J. et al., Biol.Chem. [biochemistry] 265 (20), 11502-11507 (1990)</div>
      <div id="p0556" num="0556" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0557" num="0557" class="description-paragraph style-scope patent-text">Official signs: ITGB6</div>
      <div id="p0558" num="0558" class="description-paragraph style-scope patent-text">Other titles: integrin  -6</div>
      <div id="p0559" num="0559" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0560" num="0560" class="description-paragraph style-scope patent-text">Hundred strong companies: US 7,943,742- hybridoma clone 6.3G9 and 6.8G6 are respectively with ATCC accession number ATCC PTA-
3649 and ATCC PTA-3645 preservation.</div>
      <div id="p0561" num="0561" class="description-paragraph style-scope patent-text">Hundred strong companies: US 7,465,449- in some embodiments, antibody include with hybridoma 6.1A8,6.3G9,
The identical heavy chain of antibody and light chain that 6.8G6,6.2B1,6.2B10,6.2A1,6.2E5,7.1G10,7.7G5 or 7.1C5 are generated
Polypeptide sequence.</div>
      <div id="p0562" num="0562" class="description-paragraph style-scope patent-text">Centocor Inc, Johnson &amp; Johnson (Centocor (J&amp;J)): US 7,550,142US 7,163,681</div>
      <div id="p0563" num="0563" class="description-paragraph style-scope patent-text">Such as in US 7,550,142-have include amino acid sequence shown in SEQ ID NO:7 and SEQ ID NO:8
The human heavy chain of column and the antibody in human light chain variable area.</div>
      <div id="p0564" num="0564" class="description-paragraph style-scope patent-text">Seattle Genetics Inc.: 15H3 (Ryan MC. et al., Cancer Res [cancer research] on April 15th, 2012
72 (8 supplementary issues): 4630)</div>
      <div id="p0565" num="0565" class="description-paragraph style-scope patent-text">(41) CEACAM5 (Carcinoembryonic antigen-associated cell adhesion molecule 5)</div>
      <div id="p0566" num="0566" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0567" num="0567" class="description-paragraph style-scope patent-text">Genbank accession number M17303</div>
      <div id="p0568" num="0568" class="description-paragraph style-scope patent-text">Genbank version number M17303.1 GI:178676</div>
      <div id="p0569" num="0569" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0570" num="0570" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0571" num="0571" class="description-paragraph style-scope patent-text">Genbank accession number AAB59513</div>
      <div id="p0572" num="0572" class="description-paragraph style-scope patent-text">Genbank version number AAB59513.1 GI:178677</div>
      <div id="p0573" num="0573" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0574" num="0574" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0575" num="0575" class="description-paragraph style-scope patent-text">BeaucheminN. et al., Mol.Cell.Biol. [molecular cytobiology] 7 (9), 3221-3230 (1987)</div>
      <div id="p0576" num="0576" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0577" num="0577" class="description-paragraph style-scope patent-text">Official signs: CEACAM5</div>
      <div id="p0578" num="0578" class="description-paragraph style-scope patent-text">Other alias: CD66e, CEA</div>
      <div id="p0579" num="0579" class="description-paragraph style-scope patent-text">Other titles: meconium antigen 100</div>
      <div id="p0580" num="0580" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0581" num="0581" class="description-paragraph style-scope patent-text">AstraZeneca-Midi Miao Ni company (AstraZeneca-MedImmune): US 20100330103US
20080057063US 20020142359</div>
      <div id="p0582" num="0582" class="description-paragraph style-scope patent-text">Such as with the antibody for containing following sequence of complementary determining region (CDR): heavy chainCDR1-DNYMH, CDR2-
WIDPENGDTE YAPKFRG, CDR3-LIYAGYLAMD YWith light chain CDR1-SASSSVTYMH, CDR2-STSNLAS, CDR3-
QQRSTYPLT</div>
      <div id="p0583" num="0583" class="description-paragraph style-scope patent-text">With European Cell Culture Collection (European Collection ofCell Cultures, ECACC)
The hybridoma 806.077 of 96022936 preservation of deposit number.</div>
      <div id="p0584" num="0584" class="description-paragraph style-scope patent-text">RCT company (Research Corporation Technologies, Inc.): US 5,047,507</div>
      <div id="p0585" num="0585" class="description-paragraph style-scope patent-text">Beyer Co., Ltd (Bayer Corporation): US 6,013,772</div>
      <div id="p0586" num="0586" class="description-paragraph style-scope patent-text">Biological company, alliance (BioAlliance): US 7,982,017US 7,674,605</div>
      <div id="p0587" num="0587" class="description-paragraph style-scope patent-text">US 7,674,605</div>
      <div id="p0588" num="0588" class="description-paragraph style-scope patent-text">Weight chain variabl area sequence comprising the amino acid sequence from SEQ ID NO:1 and the ammonia from SEQ ID NO:2
The antibody of the light-chain variable sequence of base acid sequence.</div>
      <div id="p0589" num="0589" class="description-paragraph style-scope patent-text">Weight chain variabl area sequence comprising the amino acid sequence from SEQ ID NO:5 and the ammonia from SEQ ID NO:6
The antibody of the light-chain variable sequence of base acid sequence.</div>
      <div id="p0590" num="0590" class="description-paragraph style-scope patent-text">Cell technology treats Co., Ltd (Celltech Therapeutics Limited): US 5,877,293</div>
      <div id="p0591" num="0591" class="description-paragraph style-scope patent-text">Dow Chemical (The Dow Chemical Company): US 5,472,693US 6,417,337US
6,333,405</div>
      <div id="p0592" num="0592" class="description-paragraph style-scope patent-text">US 5,472,693- such as ATCC CRL-11215</div>
      <div id="p0593" num="0593" class="description-paragraph style-scope patent-text">US 6,417,337- such as ATCC CRL-12208</div>
      <div id="p0594" num="0594" class="description-paragraph style-scope patent-text">US 6,333,405- such as ATCC CRL-12208</div>
      <div id="p0595" num="0595" class="description-paragraph style-scope patent-text">Immune medicine company (Immunomedics, Inc): US 7,534,431US 7,230,084US 7,300,
644US 6,730,300US 20110189085</div>
      <div id="p0596" num="0596" class="description-paragraph style-scope patent-text">The antibody of the CDR of CDR and heavy chain variable region with light chain variable region, the CDR of light chain variable region includes: CDR1,
The CDR1 includes KASQDVGTSVA (SEQ ID NO:20)CDR2, the CDR2 include WTSTRHT (SEQ ID NO:21)With
CDR3, the CDR3 include QQYSLYRS (SEQ ID NO:22)And the CDR of the heavy chain variable region of the CEA antibodie includes:
CDR1, the CDR1 include TYWMS (SEQ ID NO:23)CDR2, the CDR2 include EIHPDSSTINYAPSLKD (SEQ ID
NO:24)And CDR3, the CDR3 include LYFGFPWFAY (SEQ ID NO:25).</div>
      <div id="p0597" num="0597" class="description-paragraph style-scope patent-text">US 20100221175US 20090092598US 20070202044US 20110064653US
20090185974US 20080069775.</div>
      <div id="p0598" num="0598" class="description-paragraph style-scope patent-text">(42) MET (met proto-oncogeneHepatocyte growth factor receptor)</div>
      <div id="p0599" num="0599" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0600" num="0600" class="description-paragraph style-scope patent-text">Genbank accession number M35073</div>
      <div id="p0601" num="0601" class="description-paragraph style-scope patent-text">Genbank version number M35073.1 GI:187553</div>
      <div id="p0602" num="0602" class="description-paragraph style-scope patent-text">Genbank record update date: on March 6th, 2012 morning 11:12</div>
      <div id="p0603" num="0603" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0604" num="0604" class="description-paragraph style-scope patent-text">Genbank accession number AAA59589</div>
      <div id="p0605" num="0605" class="description-paragraph style-scope patent-text">Genbank version number AAA59589.1 GI:553531</div>
      <div id="p0606" num="0606" class="description-paragraph style-scope patent-text">Genbank record update date: on March 6th, 2012 morning 11:12</div>
      <div id="p0607" num="0607" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0608" num="0608" class="description-paragraph style-scope patent-text">DeanM. et al., Nature [nature] 318 (6044), 385-388 (1985)</div>
      <div id="p0609" num="0609" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0610" num="0610" class="description-paragraph style-scope patent-text">Official signs: MET</div>
      <div id="p0611" num="0611" class="description-paragraph style-scope patent-text">Other alias: AUTS9, HGFR, RCCP2, c-Met</div>
      <div id="p0612" num="0612" class="description-paragraph style-scope patent-text">Other titles: HGF receptorHGF/SF receptorSF receptorHepatocyte growth factor receptorMet proto-oncogene junket ammonia
Acid kinaseImmunohistochemistryDispersion factor receptorTyrosine protein kinase Met</div>
      <div id="p0613" num="0613" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0614" num="0614" class="description-paragraph style-scope patent-text">An Gen Knicks company (Abgenix)/Pfizer (Pfizer): US 20100040629</div>
      <div id="p0615" num="0615" class="description-paragraph style-scope patent-text">For example, the hybridoma 13.3.2 with American type culture collection (ATCC) accession number PTA-5026 is produced
Raw antibodyThe antibody that hybridoma 9.1.2 with ATCC accession number PTA-5027 is generatedWith ATCC accession number PTA-5028
Hybridoma 8.70.2 generate antibodyOr the antibody that the hybridoma 6.90.3 with ATCC accession number PTA-5029 is generated.</div>
      <div id="p0616" num="0616" class="description-paragraph style-scope patent-text">Amgen (Amgen)/Pfizer: US 20050054019</div>
      <div id="p0617" num="0617" class="description-paragraph style-scope patent-text">For example, comprising the heavy chain with amino acid sequence shown in SEQ ID NO:2, (wherein X2 is glutamic acid, and X4 is silk
Propylhomoserin) and light chain (wherein X8 is alanine) with amino acid sequence shown in SEQ ID NO:4, signal-sequenceless it is anti-
BodyComprising the heavy chain with amino acid sequence shown in SEQ ID NO:6 and there is amino acid sequence shown in SEQ ID NO:8
Light chain, signal-sequenceless antibodyComprising the heavy chain with amino acid sequence shown in SEQ ID NO:10 and there is SEQ
The antibody of the light chain of amino acid sequence shown in ID NO:12, signal-sequencelessOr comprising with shown in SEQ ID NO:14
The heavy chain of amino acid sequence and antibody with amino acid sequence light chain shown in SEQ ID NO:16, signal-sequenceless.</div>
      <div id="p0618" num="0618" class="description-paragraph style-scope patent-text">A Gulang drugmaker (Agouron Pharmaceuticals) (Xian Shu Pfizer): US 20060035907</div>
      <div id="p0619" num="0619" class="description-paragraph style-scope patent-text">Li Lai company (Eli Lilly): US 20100129369</div>
      <div id="p0620" num="0620" class="description-paragraph style-scope patent-text">Genentech corp: US 5,686,292US 20100028337US 20100016241US
20070129301US 20070098707US 20070092520,US 20060270594US 20060134104US
20060035278US 20050233960US 20050037431</div>
      <div id="p0621" num="0621" class="description-paragraph style-scope patent-text">US 5,686,292- such as ATCC HB-11894 and ATCC HB-11895</div>
      <div id="p0622" num="0622" class="description-paragraph style-scope patent-text">US 20100016241- such as ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (hybridoma
5D5.11.6)</div>
      <div id="p0623" num="0623" class="description-paragraph style-scope patent-text">Taiwan National Defense Medical Center (National Defense Medical Center, Taiwan): Lu RM. et al.,
Biomaterials. [biomaterial] in April, 201132(12):3265-74.</div>
      <div id="p0624" num="0624" class="description-paragraph style-scope patent-text">Novartis Co., Ltd (Novartis): US 20090175860</div>
      <div id="p0625" num="0625" class="description-paragraph style-scope patent-text">For example, the sequence of CDR1, CDR2 and CDR3 comprising heavy chain 4687 and CDR1, CDR2 and CDR3 of light chain 5097
Sequence antibody, wherein the sequence of CDR1, CDR2 and CDR3 of heavy chain 4687 are the residue 26- of SEQ ID NO:58 respectively
35,50-65 and 98-102The sequence of CDR1, CDR2 and CDR3 of light chain 5097 are residue 24-39,55- of SEQ ID NO:37
61 and 94-100.</div>
      <div id="p0626" num="0626" class="description-paragraph style-scope patent-text">Pharmacia Corp (Pharmacia Corporation): US 20040166544</div>
      <div id="p0627" num="0627" class="description-paragraph style-scope patent-text">Pierre's method C Compaq (Pierre Fabre): US 20110239316, US 20110097262, US
20100115639</div>
      <div id="p0628" num="0628" class="description-paragraph style-scope patent-text">Samsung (Sumsung): US 20110129481- is for example with accession number KCLRF-BP-00219 or accession number
The monoclonal antibody that the hybridoma of KCLRF-BP-00223 generates.</div>
      <div id="p0629" num="0629" class="description-paragraph style-scope patent-text">Samsung: hybridoma of the US 20110104176- for example with accession number KCLRF-BP-00220 generates
Antibody.</div>
      <div id="p0630" num="0630" class="description-paragraph style-scope patent-text">Turin University Medical College (University of Turin Medical School): DN-30Pacchiana G.
Et al., J Biol Chem. [journal of biological chemistry] on November 12nd, 2010285(46):36149-57</div>
      <div id="p0631" num="0631" class="description-paragraph style-scope patent-text">Winfried Vahland that research institute (Van Andel Research Institute): Jiao Y. et al., Mol
Biotechnol. [molecular biotechnology] in September, 200531(1):41-54.</div>
      <div id="p0632" num="0632" class="description-paragraph style-scope patent-text">(43) MUC1 (mucin 1, cell surface are related)</div>
      <div id="p0633" num="0633" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0634" num="0634" class="description-paragraph style-scope patent-text">Genbank accession number J05581</div>
      <div id="p0635" num="0635" class="description-paragraph style-scope patent-text">Genbank version number J05581.1 GI:188869</div>
      <div id="p0636" num="0636" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0637" num="0637" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0638" num="0638" class="description-paragraph style-scope patent-text">Genbank accession number AAA59876</div>
      <div id="p0639" num="0639" class="description-paragraph style-scope patent-text">Genbank version number AAA59876.1 GI:188870</div>
      <div id="p0640" num="0640" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:48</div>
      <div id="p0641" num="0641" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0642" num="0642" class="description-paragraph style-scope patent-text">Gendler S.J. et al., J.Biol.Chem. [journal of biological chemistry] 265 (25), 15286-15293 (1990)</div>
      <div id="p0643" num="0643" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0644" num="0644" class="description-paragraph style-scope patent-text">Official signs: MUC1</div>
      <div id="p0645" num="0645" class="description-paragraph style-scope patent-text">Other alias: RP11-263K19.2, CD227, EMA, H23AG, KL-6, MAM6, MUC-1, MUC-1/SEC, MUC-
1/XMUC1/ZDPEMPEMTPUM</div>
      <div id="p0646" num="0646" class="description-paragraph style-scope patent-text">Other titles: DF3 antigenH23 antigenBreast cancer correlation antigen DF3Cancer associated mucinEpithelium saliva albumen
(episialin)krebs von den Lungen-6Mucin 1, cross-filmMucin1Peanut reactivity uromucoid
Polymorphic epithelial mucinTumour associated epithelium mucoproteinTumour associated epithelium membranous antigenTumor-associated mucin</div>
      <div id="p0647" num="0647" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0648" num="0648" class="description-paragraph style-scope patent-text">Chief Si Te drugmaker, Ah tower's Thunder God department (AltaRex)-(Quest Pharma Tech): US 6,716,966-
The Alt-1 antibody generated such as hybridoma ATCC PTA-975.</div>
      <div id="p0649" num="0649" class="description-paragraph style-scope patent-text">Ah tower's Thunder God department-chief Si Te drugmaker: US 7,147,850</div>
      <div id="p0650" num="0650" class="description-paragraph style-scope patent-text">CRT:5E5-<span class="patent-image-not-available style-scope patent-text"></span>AL. et al., the 96-107 pages of the phase of volume 16 the 2nd of Glycobiology [glycobiology],
2006HMFG2-Burchell J. et al., CancerRes. [cancer research], 47,5476-5482 (1987)Referring to WO
2015/159076</div>
      <div id="p0651" num="0651" class="description-paragraph style-scope patent-text">(the website: http://www.glycotope.com/ Glycotope GT-MAB:GT-MAB 2.5-GEX
pipeline/pankomab-gex)</div>
      <div id="p0652" num="0652" class="description-paragraph style-scope patent-text">Immunogen Inc. (Immunogen): US 7,202,346</div>
      <div id="p0653" num="0653" class="description-paragraph style-scope patent-text">For example, antibody MJ-170: hybridoma cell line MJ-170ATCC accession number PTA-5286 monoclonal antibody MJ-
171: hybridoma cell line MJ-171ATCC accession number PTA-5287Monoclonal antibody MJ-172: hybridoma cell line MJ-
172ATCC accession number PTA-5288Or monoclonal antibody MJ-173: hybridoma cell line MJ-173ATCC accession number PTA-5302</div>
      <div id="p0654" num="0654" class="description-paragraph style-scope patent-text">Immune medicine company: US 6,653,104</div>
      <div id="p0655" num="0655" class="description-paragraph style-scope patent-text">Ramot company, Tel Aviv university (Ramot Tel Aviv Uni): US 7,897,351</div>
      <div id="p0656" num="0656" class="description-paragraph style-scope patent-text">Lei Gen university (Regents Uni.) CA:US 7,183,388US 20040005647US 20030077676.</div>
      <div id="p0657" num="0657" class="description-paragraph style-scope patent-text">Roche GlycArt company (Roche GlycArt): US 8,021,856</div>
      <div id="p0658" num="0658" class="description-paragraph style-scope patent-text">Russian country's Cancer Research Center (Russian National Cancer Research Center):
Imuteran-Ivanov PK. et al., Biotechnol J. [biotechnology magazine] in July, 20072(7):863-70</div>
      <div id="p0659" num="0659" class="description-paragraph style-scope patent-text">Brunswick polytechnical university (Technische Univ Braunschweig): (IIB6, HT186-B7, HT186-
D11, HT186-G2, HT200-3A-C1, HT220-M-D1, HT220-M-G8)-Thie H. et al., PLoS One. [public section
Learn library: comprehensive] on January 14th, 20116(1):e15921</div>
      <div id="p0660" num="0660" class="description-paragraph style-scope patent-text">(44) CA9 (carbonic anhydrase IX)</div>
      <div id="p0661" num="0661" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0662" num="0662" class="description-paragraph style-scope patent-text">Genbank accession number X66839</div>
      <div id="p0663" num="0663" class="description-paragraph style-scope patent-text">Genbank version number X66839.1 GI:1000701</div>
      <div id="p0664" num="0664" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:15</div>
      <div id="p0665" num="0665" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0666" num="0666" class="description-paragraph style-scope patent-text">Genbank accession number CAA47315</div>
      <div id="p0667" num="0667" class="description-paragraph style-scope patent-text">Genbank version number CAA47315.1 GI:1000702</div>
      <div id="p0668" num="0668" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:15</div>
      <div id="p0669" num="0669" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0670" num="0670" class="description-paragraph style-scope patent-text">Pastorek J. et al., Oncogene [oncogene] 9 (10), 2877-2888 (1994)</div>
      <div id="p0671" num="0671" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0672" num="0672" class="description-paragraph style-scope patent-text">Official signs: CA9</div>
      <div id="p0673" num="0673" class="description-paragraph style-scope patent-text">Other alias: CAIX, MN</div>
      <div id="p0674" num="0674" class="description-paragraph style-scope patent-text">Other titles: CA-IXP54/58NRCC related antigen G250RCC GAP-associated protein GAP G250Carbonate dehydratase IX
Carbonic anhydrase 9Carbonate dehydrataseMembranous antigen MNpMW1Clear-cell carcinoma related antigen G250</div>
      <div id="p0675" num="0675" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0676" num="0676" class="description-paragraph style-scope patent-text">An Gen Knicks company/Amgen: US 20040018198</div>
      <div id="p0677" num="0677" class="description-paragraph style-scope patent-text">Affine body: the anti-affine body molecule of CAIX</div>
      <div id="p0678" num="0678" class="description-paragraph style-scope patent-text">(http://www.affibody.com/en/Product-Portfolio/Pipeline/)</div>
      <div id="p0679" num="0679" class="description-paragraph style-scope patent-text">Beyer Co., Ltd: US 7,462,696</div>
      <div id="p0680" num="0680" class="description-paragraph style-scope patent-text">Beyer Co., Ltd/Mo Fuxisi company (Morphosys): 3ee9mAb-Petrul HM. et al., Mol Cancer
Ther. [molecule treatment of cancer] 2 months 201211(2):340-9</div>
      <div id="p0681" num="0681" class="description-paragraph style-scope patent-text">Harvard Medical School (Harvard Medical School): antibody G10, G36, G37, G39, G45, G57, G106,
G119, G6, G27, G40 and G125.Xu C. et al., PLoS One. [Public science library: comprehensive] on March 10th, 20105
(3):e9625</div>
      <div id="p0682" num="0682" class="description-paragraph style-scope patent-text">Ins of Virology, the academy of sciences, Slovakia (Bayer) (Institute of Virology, Slovak Academy
of Sciences(Bayer))-US 5,955,075</div>
      <div id="p0683" num="0683" class="description-paragraph style-scope patent-text">For example, M75-ATCC accession number HB 11128 or MN12-ATCC accession number HB 11647</div>
      <div id="p0684" num="0684" class="description-paragraph style-scope patent-text">Ins of Virology, the academy of sciences, Slovakia: US 7,816,493</div>
      <div id="p0685" num="0685" class="description-paragraph style-scope patent-text">Such as the M75 monoclonal antibody secreted from hybridoma VU-M75, the hybridoma is with 11128 preservation of ATCC No.HB
In American type culture collectionOr the V/10 monoclonal antibody secreted from hybridoma V/10-VU, the hybridoma is to log in
Number LMBP 6009CB is deposited in Belgium's joint Organism Depositary LMBP plasmid collection of Ghent, Belgium university
International Depository Authority (International Depository Authority of the Belgian Coordinated
Collection of Microorganisms(BCCM)at the Laboratorium voor Moleculaire
Bioloqie-Plasmidencollectie(LMBP)at the Universeit Gent in Gent,Belgium)</div>
      <div id="p0686" num="0686" class="description-paragraph style-scope patent-text">The academy of sciences, Slovakia Ins of Virology US 20080177046US 20080176310US
20080176258US 20050031623</div>
      <div id="p0687" num="0687" class="description-paragraph style-scope patent-text">Novartis Co., Ltd: US 20090252738</div>
      <div id="p0688" num="0688" class="description-paragraph style-scope patent-text">Wei Li Ces Co., Ltd (Wilex): US 7,691,375- such as hybridoma cell line DSM ASC 2526 is generated anti-
Body.</div>
      <div id="p0689" num="0689" class="description-paragraph style-scope patent-text">Wei Li Ces Co., Ltd (Wilex): US 20110123537Rencarex:Kennett RH. et al., Curr Opin
Mol Ther. [comment of the molecular therapy present age] 2 months 20035(1):70-5</div>
      <div id="p0690" num="0690" class="description-paragraph style-scope patent-text">Xencor:US 20090162382</div>
      <div id="p0691" num="0691" class="description-paragraph style-scope patent-text">(45) EGFRvIII (EGF-R ELISA (EGFR), transcriptional variants 3</div>
      <div id="p0692" num="0692" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0693" num="0693" class="description-paragraph style-scope patent-text">Genbank accession number NM_201283</div>
      <div id="p0694" num="0694" class="description-paragraph style-scope patent-text">Genbank version number NM_201283.1 GI:41327733</div>
      <div id="p0695" num="0695" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p0696" num="0696" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0697" num="0697" class="description-paragraph style-scope patent-text">Genbank accession number NP_958440</div>
      <div id="p0698" num="0698" class="description-paragraph style-scope patent-text">Genbank version number NP_958440.1 GI:41327734</div>
      <div id="p0699" num="0699" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p0700" num="0700" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0701" num="0701" class="description-paragraph style-scope patent-text">Batra SK. et al., Cell GrowthDiffer [cell Growth and Differentiation] 19956:1251-1259.</div>
      <div id="p0702" num="0702" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0703" num="0703" class="description-paragraph style-scope patent-text">US 7,628,986 and US 7,736,644 (Amgen)</div>
      <div id="p0704" num="0704" class="description-paragraph style-scope patent-text">For example, being selected from the heavy chain variable amino acid sequence for the group being made of SEQ ID NO:142 and variant and being selected from
By the chain variable region amino acid sequence for the group that SEQ ID NO:144 and variant form.</div>
      <div id="p0705" num="0705" class="description-paragraph style-scope patent-text">US 20100111979 (Amgen)</div>
      <div id="p0706" num="0706" class="description-paragraph style-scope patent-text">For example, the antibody comprising following heavy chain amino acid sequence, which includes: CDR1, the CDR1 by
Select free antibody 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID NO:4), 150 (SEQ ID
NO:5)095(SEQ ID NO:7)250(SEQ ID NO:9)139(SEQ ID NO:10)211(SEQ ID NO:12)
124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16) and 333 (SEQ ID NO:17)
The Sequence composition of the group of the amino acid sequence composition in the area CDR1CDR2, the CDR2 by select free antibody 13.1.2 (SEQ ID NO:
138)131(SEQ ID NO:2)170(SEQ ID NO:4)150(SEQ ID NO:5)095(SEQ ID NO:7)250
(SEQ ID NO:9)139(SEQ ID NO:10)211(SEQ ID NO:12)124(SEQ ID NO:13)318(SEQ
ID NO:15), the group of the amino acid sequence composition in the area CDR2 of 342 (SEQ ID NO:16) and 333 (SEQ ID NO:17)
Sequence compositionAnd CDR3, the CDR3 by select free antibody 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2),
170(SEQ ID NO:4)150(SEQ ID NO:5)095(SEQ ID NO:7)250(SEQ ID NO:9)139(SEQ
ID NO:10)211(SEQ ID NO:12)124(SEQ ID NO:13)318(SEQ ID NO:15)342(SEQ ID
NO:16) and the amino acid sequence in the area CDR3 of 333 (SEQ ID NO:17) composition group Sequence composition.</div>
      <div id="p0707" num="0707" class="description-paragraph style-scope patent-text">US 20090240038 (Amgen)</div>
      <div id="p0708" num="0708" class="description-paragraph style-scope patent-text">For example, the antibody at least one of heavy chain or light chain polypeptide includes and is selected from by SEQ ID NO:2, SEQ
The amino acid sequence of the group of ID NO:19, SEQ ID NO:142, SEQ ID NO:144 and any combination thereof composition has at least
The amino acid sequence of 90% identity.</div>
      <div id="p0709" num="0709" class="description-paragraph style-scope patent-text">US 20090175887 (Amgen)</div>
      <div id="p0710" num="0710" class="description-paragraph style-scope patent-text">Free antibody 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID are selected for example, having
NO:4)150(SEQ ID NO:5)095(SEQ ID NO:7)250(SEQ ID NO:9)139(SEQ ID NO:10)
211 (SEQ ID NO:12), 124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16) and 333
The antibody of the heavy chain amino acid sequence of the group of the heavy chain amino acid sequence composition of (SEQ ID NO:17).</div>
      <div id="p0711" num="0711" class="description-paragraph style-scope patent-text">US 20090156790 (Amgen)</div>
      <div id="p0712" num="0712" class="description-paragraph style-scope patent-text">For example, the antibody with heavy chain polypeptide and light chain polypeptide, wherein at least one of heavy chain or light chain polypeptide include
It is made of with being selected from SEQ ID NO:2, SEQ ID NO:19, SEQ ID NO:142, SEQ ID NO:144 and any combination thereof
Group amino acid sequence have at least 90% identity amino acid sequence.</div>
      <div id="p0713" num="0713" class="description-paragraph style-scope patent-text">US 20090155282, US 20050059087 and US 20050053608 (Amgen)</div>
      <div id="p0714" num="0714" class="description-paragraph style-scope patent-text">For example, select free antibody 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID NO:
4)150(SEQ ID NO:5)095(SEQ ID NO:7)250(SEQ ID NO:9)139(SEQ ID NO:10)211
(SEQ ID NO:12), 124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16) and 333 (SEQ
ID NO:17) heavy chain amino acid sequence composition group heavy chain of antibody amino acid sequence.</div>
      <div id="p0715" num="0715" class="description-paragraph style-scope patent-text">MR1-1(US 7,129,332Du Ke company (Duke))</div>
      <div id="p0716" num="0716" class="description-paragraph style-scope patent-text">For example, the variant antibodies of the sequence with SEQ ID NO.18, which has the S98P- in CDR3 VH
F92W displacement in T99Y displacement and CDR3 VL.</div>
      <div id="p0717" num="0717" class="description-paragraph style-scope patent-text">L8A4, H10, Y10 (Wikstrand CJ. et al., Cancer Res. [cancer research] 15 days July nineteen ninety-five55
(14):3140-8Du Ke company)</div>
      <div id="p0718" num="0718" class="description-paragraph style-scope patent-text">US 20090311803 (Harvard University (Harvard University))</div>
      <div id="p0719" num="0719" class="description-paragraph style-scope patent-text">For example, the SEQ ID NO:9 of the antibody heavy chain variable region and SEQ ID NO:3 of chain variable region amino acid sequence</div>
      <div id="p0720" num="0720" class="description-paragraph style-scope patent-text">US 20070274991 (EMD72000, also referred to as matuzumab (matuzumab)Harvard University)</div>
      <div id="p0721" num="0721" class="description-paragraph style-scope patent-text">For example, the SEQ ID NO:3 and 9 of difference light chain and heavy chain</div>
      <div id="p0722" num="0722" class="description-paragraph style-scope patent-text">US 6,129,915 (Schering Corp (Schering))</div>
      <div id="p0723" num="0723" class="description-paragraph style-scope patent-text">For example, SEQ.ID NO:1,2,3,4,5 and 6.</div>
      <div id="p0724" num="0724" class="description-paragraph style-scope patent-text">MAb CH12-Wang H. et al., FASEB J. [U.S.'s Bioexperiment learns federation's proceedings] in January, 2012
26 (1): 73-80 (Shanghai Cancer Institute (Shanghai Cancer Institute)).</div>
      <div id="p0725" num="0725" class="description-paragraph style-scope patent-text">RAbDMvIII-Gupta P. et al., BMC Biotechnol. [BMC biotechnology] on October 7th, 201010:
72 (Stanford University Medical center (Stanford University Medical Center)).</div>
      <div id="p0726" num="0726" class="description-paragraph style-scope patent-text">MAb Ua30-Ohman L. et al., Tumour Biol. [oncobiology] April in March, 2002-23(2):61-
9 (University of Uppsala (Uppsala University)).</div>
      <div id="p0727" num="0727" class="description-paragraph style-scope patent-text">Han DG. et al., Nan Fang Yi Ke Da Xue Xue Bao. [Nanfang Medical Univ's journal] 2010 1
Month30 (1): 25-9 (Xi'an Communications University (Xi'an Jiaotong University)).</div>
      <div id="p0728" num="0728" class="description-paragraph style-scope patent-text">(46) CD33 (CD33 molecule)</div>
      <div id="p0729" num="0729" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0730" num="0730" class="description-paragraph style-scope patent-text">Genbank accession number M_23197</div>
      <div id="p0731" num="0731" class="description-paragraph style-scope patent-text">Genbank version number NM_23197.1 GI:180097</div>
      <div id="p0732" num="0732" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0733" num="0733" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0734" num="0734" class="description-paragraph style-scope patent-text">Genbank accession number AAA51948</div>
      <div id="p0735" num="0735" class="description-paragraph style-scope patent-text">Genbank version number AAA51948.1 GI:188098</div>
      <div id="p0736" num="0736" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p0737" num="0737" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0738" num="0738" class="description-paragraph style-scope patent-text">Simmons D. et al., J.Immunol. [Journal of Immunology] 141 (8), 2797-2800 (1988)</div>
      <div id="p0739" num="0739" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0740" num="0740" class="description-paragraph style-scope patent-text">Official signs: CD33</div>
      <div id="p0741" num="0741" class="description-paragraph style-scope patent-text">Other alias: SIGLEC-3, SIGLEC3, p67</div>
      <div id="p0742" num="0742" class="description-paragraph style-scope patent-text">Other titles: CD33 antigen (gp67)gp67Myeloid cell surface antigen CD33The agglutination of sialic acid combination Ig sample
Element 3Sialic acid combination Ig sample agglutinin</div>
      <div id="p0743" num="0743" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0744" num="0744" class="description-paragraph style-scope patent-text">H195 (lintuzumab (Lintuzumab))-Raza A. et al., Leuk Lymphoma. [leukaemia and lymph
Tumor] in August, 200950(8):1336-44US 6,759,045 (Seattle Genetics Inc./immune medicine company)</div>
      <div id="p0745" num="0745" class="description-paragraph style-scope patent-text">MAb OKT9:Sutherland, D.R. et al., Proc Natl Acad Sci USA [National Academy of Sciences institute
Periodical] 78 (7): 4515-4519 1981, Schneider, C. et al., J Biol Chem [journal of biological chemistry] 257,8516-
8522(1982)</div>
      <div id="p0746" num="0746" class="description-paragraph style-scope patent-text">MAb E6:Hoogenboom, H.R. et al., J Immunol [Journal of Immunology] 144,3211-3217 (1990)</div>
      <div id="p0747" num="0747" class="description-paragraph style-scope patent-text">US 6,590,088 (Human Genome Sciences)</div>
      <div id="p0748" num="0748" class="description-paragraph style-scope patent-text">For example, SEQ ID NO:1 and 2 and ATCC accession number 97521</div>
      <div id="p0749" num="0749" class="description-paragraph style-scope patent-text">US 7,557,189 (Immunogen Inc.)</div>
      <div id="p0750" num="0750" class="description-paragraph style-scope patent-text">For example, the antibody comprising heavy chain variable region and light chain variable region or its segment, which includes to have
Three CDR of the amino acid sequence of SEQ ID NO:1-3, the light chain variable region include the amino acid with SEQ ID NO:4-6
Three CDR of sequence.</div>
      <div id="p0751" num="0751" class="description-paragraph style-scope patent-text">(47) CD19 (CD19 molecule)</div>
      <div id="p0752" num="0752" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0753" num="0753" class="description-paragraph style-scope patent-text">Genbank accession number NM_001178098</div>
      <div id="p0754" num="0754" class="description-paragraph style-scope patent-text">Genbank version number NM_001178098.1 GI:296010920</div>
      <div id="p0755" num="0755" class="description-paragraph style-scope patent-text">Genbank records update date: the morning 12:43 on the 10th of September in 2012</div>
      <div id="p0756" num="0756" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0757" num="0757" class="description-paragraph style-scope patent-text">Genbank accession number NP_001171569</div>
      <div id="p0758" num="0758" class="description-paragraph style-scope patent-text">Genbank version number NP_001171569.1 GI:296010921</div>
      <div id="p0759" num="0759" class="description-paragraph style-scope patent-text">Genbank records update date: the morning 12:43 on the 10th of September in 2012</div>
      <div id="p0760" num="0760" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0761" num="0761" class="description-paragraph style-scope patent-text">Tedder TF. et al., J.Immunol. [Journal of Immunology] 143 (2): 712-7 (1989)</div>
      <div id="p0762" num="0762" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0763" num="0763" class="description-paragraph style-scope patent-text">Official signs: CD19</div>
      <div id="p0764" num="0764" class="description-paragraph style-scope patent-text">Other alias: B4, CVID3</div>
      <div id="p0765" num="0765" class="description-paragraph style-scope patent-text">Other titles: bone-marrow-derived lymphocyte antigens c D19Bone-marrow-derived lymphocyte surface antigen B4T cell surface antigen Leu-12Point
Change antigens c D19</div>
      <div id="p0766" num="0766" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0767" num="0767" class="description-paragraph style-scope patent-text">Immunogen Inc.: HuB4-Al-Katib AM. et al., Clin Cancer Res. [Clinical Cancer Research] 2009
June 1515(12):4038-45.</div>
      <div id="p0768" num="0768" class="description-paragraph style-scope patent-text">4G7:K  glerM. et al., Protein Eng Des Sel. [protein engineering, design and selection] 2009 3
Month22(3):135-47</div>
      <div id="p0769" num="0769" class="description-paragraph style-scope patent-text">For example, Knappik, A. et al. J Mol Biol [J. Mol. BioL] 2 months 2000296(1):57-86
Fig. 3 in sequence</div>
      <div id="p0770" num="0770" class="description-paragraph style-scope patent-text">AstraZeneca/Midi Miao Ni company: MEDI-551-Herbst R. et al., J Pharmacol Exp Ther. [medicine
Of science and experimental therapy magazine] in October, 2010335(1):213-22</div>
      <div id="p0771" num="0771" class="description-paragraph style-scope patent-text">Glenn mark pharmacy (Glenmark Pharmaceuticals): GBR-401-Hou S. et al., Mol Cancer
Ther [molecule treatment of cancer] in November, 2011 (meeting digest supplementary issue) C164</div>
      <div id="p0772" num="0772" class="description-paragraph style-scope patent-text">US 7,109,304 (immune medicine company)</div>
      <div id="p0773" num="0773" class="description-paragraph style-scope patent-text">For example, the antibody of the sequence (SEQ ID NO:10) of sequence (SEQ ID NO:7) and hA19VH comprising hA19Vk</div>
      <div id="p0774" num="0774" class="description-paragraph style-scope patent-text">US 7,902,338 (immune medicine company)</div>
      <div id="p0775" num="0775" class="description-paragraph style-scope patent-text">For example, following antibody or its antigen-binding fragment, it includes complementary determining region of light chain CDR sequence SEQ ID NO:
The CDR3 of 16 CDR1 (KASQSVDYDGDSYLN), the CDR2 (DASNLVS) of SEQ ID NO:17 and SEQ ID NO:18
(QQSTEDPWT) and the CDR2 of the CDR1 (SYWMN) of heavy CDR sequences SEQ ID NO:19, SEQ ID NO:20
It (QIWPGDGDTNYNGKFKG) and the CDR3 (RETTTVGRYYYAMDY) of SEQ ID NO:21, and also include human antibody frame
(FR) and constant-region sequences, wherein one or more Framework Region amino acid residues from the associated frame members region sequence of parent murine antibody into
Line replacement, and wherein the displaced FR residue includes the Serine phenylpropyl alcohol at the Kabat residue 91 of heavy chain variable region
Propylhomoserin.</div>
      <div id="p0776" num="0776" class="description-paragraph style-scope patent-text">Plum Drakens company: MDX-1342-Cardarelli PM. et al., Cancer Immunol Immunother.
[Cancer Immunol and immunization therapy] 2 months 201059(2):257-65.</div>
      <div id="p0777" num="0777" class="description-paragraph style-scope patent-text">Mo Fuxisi company/Xencor:MOR-208/XmAb-5574-Zalevsky J. et al., Blood [blood]
.2009 on April 16, in113(16):3735-43</div>
      <div id="p0778" num="0778" class="description-paragraph style-scope patent-text">US 7,968,687 (Seattle Genetics Inc.)</div>
      <div id="p0779" num="0779" class="description-paragraph style-scope patent-text">Heavy chain variable domain comprising the amino acid sequence containing SEQ ID NO:9 and the amino containing SEQ ID NO:24
The antibody or antigen-binding fragment of the light-chain variable domain of acid sequence.</div>
      <div id="p0780" num="0780" class="description-paragraph style-scope patent-text">4G7chim-Lang P. et al., Blood [blood] .2004 May 15103 (10): (Di Bingen is big by 3982-5
It learns (University ofT  bingen))</div>
      <div id="p0781" num="0781" class="description-paragraph style-scope patent-text">For example, Fig. 6 and SEQ ID No:80 of US 20120082664</div>
      <div id="p0782" num="0782" class="description-paragraph style-scope patent-text">Medical College of Zhejiang Univ. (Zhejiang University School ofMedicine): 2E8-Zhang J. etc.
People, J Drug Target. [drug targeting magazine] in November, 201018(9):675-8</div>
      <div id="p0783" num="0783" class="description-paragraph style-scope patent-text">(48) IL2RA (IL-2R )NCBI reference sequences: NM_000417.2)</div>
      <div id="p0784" num="0784" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0785" num="0785" class="description-paragraph style-scope patent-text">Genbank accession number NM_000417</div>
      <div id="p0786" num="0786" class="description-paragraph style-scope patent-text">Genbank version number NM_000417.2 GI:269973860</div>
      <div id="p0787" num="0787" class="description-paragraph style-scope patent-text">Genbank records update date: 04:59 afternoon on the 9th of September in 2012</div>
      <div id="p0788" num="0788" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0789" num="0789" class="description-paragraph style-scope patent-text">Genbank accession number NP_000408</div>
      <div id="p0790" num="0790" class="description-paragraph style-scope patent-text">Genbank version number NP_000408.1 GI:4557667</div>
      <div id="p0791" num="0791" class="description-paragraph style-scope patent-text">Genbank records update date: 04:59 afternoon on the 9th of September in 2012</div>
      <div id="p0792" num="0792" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0793" num="0793" class="description-paragraph style-scope patent-text">Kuziel W.A. et al., J.Invest.Dermatol. [dermatological studies magazine] 94 (6 supplementary issue), 27S-32S
(1990)</div>
      <div id="p0794" num="0794" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0795" num="0795" class="description-paragraph style-scope patent-text">Official signs: IL2RA</div>
      <div id="p0796" num="0796" class="description-paragraph style-scope patent-text">Other alias: RP11-536K7.1, CD25, IDDM10, IL2R, TCGFR</div>
      <div id="p0797" num="0797" class="description-paragraph style-scope patent-text">Other titles: FIL-2 receptor subunit IL-2-RAIL-2R subunit IL2-RATAC antigenProleulzin by
Body subunit p55</div>
      <div id="p0798" num="0798" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0799" num="0799" class="description-paragraph style-scope patent-text">(the Novartis Co., Ltd/University College London (UCL): basiliximab (Baxilisimab) of US 6,383,487
[Simulect])</div>
      <div id="p0800" num="0800" class="description-paragraph style-scope patent-text">US 6,521,230 (Novartis Co., Ltd/University College London: basiliximab [Simulect])</div>
      <div id="p0801" num="0801" class="description-paragraph style-scope patent-text">For example, the antibody with antigen binding site includes at least one domain, which includes to have in SEQ.ID.NO:7
Amino acid sequence CDR1, the CDR2 with the amino acid sequence in SEQ.ID.NO:8 and with the ammonia in SEQ.ID.NO:9
The CDR3 of base acid sequenceOr sequence includes and sequence as a whole as a whole by described CDR1, CDR2 and CDR3
The identical amino acid sequence in SEQ.ID.NO:7,8 and 9 at least 90%.</div>
      <div id="p0802" num="0802" class="description-paragraph style-scope patent-text">Daclizumab (Daclizumab)-Rech AJ. et al., Ann N Y Acad Sci. [NY Academy of Sciences annual report]
In September, 20091174:99-106 (Roche Holding Ag)</div>
      <div id="p0803" num="0803" class="description-paragraph style-scope patent-text">(49) AXL (axl receptor tyrosine kinase)</div>
      <div id="p0804" num="0804" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0805" num="0805" class="description-paragraph style-scope patent-text">Genbank accession number M76125</div>
      <div id="p0806" num="0806" class="description-paragraph style-scope patent-text">Genbank version number M76125.1 GI:292869</div>
      <div id="p0807" num="0807" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:53</div>
      <div id="p0808" num="0808" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0809" num="0809" class="description-paragraph style-scope patent-text">Genbank accession number AAA61243</div>
      <div id="p0810" num="0810" class="description-paragraph style-scope patent-text">Genbank version number AAA61243.1 GI:29870</div>
      <div id="p0811" num="0811" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:53</div>
      <div id="p0812" num="0812" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0813" num="0813" class="description-paragraph style-scope patent-text">O'Bryan J.P. et al., Mol.Cell.Biol. [molecular cytobiology] 11 (10), 5016-5031
(1991)Bergsagel P.L. et al., J.Immunol. [Journal of Immunology] 148 (2), 590-596 (1992)</div>
      <div id="p0814" num="0814" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0815" num="0815" class="description-paragraph style-scope patent-text">Official signs: AXL</div>
      <div id="p0816" num="0816" class="description-paragraph style-scope patent-text">Other alias: JTK11, UFO</div>
      <div id="p0817" num="0817" class="description-paragraph style-scope patent-text">Other titles: AXL oncogeneAXL transforming sequence/geneOncogene AXLReceptor tyrosine kinases UFO</div>
      <div id="p0818" num="0818" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0819" num="0819" class="description-paragraph style-scope patent-text">YW327.6S2-Ye X. et al., Oncogene [oncogene] .2010 September 23rd29(38):5254-64.(base
Because of Imtech)</div>
      <div id="p0820" num="0820" class="description-paragraph style-scope patent-text">Bergen biopharmaceutical company (BergenBio): BGB324 (http://www.bergenbio.com/BGB324)</div>
      <div id="p0821" num="0821" class="description-paragraph style-scope patent-text">(50) CD30-TNFRSF8 (tumor necrosis factor receptor superfamily member 8)</div>
      <div id="p0822" num="0822" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0823" num="0823" class="description-paragraph style-scope patent-text">Genbank accession number M83554</div>
      <div id="p0824" num="0824" class="description-paragraph style-scope patent-text">Genbank version number M83554.1 GI:180095</div>
      <div id="p0825" num="0825" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:53</div>
      <div id="p0826" num="0826" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0827" num="0827" class="description-paragraph style-scope patent-text">Genbank accession number AAA51947</div>
      <div id="p0828" num="0828" class="description-paragraph style-scope patent-text">Genbank version number AAA51947.1 GI:180096</div>
      <div id="p0829" num="0829" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:53</div>
      <div id="p0830" num="0830" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0831" num="0831" class="description-paragraph style-scope patent-text">Durkop H. et al., Cell [cell] 68 (3), 421-427 (1992)</div>
      <div id="p0832" num="0832" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0833" num="0833" class="description-paragraph style-scope patent-text">Official signs: TNFRSF8</div>
      <div id="p0834" num="0834" class="description-paragraph style-scope patent-text">Other alias: CD30, D1S166E, Ki-1</div>
      <div id="p0835" num="0835" class="description-paragraph style-scope patent-text">Other titles: CD30L receptorKi-1 antigenCytokine Receptor CD30Lymphocyte activation antigens CD30It is swollen
Tumor necrosis factor receptor superfamily member 8</div>
      <div id="p0836" num="0836" class="description-paragraph style-scope patent-text">(51) BCMA (B cell maturation antigen)-TNFRSF17 (A member of the TNF receptor family 17)</div>
      <div id="p0837" num="0837" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0838" num="0838" class="description-paragraph style-scope patent-text">Genbank accession number Z29574</div>
      <div id="p0839" num="0839" class="description-paragraph style-scope patent-text">Genbank version number Z29574.1 GI:471244</div>
      <div id="p0840" num="0840" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:40</div>
      <div id="p0841" num="0841" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0842" num="0842" class="description-paragraph style-scope patent-text">Genbank accession number CAA82690</div>
      <div id="p0843" num="0843" class="description-paragraph style-scope patent-text">Genbank version number CAA82690.1 GI:471245</div>
      <div id="p0844" num="0844" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:40</div>
      <div id="p0845" num="0845" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0846" num="0846" class="description-paragraph style-scope patent-text">Laabi Y. et al., Nucleic Acids Res. [nucleic acids research] 22 (7), 1147-1154 (1994)</div>
      <div id="p0847" num="0847" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0848" num="0848" class="description-paragraph style-scope patent-text">Official signs: TNFRSF17</div>
      <div id="p0849" num="0849" class="description-paragraph style-scope patent-text">Other alias: BCM, BCMA, CD269</div>
      <div id="p0850" num="0850" class="description-paragraph style-scope patent-text">Other titles: B cell maturation antigenBcell maturation factorB cell maturation proteinTumor Necrosis Factor Receptors is super
Family member 17</div>
      <div id="p0851" num="0851" class="description-paragraph style-scope patent-text">(52) CT Ag-CTA (cancer testis antigen)</div>
      <div id="p0852" num="0852" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0853" num="0853" class="description-paragraph style-scope patent-text">Fratta E. et al. Mol Oncol. [molecular weight tumor] in April, 20115(2):164-82Lim SH. et al.,
Am J Blood Res. [United States blood research magazine] 20122(1):29-35.</div>
      <div id="p0854" num="0854" class="description-paragraph style-scope patent-text">(53) CD174 (Lewis Y)-FUT3 (fucosyltransferase 3 (galactoside 3 (4)-L-fucose group-transfer
Enzyme, Lewis blood group)</div>
      <div id="p0855" num="0855" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0856" num="0856" class="description-paragraph style-scope patent-text">Genbank accession number NM000149</div>
      <div id="p0857" num="0857" class="description-paragraph style-scope patent-text">Genbank version number NM000149.3 GI:148277008</div>
      <div id="p0858" num="0858" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 04:49</div>
      <div id="p0859" num="0859" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0860" num="0860" class="description-paragraph style-scope patent-text">Genbank accession number NP_000140</div>
      <div id="p0861" num="0861" class="description-paragraph style-scope patent-text">Genbank version number NP_000140.1 GI:4503809</div>
      <div id="p0862" num="0862" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 26th, 2012 04:49</div>
      <div id="p0863" num="0863" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0864" num="0864" class="description-paragraph style-scope patent-text">Kukowska-Latallo, J.F. et al., Genes Dev. [gene and development] 4 (8), 1288-1303 (1990)</div>
      <div id="p0865" num="0865" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0866" num="0866" class="description-paragraph style-scope patent-text">Official signs: FUT3</div>
      <div id="p0867" num="0867" class="description-paragraph style-scope patent-text">Other alias: CD174, FT3B, FucT-III, LE, Les</div>
      <div id="p0868" num="0868" class="description-paragraph style-scope patent-text">Other titles: Lewis FT-(1,3/1,4)-fucosyltransferaseLewis blood group  -4- fucosido turns
Move enzymeFucosyl transferase I IIGalactoside 3 (4)-L-fucose based transferase</div>
      <div id="p0869" num="0869" class="description-paragraph style-scope patent-text">(54) CLEC14A (14 member A of c-type lectin domain familyGenbank accession number NM175060)</div>
      <div id="p0870" num="0870" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0871" num="0871" class="description-paragraph style-scope patent-text">Genbank accession number NM175060</div>
      <div id="p0872" num="0872" class="description-paragraph style-scope patent-text">Genbank version number NM175060.2 GI:371123930</div>
      <div id="p0873" num="0873" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on April 1st, 2012 03:34</div>
      <div id="p0874" num="0874" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0875" num="0875" class="description-paragraph style-scope patent-text">Genbank accession number NP_778230</div>
      <div id="p0876" num="0876" class="description-paragraph style-scope patent-text">Genbank version number NP_778230.1 GI:28269707</div>
      <div id="p0877" num="0877" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on April 1st, 2012 03:34</div>
      <div id="p0878" num="0878" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0879" num="0879" class="description-paragraph style-scope patent-text">Official signs: CLEC14A</div>
      <div id="p0880" num="0880" class="description-paragraph style-scope patent-text">Other alias: UNQ236/PRO269, C14orf27, CEG1, EGFR-5</div>
      <div id="p0881" num="0881" class="description-paragraph style-scope patent-text">Other titles: 14 member A of c-type lectin domain familyAlbumen containing ClECT and EGF sample domainEpidermal growth factor
Receptor 5</div>
      <div id="p0882" num="0882" class="description-paragraph style-scope patent-text">(55) GRP78-HSPA5 (heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa)</div>
      <div id="p0883" num="0883" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0884" num="0884" class="description-paragraph style-scope patent-text">Genbank accession number NM005347</div>
      <div id="p0885" num="0885" class="description-paragraph style-scope patent-text">Genbank version number NM005347.4 GI:305855105</div>
      <div id="p0886" num="0886" class="description-paragraph style-scope patent-text">Genbank records update date: 01:42 afternoon on the 30th of September in 2012</div>
      <div id="p0887" num="0887" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0888" num="0888" class="description-paragraph style-scope patent-text">Genbank accession number NP_005338</div>
      <div id="p0889" num="0889" class="description-paragraph style-scope patent-text">Genbank version number NP_005338.1 GI:16507237</div>
      <div id="p0890" num="0890" class="description-paragraph style-scope patent-text">Genbank records update date: 01:42 afternoon on the 30th of September in 2012</div>
      <div id="p0891" num="0891" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0892" num="0892" class="description-paragraph style-scope patent-text">Ting J. et al., DNA 7 (4), 275-286 (1988)</div>
      <div id="p0893" num="0893" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0894" num="0894" class="description-paragraph style-scope patent-text">Official signs: HSPA5</div>
      <div id="p0895" num="0895" class="description-paragraph style-scope patent-text">Other alias: BIP, GRP78, MIF2</div>
      <div id="p0896" num="0896" class="description-paragraph style-scope patent-text">Other titles: 78kDa glucose-regulated proteinEndoplasmic Ca (2+) binding protein grp78Immunoglobulin weight
Chain binding protein</div>
      <div id="p0897" num="0897" class="description-paragraph style-scope patent-text">(56) CD70 (CD70 molecule) L08096</div>
      <div id="p0898" num="0898" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0899" num="0899" class="description-paragraph style-scope patent-text">Genbank accession number L08096</div>
      <div id="p0900" num="0900" class="description-paragraph style-scope patent-text">Genbank version number L08096.1 GI:307127</div>
      <div id="p0901" num="0901" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2012 morning 08:54</div>
      <div id="p0902" num="0902" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0903" num="0903" class="description-paragraph style-scope patent-text">Genbank accession number AAA36175</div>
      <div id="p0904" num="0904" class="description-paragraph style-scope patent-text">Genbank version number AAA36175.1 GI:307128</div>
      <div id="p0905" num="0905" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2012 morning 08:54</div>
      <div id="p0906" num="0906" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0907" num="0907" class="description-paragraph style-scope patent-text">Goodwin R.G. et al., Cell [cell] 73 (3), 447-456 (1993)</div>
      <div id="p0908" num="0908" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0909" num="0909" class="description-paragraph style-scope patent-text">Official signs: CD70</div>
      <div id="p0910" num="0910" class="description-paragraph style-scope patent-text">Other alias: CD27L, CD27LG, TNFSF7</div>
      <div id="p0911" num="0911" class="description-paragraph style-scope patent-text">Other titles: CD27 ligandCD27-LCD70 antigenKi-24 antigenSurface antigen CD70Tumor necrosis factor
(ligand) superfamily member 7Tumor necrosis factor ligand superfamily member 7</div>
      <div id="p0912" num="0912" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0913" num="0913" class="description-paragraph style-scope patent-text">For the MDX-1411 (plum Drakens company) of CD70</div>
      <div id="p0914" num="0914" class="description-paragraph style-scope patent-text">H1F6 (Oflazoglu, E. et al., Clin Cancer Res. [cancer research] on October 1st, 200814(19):
6171-80Seattle Genetics Inc.)</div>
      <div id="p0915" num="0915" class="description-paragraph style-scope patent-text">For example, with reference to US 20060083736 SEQ ID NO:1,2,11 and 12 and Fig. 1.</div>
      <div id="p0916" num="0916" class="description-paragraph style-scope patent-text">(57) stem cell specific antigen.</div>
      <div id="p0917" num="0917" class="description-paragraph style-scope patent-text">Such as:</div>
      <div id="p0918" num="0918" class="description-paragraph style-scope patent-text">5T4 (see below entry (63))</div>
      <div id="p0919" num="0919" class="description-paragraph style-scope patent-text">CD25 (sees above entry (48))</div>
      <div id="p0920" num="0920" class="description-paragraph style-scope patent-text">CD32</div>
      <div id="p0921" num="0921" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0922" num="0922" class="description-paragraph style-scope patent-text">Genbank accession number ABK42161</div>
      <div id="p0923" num="0923" class="description-paragraph style-scope patent-text">Genbank version number ABK42161.1 GI:117616286</div>
      <div id="p0924" num="0924" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 25th, 2007 03:00</div>
      <div id="p0925" num="0925" class="description-paragraph style-scope patent-text">LGR5/GPR49</div>
      <div id="p0926" num="0926" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0927" num="0927" class="description-paragraph style-scope patent-text">Genbank accession number NM_003667</div>
      <div id="p0928" num="0928" class="description-paragraph style-scope patent-text">Genbank version number NM_003667.2 GI:24475886</div>
      <div id="p0929" num="0929" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 22nd, 2012 03:38</div>
      <div id="p0930" num="0930" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0931" num="0931" class="description-paragraph style-scope patent-text">Genbank accession number NP_003658</div>
      <div id="p0932" num="0932" class="description-paragraph style-scope patent-text">Genbank version number NP_003658.1 GI:4504379</div>
      <div id="p0933" num="0933" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 22nd, 2012 03:38</div>
      <div id="p0934" num="0934" class="description-paragraph style-scope patent-text">Prominin/CD133</div>
      <div id="p0935" num="0935" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0936" num="0936" class="description-paragraph style-scope patent-text">Genbank accession number NM_006017</div>
      <div id="p0937" num="0937" class="description-paragraph style-scope patent-text">Genbank version number NM_006017.2 GI:224994187</div>
      <div id="p0938" num="0938" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p0939" num="0939" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0940" num="0940" class="description-paragraph style-scope patent-text">Genbank accession number NP_006008</div>
      <div id="p0941" num="0941" class="description-paragraph style-scope patent-text">Genbank version number NP_006008.1 GI:5174387</div>
      <div id="p0942" num="0942" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p0943" num="0943" class="description-paragraph style-scope patent-text">(58)ASG-5</div>
      <div id="p0944" num="0944" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0945" num="0945" class="description-paragraph style-scope patent-text">(Smith L.M. et al., AACR 2010Annual Meeting [AACR annual meeting in 2010] (digest #2590)
Gudas J.M. et al. AACR 2010Annual Meeting [AACR annual meeting in 2010] (digest #4393)</div>
      <div id="p0946" num="0946" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p0947" num="0947" class="description-paragraph style-scope patent-text">Anti- AGS-5 antibody: M6.131 (Smith, L.M. et al., AACR 2010Annual Meeting [AACR 2010 years
Annual meeting] (digest #2590)</div>
      <div id="p0948" num="0948" class="description-paragraph style-scope patent-text">(59) ENPP3 (extracellular nucleotides pyrophosphatase/phosphodiesterase 3)</div>
      <div id="p0949" num="0949" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0950" num="0950" class="description-paragraph style-scope patent-text">Genbank accession number AF005632</div>
      <div id="p0951" num="0951" class="description-paragraph style-scope patent-text">Genbank version number AF005632.2 GI:4432589</div>
      <div id="p0952" num="0952" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 09:41</div>
      <div id="p0953" num="0953" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0954" num="0954" class="description-paragraph style-scope patent-text">Genbank accession number AAC51813</div>
      <div id="p0955" num="0955" class="description-paragraph style-scope patent-text">Genbank version number AAC51813.1 GI:2465540</div>
      <div id="p0956" num="0956" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 09:41</div>
      <div id="p0957" num="0957" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0958" num="0958" class="description-paragraph style-scope patent-text">Jin-HuaP. et al., Genomics [genomics] 45 (2), 412-415 (1997)</div>
      <div id="p0959" num="0959" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0960" num="0960" class="description-paragraph style-scope patent-text">Official signs: ENPP3</div>
      <div id="p0961" num="0961" class="description-paragraph style-scope patent-text">Other alias: RP5-988G15.3, B10, CD203c, NPP3, PD-I , PDNP3</div>
      <div id="p0962" num="0962" class="description-paragraph style-scope patent-text">Other titles: E-NPP 3DJ1005H11.3 (phosphodiesterase I/ nuotide pyrophosphatase 3)dJ914N13.3
(phosphodiesterase I/ nuotide pyrophosphatase 3)Extracellular nucleotides pyrophosphatase/phosphodiesterase family member 3gp130RB13-
6Phosphodiesterase I Phosphodiesterase I/ nuotide pyrophosphatase 3Phosphodiesterase-I </div>
      <div id="p0963" num="0963" class="description-paragraph style-scope patent-text">(60) PRR4 (Pro-rich 4 (tears))</div>
      <div id="p0964" num="0964" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0965" num="0965" class="description-paragraph style-scope patent-text">Genbank accession number NM_007244</div>
      <div id="p0966" num="0966" class="description-paragraph style-scope patent-text">Genbank version number NM_007244.2 GI:154448885</div>
      <div id="p0967" num="0967" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 28th, 2012 12:39</div>
      <div id="p0968" num="0968" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0969" num="0969" class="description-paragraph style-scope patent-text">Genbank accession number NP_009175</div>
      <div id="p0970" num="0970" class="description-paragraph style-scope patent-text">Genbank version number NP_009175.2 GI:154448886</div>
      <div id="p0971" num="0971" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 28th, 2012 12:39</div>
      <div id="p0972" num="0972" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0973" num="0973" class="description-paragraph style-scope patent-text">Dickinson D.P. et al., Invest.Ophthalmol.Vis.Sci. [ophthalmology research and eyesight] 36
(10),2020-2031(1995)</div>
      <div id="p0974" num="0974" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0975" num="0975" class="description-paragraph style-scope patent-text">Official signs: PRR4</div>
      <div id="p0976" num="0976" class="description-paragraph style-scope patent-text">Other alias: LPRP, PROL4</div>
      <div id="p0977" num="0977" class="description-paragraph style-scope patent-text">Other titles: Pro-rich dacryolinThe albumen 4 of the relevant Pro-rich of nasopharyngeal carcinomaPro-rich
Polypeptide 4The albumen 4 of Pro-rich</div>
      <div id="p0978" num="0978" class="description-paragraph style-scope patent-text">(61) GCC-GUCY2C (guanylate cyclase 2C (heat-staple enterotoxin receptor)</div>
      <div id="p0979" num="0979" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0980" num="0980" class="description-paragraph style-scope patent-text">Genbank accession number NM_004963</div>
      <div id="p0981" num="0981" class="description-paragraph style-scope patent-text">Genbank version number NM_004963.3 GI:222080082</div>
      <div id="p0982" num="0982" class="description-paragraph style-scope patent-text">Genbank records update date: 01:50 afternoon on the 2nd of September in 2012</div>
      <div id="p0983" num="0983" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0984" num="0984" class="description-paragraph style-scope patent-text">Genbank accession number NP_004954</div>
      <div id="p0985" num="0985" class="description-paragraph style-scope patent-text">Genbank version number NP_004954.2 GI:222080083</div>
      <div id="p0986" num="0986" class="description-paragraph style-scope patent-text">Genbank records update date: 01:50 afternoon on the 2nd of September in 2012</div>
      <div id="p0987" num="0987" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p0988" num="0988" class="description-paragraph style-scope patent-text">De Sauvage F.J. et al., J.Biol.Chem. [journal of biological chemistry] 266 (27), 17912-17918
(1991)Singh S. et al., Biochem.Biophys.Res.Commun. [biochemistry and biophysical research communication]
179(3),1455-1463(1991)</div>
      <div id="p0989" num="0989" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p0990" num="0990" class="description-paragraph style-scope patent-text">Official signs: GUCY2C:</div>
      <div id="p0991" num="0991" class="description-paragraph style-scope patent-text">Other alias: DIAR6, GUC2C, MUCIL, STAR</div>
      <div id="p0992" num="0992" class="description-paragraph style-scope patent-text">Other titles: GC-CSTA receptorGuanylyl cyclase-ChSTARHeat-staple enterotoxin receptorIntestines guanylic acid
Cyclase</div>
      <div id="p0993" num="0993" class="description-paragraph style-scope patent-text">(62) Liv-1-SLC39A6 (sapiens's Solute Carrier family 39 (Zinc transporter) member 6)</div>
      <div id="p0994" num="0994" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p0995" num="0995" class="description-paragraph style-scope patent-text">Genbank accession number U41060</div>
      <div id="p0996" num="0996" class="description-paragraph style-scope patent-text">Genbank version number U41060.2 GI:12711792</div>
      <div id="p0997" num="0997" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on November 30th, 2009 04:35</div>
      <div id="p0998" num="0998" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p0999" num="0999" class="description-paragraph style-scope patent-text">Genbank accession number AAA96258</div>
      <div id="p1000" num="1000" class="description-paragraph style-scope patent-text">Genbank version number AAA96258.2 GI:12711793</div>
      <div id="p1001" num="1001" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on November 30th, 2009 04:35</div>
      <div id="p1002" num="1002" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1003" num="1003" class="description-paragraph style-scope patent-text">Taylor KM. et al., Biochim Biophys Acta. [Acta Biochimica et Biophysica Sinica] in April, 2003
1 day1611(1-2):16-30</div>
      <div id="p1004" num="1004" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1005" num="1005" class="description-paragraph style-scope patent-text">Official signs: SLC39A6</div>
      <div id="p1006" num="1006" class="description-paragraph style-scope patent-text">Other alias: LIV-1</div>
      <div id="p1007" num="1007" class="description-paragraph style-scope patent-text">Other titles: LIV-1 albumen (estrogen regulation)ZIP-6Estrogen modulin LIV-1Sapiens's Solute Carrier family
39 (metal-ions transportation albumen) members 639 member 6 of sapiens's Solute Carrier familyZinc transporter ZIP6Zrt and Irt sample albumen 6</div>
      <div id="p1008" num="1008" class="description-paragraph style-scope patent-text">(63) 5T4, trophocyte's glycoprotein, TPBG-TPBG (trophocyte's glycoprotein)</div>
      <div id="p1009" num="1009" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1010" num="1010" class="description-paragraph style-scope patent-text">Genbank accession number AJ012159</div>
      <div id="p1011" num="1011" class="description-paragraph style-scope patent-text">Genbank version number AJ012159.1 GI:3805946</div>
      <div id="p1012" num="1012" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 1st, 2011 morning 10:27</div>
      <div id="p1013" num="1013" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1014" num="1014" class="description-paragraph style-scope patent-text">Genbank accession number CAA09930</div>
      <div id="p1015" num="1015" class="description-paragraph style-scope patent-text">Genbank version number CAA09930.1 GI:3805947</div>
      <div id="p1016" num="1016" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 1st, 2011 morning 10:27</div>
      <div id="p1017" num="1017" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1018" num="1018" class="description-paragraph style-scope patent-text">King K.W. et al., Biochim.Biophys.Acta [Acta Biochimica et Biophysica Sinica] 1445 (3),
257-270(1999)</div>
      <div id="p1019" num="1019" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1020" num="1020" class="description-paragraph style-scope patent-text">Official signs: TPBG</div>
      <div id="p1021" num="1021" class="description-paragraph style-scope patent-text">Other alias: 5T4,5T4AG, M6P1</div>
      <div id="p1022" num="1022" class="description-paragraph style-scope patent-text">Other titles: 5T4 carcinomebryonic antigen5T4 cancer embryo trophocyte's glycoprotein5T4 cancer trophocyte's glycoprotein</div>
      <div id="p1023" num="1023" class="description-paragraph style-scope patent-text">Referring to WO 2015/155345</div>
      <div id="p1024" num="1024" class="description-paragraph style-scope patent-text">(64) CD56-NCMA1 (N-CAM 1)</div>
      <div id="p1025" num="1025" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1026" num="1026" class="description-paragraph style-scope patent-text">Genbank accession number NM_000615</div>
      <div id="p1027" num="1027" class="description-paragraph style-scope patent-text">Genbank version number NM_000615.6 GI:336285433</div>
      <div id="p1028" num="1028" class="description-paragraph style-scope patent-text">Genbank records update date: 02:32 afternoon on the 23rd of September in 2012</div>
      <div id="p1029" num="1029" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1030" num="1030" class="description-paragraph style-scope patent-text">Genbank accession number NP_000606</div>
      <div id="p1031" num="1031" class="description-paragraph style-scope patent-text">Genbank version number NP_000606.3 GI:94420689</div>
      <div id="p1032" num="1032" class="description-paragraph style-scope patent-text">Genbank records update date: 02:32 afternoon on the 23rd of September in 2012</div>
      <div id="p1033" num="1033" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1034" num="1034" class="description-paragraph style-scope patent-text">Dickson, G. et al., Cell [cell] 50 (7), 1119-1130 (1987)</div>
      <div id="p1035" num="1035" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1036" num="1036" class="description-paragraph style-scope patent-text">Official signs: NCAM1</div>
      <div id="p1037" num="1037" class="description-paragraph style-scope patent-text">Other alias: CD56, MSK39, NCAM</div>
      <div id="p1038" num="1038" class="description-paragraph style-scope patent-text">Other titles: the antigen of monoclonal antibody 5.1H11 identificationN-CAM (NCAM)</div>
      <div id="p1039" num="1039" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1040" num="1040" class="description-paragraph style-scope patent-text">Immunogen Inc.: HuN901 (Smith SV. et al., Curr Opin Mol Ther. [comment of the molecular therapy present age]
In August, 20057(4):394-401)</div>
      <div id="p1041" num="1041" class="description-paragraph style-scope patent-text">For example, with reference to from mouse N901 antibody humanization.Referring to Roguska, M.A. et al. Proc Natl Acad Sci
USA [National Academy of Sciences proceeding] 2 months 1994Fig. 1 b and Fig. 1 e of 91:969-973.</div>
      <div id="p1042" num="1042" class="description-paragraph style-scope patent-text">(65) CanAg (tumor associated antigen CA242)</div>
      <div id="p1043" num="1043" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1044" num="1044" class="description-paragraph style-scope patent-text">Haglund C. et al., Br J Cancer [British Journal of Cancer] 60:845-851,1989Baeckstrom D.
Et al., J Biol Chem [journal of biological chemistry] 266:21537-21547,1991</div>
      <div id="p1045" num="1045" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1046" num="1046" class="description-paragraph style-scope patent-text">HuC242 (Tolcher AW et al., J Clin Oncol. [Journal of Clinical Oncology] on January 15th, 200321
(2):211-22Immunogen Inc.)</div>
      <div id="p1047" num="1047" class="description-paragraph style-scope patent-text">For example, with reference to US 20080138898A1 SEQ ID NO:1 and 2</div>
      <div id="p1048" num="1048" class="description-paragraph style-scope patent-text">(66) FOLR1 (folacin receptor 1)</div>
      <div id="p1049" num="1049" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1050" num="1050" class="description-paragraph style-scope patent-text">Genbank accession number J05013</div>
      <div id="p1051" num="1051" class="description-paragraph style-scope patent-text">Genbank version number J05013.1 GI:182417</div>
      <div id="p1052" num="1052" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p1053" num="1053" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1054" num="1054" class="description-paragraph style-scope patent-text">Genbank accession number AAA35823</div>
      <div id="p1055" num="1055" class="description-paragraph style-scope patent-text">Genbank version number AAA35823.1 GI:182418</div>
      <div id="p1056" num="1056" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:47</div>
      <div id="p1057" num="1057" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1058" num="1058" class="description-paragraph style-scope patent-text">Elwood P.C. et al., J.Biol.Chem. [journal of biological chemistry] 264 (25), 14893-14901 (1989)</div>
      <div id="p1059" num="1059" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1060" num="1060" class="description-paragraph style-scope patent-text">Official signs: FOLR1</div>
      <div id="p1061" num="1061" class="description-paragraph style-scope patent-text">Other alias: FBP, FOLR</div>
      <div id="p1062" num="1062" class="description-paragraph style-scope patent-text">Other titles: FR- KB cell FBPAdult folate binding proteinFolate binding proteinFolacin receptor Folic acid
Receptor, adultOvarian neoplasm related antigen MOv18</div>
      <div id="p1063" num="1063" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1064" num="1064" class="description-paragraph style-scope patent-text">M9346A-Whiteman KR. et al., Cancer Res [cancer research] on April 15th, 201272 (8 supplementary issues<span class="patent-image-not-available style-scope patent-text"></span>):
4628 (Immunogen Inc.)</div>
      <div id="p1065" num="1065" class="description-paragraph style-scope patent-text">(67) GPNMB (glycoprotein (cross-film) nmb)</div>
      <div id="p1066" num="1066" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1067" num="1067" class="description-paragraph style-scope patent-text">Genbank accession number X76534</div>
      <div id="p1068" num="1068" class="description-paragraph style-scope patent-text">Genbank version number X76534.1 GI:666042</div>
      <div id="p1069" num="1069" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:10</div>
      <div id="p1070" num="1070" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1071" num="1071" class="description-paragraph style-scope patent-text">Genbank accession number CAA54044</div>
      <div id="p1072" num="1072" class="description-paragraph style-scope patent-text">Genbank version number CAA54044.1 GI:666043</div>
      <div id="p1073" num="1073" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:10</div>
      <div id="p1074" num="1074" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1075" num="1075" class="description-paragraph style-scope patent-text">Weterman M.A. et al., Int.J.Cancer [international cancer periodical] 60 (1), 73-81 (1995)</div>
      <div id="p1076" num="1076" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1077" num="1077" class="description-paragraph style-scope patent-text">Official signs: GPNMB</div>
      <div id="p1078" num="1078" class="description-paragraph style-scope patent-text">Other alias: UNQ1725/PRO9925, HGFIN, NMB</div>
      <div id="p1079" num="1079" class="description-paragraph style-scope patent-text">Other titles: glycoprotein NMBGlycoprotein nmb sample albumenBone cerebroysin (osteoactivin)Transmembrane glycoprotein
HGFINTransmembrane glycoprotein NMB</div>
      <div id="p1080" num="1080" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1081" num="1081" class="description-paragraph style-scope patent-text">Sai Desi medical company (Celldex Therapeutics): CR011 (Tse KF. et al., Clin Cancer
Res. [Clinical Cancer Research] 2 months 2006 1512(4):1373-82)</div>
      <div id="p1082" num="1082" class="description-paragraph style-scope patent-text">For example, with reference to EP 1827492B1 SEQ ID NO:22,24,26,31,33 and 35</div>
      <div id="p1083" num="1083" class="description-paragraph style-scope patent-text">(68) TIM-1-HAVCR1 (hepatitis A virus cell receptor 1)</div>
      <div id="p1084" num="1084" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1085" num="1085" class="description-paragraph style-scope patent-text">Genbank accession number AF043724</div>
      <div id="p1086" num="1086" class="description-paragraph style-scope patent-text">Genbank version number AF043724.1 GI:2827453</div>
      <div id="p1087" num="1087" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 06:24</div>
      <div id="p1088" num="1088" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1089" num="1089" class="description-paragraph style-scope patent-text">Genbank accession number AAC39862</div>
      <div id="p1090" num="1090" class="description-paragraph style-scope patent-text">Genbank version number AAC39862.1 GI:2827454</div>
      <div id="p1091" num="1091" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 06:24</div>
      <div id="p1092" num="1092" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1093" num="1093" class="description-paragraph style-scope patent-text">FeigelstockD. et al., J.Virol. [Journal of Virology] 72 (8), 6621-6628 (1998)</div>
      <div id="p1094" num="1094" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1095" num="1095" class="description-paragraph style-scope patent-text">Official signs: HAVCR1</div>
      <div id="p1096" num="1096" class="description-paragraph style-scope patent-text">Other alias: HAVCR, HAVCR-1, KIM-1, KIM1, TIM, TIM-1, TIM1, TIMD-1, TIMD1</div>
      <div id="p1097" num="1097" class="description-paragraph style-scope patent-text">Other titles: T cell immunoglobulin domain and mucoprotein domain albumen 1T cell Membrane Protein 1Kidney injury molecule-1</div>
      <div id="p1098" num="1098" class="description-paragraph style-scope patent-text">(69) RG-1/ tumor of prostate target Mindin-Mindin/RG-1</div>
      <div id="p1099" num="1099" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1100" num="1100" class="description-paragraph style-scope patent-text">Parry R. et al., CancerRes. [cancer research] on September 15th, 200565(18):8397-405</div>
      <div id="p1101" num="1101" class="description-paragraph style-scope patent-text">(70) B7-H4-VTCN1 (the t cell activation inhibitor 1 in the domain containing V-set</div>
      <div id="p1102" num="1102" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1103" num="1103" class="description-paragraph style-scope patent-text">Genbank accession number BX648021</div>
      <div id="p1104" num="1104" class="description-paragraph style-scope patent-text">Genbank version number BX648021.1 GI:34367180</div>
      <div id="p1105" num="1105" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 08:40</div>
      <div id="p1106" num="1106" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1107" num="1107" class="description-paragraph style-scope patent-text">Sica GL. et al., Immunity. [immune] in June, 200318(6):849-61</div>
      <div id="p1108" num="1108" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1109" num="1109" class="description-paragraph style-scope patent-text">Official signs: VTCN1</div>
      <div id="p1110" num="1110" class="description-paragraph style-scope patent-text">Other alias: RP11-229A19.4, B7-H4, B7H4, B7S1, B7X, B7h.5, PRO1291, VCTN1</div>
      <div id="p1111" num="1111" class="description-paragraph style-scope patent-text">Other titles: B7 family member, H4B7 superfamily member 1T cell costimulatory molecules B7xT- cell co-stimulatory
Molecule B7xThe t cell activation inhibitor 1 in the domain containing V-setImmune costimulation protein B 7-H4</div>
      <div id="p1112" num="1112" class="description-paragraph style-scope patent-text">(71) PTK7 (PTK7 protein tyrosine kinase 7)</div>
      <div id="p1113" num="1113" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1114" num="1114" class="description-paragraph style-scope patent-text">Genbank accession number AF447176</div>
      <div id="p1115" num="1115" class="description-paragraph style-scope patent-text">Genbank version number AF447176.1 GI:17432420</div>
      <div id="p1116" num="1116" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on November 28th, 2008 01:51</div>
      <div id="p1117" num="1117" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1118" num="1118" class="description-paragraph style-scope patent-text">Genbank accession number AAL39062</div>
      <div id="p1119" num="1119" class="description-paragraph style-scope patent-text">Genbank version number AAL39062.1 GI:17432421</div>
      <div id="p1120" num="1120" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on November 28th, 2008 01:51</div>
      <div id="p1121" num="1121" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1122" num="1122" class="description-paragraph style-scope patent-text">Park S.K. et al. J.Biochem. [journal of biological chemistry] 119 (2), 235-239 (1996)</div>
      <div id="p1123" num="1123" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1124" num="1124" class="description-paragraph style-scope patent-text">Official signs: PTK7</div>
      <div id="p1125" num="1125" class="description-paragraph style-scope patent-text">Other alias: CCK-4, CCK4</div>
      <div id="p1126" num="1126" class="description-paragraph style-scope patent-text">Other titles: colon cancer kinases 4Inactive tyrosine protein kinase 7False tyrosine kinase receptor 7Tyrosine egg
White kinases sample 7</div>
      <div id="p1127" num="1127" class="description-paragraph style-scope patent-text">(72) CD37 (CD37 molecule)</div>
      <div id="p1128" num="1128" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1129" num="1129" class="description-paragraph style-scope patent-text">Genbank accession number NM_001040031</div>
      <div id="p1130" num="1130" class="description-paragraph style-scope patent-text">Genbank version number NM_001040031.1 GI:91807109</div>
      <div id="p1131" num="1131" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 29th, 2012 02:08</div>
      <div id="p1132" num="1132" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1133" num="1133" class="description-paragraph style-scope patent-text">Genbank accession number NP_001035120</div>
      <div id="p1134" num="1134" class="description-paragraph style-scope patent-text">Genbank version number NP_001035120.1 GI:91807110</div>
      <div id="p1135" num="1135" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on July 29th, 2012 02:08</div>
      <div id="p1136" num="1136" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1137" num="1137" class="description-paragraph style-scope patent-text">Schwartz-Albiez R. et al., J.Immunol. [Journal of Immunology] 140 (3), 905-914 (1988)</div>
      <div id="p1138" num="1138" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1139" num="1139" class="description-paragraph style-scope patent-text">Official signs: CD37</div>
      <div id="p1140" num="1140" class="description-paragraph style-scope patent-text">Other alias: GP52-40, TSPAN26</div>
      <div id="p1141" num="1141" class="description-paragraph style-scope patent-text">Other titles: CD37 antigenCell differentiation antigen 37Leukocyte antigen CD37Swine lymphocyte antigen CD37Four
Secondary transmembrane protein -26tspan-26</div>
      <div id="p1142" num="1142" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1143" num="1143" class="description-paragraph style-scope patent-text">Boehringer Ingelheim company (Boehringer Ingelheim): mAb 37.1 (HeiderKH. et al., Blood
[blood] .2011 October 13118(15):4159-68)</div>
      <div id="p1144" num="1144" class="description-paragraph style-scope patent-text">Trubion:CD37-SMIP (G28-1scFv-Ig) ((Zhao X. et al., Blood [blood] .2007110:
2569-2577)</div>
      <div id="p1145" num="1145" class="description-paragraph style-scope patent-text">For example, with reference to US 20110171208A1 SEQ ID NO:253</div>
      <div id="p1146" num="1146" class="description-paragraph style-scope patent-text">Immunogen Inc.: K7153A (Deckert J. et al., CancerRes [cancer research] on April 15th, 201272
(8 supplementary issue): 4625)</div>
      <div id="p1147" num="1147" class="description-paragraph style-scope patent-text">(73) CD138-SDC1 (syndecan 1)</div>
      <div id="p1148" num="1148" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1149" num="1149" class="description-paragraph style-scope patent-text">Genbank accession number AJ551176</div>
      <div id="p1150" num="1150" class="description-paragraph style-scope patent-text">Genbank version number AJ551176.1 GI:29243141</div>
      <div id="p1151" num="1151" class="description-paragraph style-scope patent-text">Genbank record update date: 2 months 1 afternoons in 2011 12:09</div>
      <div id="p1152" num="1152" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1153" num="1153" class="description-paragraph style-scope patent-text">Genbank accession number CAD80245</div>
      <div id="p1154" num="1154" class="description-paragraph style-scope patent-text">Genbank version number CAD80245.1 GI:29243142</div>
      <div id="p1155" num="1155" class="description-paragraph style-scope patent-text">Genbank record update date: 2 months 1 afternoons in 2011 12:09</div>
      <div id="p1156" num="1156" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1157" num="1157" class="description-paragraph style-scope patent-text">O'Connell FP. et al., Am J Clin Pathol. [U.S. clinical pathology magazine] 2 months 2004121
(2):254-63</div>
      <div id="p1158" num="1158" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1159" num="1159" class="description-paragraph style-scope patent-text">Official signs: SDC1</div>
      <div id="p1160" num="1160" class="description-paragraph style-scope patent-text">Other alias: CD138, SDC, SYND1, syndecan</div>
      <div id="p1161" num="1161" class="description-paragraph style-scope patent-text">Other titles: CD138 antigenHeparan sulfate proteoglycan fibroblast growth factor acceptorMultiple ligand
Proteoglycans 1Syndecan -1</div>
      <div id="p1162" num="1162" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1163" num="1163" class="description-paragraph style-scope patent-text">Bioexperiment company (Biotest): chimeric MAb (nBT062)-(Jagannath S. et al., Poster ASH#
3060,2010WIPO patent application WO/2010/128087)</div>
      <div id="p1164" num="1164" class="description-paragraph style-scope patent-text">For example, with reference to US 20090232810 SEQ ID NO:1 and 2</div>
      <div id="p1165" num="1165" class="description-paragraph style-scope patent-text">Immunogen Inc.: B-B4 (Tassone P. et al., Blood [blood] 104_3688-3696)</div>
      <div id="p1166" num="1166" class="description-paragraph style-scope patent-text">For example, with reference to US 20090175863A1 SEQ ID NO:1 and 2</div>
      <div id="p1167" num="1167" class="description-paragraph style-scope patent-text">(74) CD74 (CD74 molecule, major histocompatibility complex, II class invariant chain)</div>
      <div id="p1168" num="1168" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1169" num="1169" class="description-paragraph style-scope patent-text">Genbank accession number NM_004355</div>
      <div id="p1170" num="1170" class="description-paragraph style-scope patent-text">Genbank version number NM_004355.1 GI:343403784</div>
      <div id="p1171" num="1171" class="description-paragraph style-scope patent-text">Genbank records update date: 02:30 afternoon on the 23rd of September in 2012</div>
      <div id="p1172" num="1172" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1173" num="1173" class="description-paragraph style-scope patent-text">Genbank accession number NP_004346</div>
      <div id="p1174" num="1174" class="description-paragraph style-scope patent-text">Genbank version number NP_004346.1 GI:10835071</div>
      <div id="p1175" num="1175" class="description-paragraph style-scope patent-text">Genbank records update date: 02:30 afternoon on the 23rd of September in 2012</div>
      <div id="p1176" num="1176" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1177" num="1177" class="description-paragraph style-scope patent-text">Kudo, J. et al., Nucleic Acids Res. [nucleic acids research] 13 (24), 8827-8841 (1985)</div>
      <div id="p1178" num="1178" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1179" num="1179" class="description-paragraph style-scope patent-text">Official signs: CD74</div>
      <div id="p1180" num="1180" class="description-paragraph style-scope patent-text">Other alias: DHLAG, HLADG, II, Ia- </div>
      <div id="p1181" num="1181" class="description-paragraph style-scope patent-text">Other titles: CD74 antigen (the constant polypeptide of major histocompatibility complex, II class antigen are related)HLA II
Class loading compatibility antigen  chainHLA-DR antigen correlation invariant chainHLA-DR-Ia correlation invariant chainMHC HLA-DR
ChainThe  chain of II class antigenp33</div>
      <div id="p1182" num="1182" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1183" num="1183" class="description-paragraph style-scope patent-text">Immune medicine company: hLL1 (matuzumab (Milatuzumab))-Berkova Z. et al., Expert Opin
Investig Drugs. [research drug comment of experts] in January, 201019(1):141-9)</div>
      <div id="p1184" num="1184" class="description-paragraph style-scope patent-text">For example, with reference to US 20040115193 SEQ ID NO:19,20,21,22,23 and 24</div>
      <div id="p1185" num="1185" class="description-paragraph style-scope patent-text">Genmab:HuMax-CD74 (referring to website)</div>
      <div id="p1186" num="1186" class="description-paragraph style-scope patent-text">(75) tight junction protein-CL (tight junction protein)</div>
      <div id="p1187" num="1187" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1188" num="1188" class="description-paragraph style-scope patent-text">Offner S. et al., Cancer Immunol Immunother. [Cancer Immunol and immunization therapy] 2005 5
Month54 (5): 431-45, Suzuki H. et al., Ann N Y Acad Sci. [NY Academy of Sciences annual report] in July, 2012
1258:65-70)</div>
      <div id="p1189" num="1189" class="description-paragraph style-scope patent-text">Have been described 24 members-of the family in the mankind referring to bibliography.</div>
      <div id="p1190" num="1190" class="description-paragraph style-scope patent-text">(76) EGFR (EGF-R ELISA)</div>
      <div id="p1191" num="1191" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1192" num="1192" class="description-paragraph style-scope patent-text">Genbank accession number NM_005228</div>
      <div id="p1193" num="1193" class="description-paragraph style-scope patent-text">Genbank version number NM_005228.3 GI:41927737</div>
      <div id="p1194" num="1194" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p1195" num="1195" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1196" num="1196" class="description-paragraph style-scope patent-text">Genbank accession number NP_005219</div>
      <div id="p1197" num="1197" class="description-paragraph style-scope patent-text">Genbank version number NP_005219.2 GI:29725609</div>
      <div id="p1198" num="1198" class="description-paragraph style-scope patent-text">Genbank records update date: 01:47 afternoon on the 30th of September in 2012</div>
      <div id="p1199" num="1199" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1200" num="1200" class="description-paragraph style-scope patent-text">DhomenNS. et al., Crit Rev Oncog. [comment summary occurs for tumour] 201217(1):31-50</div>
      <div id="p1201" num="1201" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1202" num="1202" class="description-paragraph style-scope patent-text">Official signs: EGFR</div>
      <div id="p1203" num="1203" class="description-paragraph style-scope patent-text">Other alias: ERBB, ERBB1, HER1, PIG61, mENA</div>
      <div id="p1204" num="1204" class="description-paragraph style-scope patent-text">Other titles: viral (v-erb-b) the oncogene homologue of birds into erythrocyte leukemiaCell growth arrestin
40Cell Proliferation inducible protein 61Proto-oncogene c-ErbB-1Receptor tyrosine protein kinase erbB-1</div>
      <div id="p1205" num="1205" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1206" num="1206" class="description-paragraph style-scope patent-text">BMS: Cetuximab (Cetuximab) (Erbitux)-Broadbridge VT. et al., Expert Rev
Anticancer Ther. [anticancer therapy comment of experts] in May, 201212(5):555-65.</div>
      <div id="p1207" num="1207" class="description-paragraph style-scope patent-text">For example, with reference to US 6217866-ATTC deposit number 9764.</div>
      <div id="p1208" num="1208" class="description-paragraph style-scope patent-text">(Amgen): Victibix (Panitumumab) (Vectibix)-Argiles G. et al., Future
Oncol. [future tumors] in April, 20128(4):373-89</div>
      <div id="p1209" num="1209" class="description-paragraph style-scope patent-text">For example, with reference to 6235883 SEQ ID NO:23-38 of US.</div>
      <div id="p1210" num="1210" class="description-paragraph style-scope patent-text">Genmab: Shandong wood monoclonal antibody (Zalutumumab)-Rivera F. et al., Expert Opin Biol Ther. are pricked
[biological therapy comment of experts] in May, 20099(5):667-74.</div>
      <div id="p1211" num="1211" class="description-paragraph style-scope patent-text">YM Bioscience Inc. (YM BioSciences): Buddhist nun's trastuzumab (Nimotuzumab)-Ramakrishnan
Et al., MS. MAb. [monoclonal antibody] -2 months in January, 20091(1):41-8.</div>
      <div id="p1212" num="1212" class="description-paragraph style-scope patent-text">For example, with reference to 5891996 SEQ ID NO:27-34 of US.</div>
      <div id="p1213" num="1213" class="description-paragraph style-scope patent-text">(77) Her3 (ErbB3)-ERBB3 (v-erb-b2 into erythrocyte leukemia viral oncogene homologue 3 (birds))</div>
      <div id="p1214" num="1214" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1215" num="1215" class="description-paragraph style-scope patent-text">Genbank accession number M34309</div>
      <div id="p1216" num="1216" class="description-paragraph style-scope patent-text">Genbank version number M34309.1 GI:183990</div>
      <div id="p1217" num="1217" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 23rd, 2010 08:47</div>
      <div id="p1218" num="1218" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1219" num="1219" class="description-paragraph style-scope patent-text">Genbank accession number AAA35979</div>
      <div id="p1220" num="1220" class="description-paragraph style-scope patent-text">Genbank version number AAA35979.1 GI:306841</div>
      <div id="p1221" num="1221" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on June 23rd, 2010 08:47</div>
      <div id="p1222" num="1222" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1223" num="1223" class="description-paragraph style-scope patent-text">Plowman, G.D. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 87 (13),
4905-4909(1990)</div>
      <div id="p1224" num="1224" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1225" num="1225" class="description-paragraph style-scope patent-text">Official signs: ERBB3</div>
      <div id="p1226" num="1226" class="description-paragraph style-scope patent-text">Other alias: ErbB-3, HER3, LCCS2, MDA-BF-1, c-erbB-3, c-erbB3, erbB3-S, p180-
ErbB3p45-sErbB3p85-sErbB3</div>
      <div id="p1227" num="1227" class="description-paragraph style-scope patent-text">Other titles: proto-oncogene sample albumen c-ErbB-3Receptor tyrosine protein kinase erbB-3Tyrosine kinase type
Cell surface receptor HER3</div>
      <div id="p1228" num="1228" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1229" num="1229" class="description-paragraph style-scope patent-text">Merrimac drugmaker (Merimack Pharma): MM-121 (Schoeberl B. et al., Cancer Res.
[cancer research] on March 15th, 201070(6):2485-2494)</div>
      <div id="p1230" num="1230" class="description-paragraph style-scope patent-text">For example, with reference to US 2011028129 SEQ ID NO:1,2,3,4,5,6,7 and 8.</div>
      <div id="p1231" num="1231" class="description-paragraph style-scope patent-text">(78) RON-MST1R (1 receptor of macrophage-stimulating (c-met related tyrosine kinases))</div>
      <div id="p1232" num="1232" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1233" num="1233" class="description-paragraph style-scope patent-text">Genbank accession number X70040</div>
      <div id="p1234" num="1234" class="description-paragraph style-scope patent-text">Genbank version number X70040.1 GI:36109</div>
      <div id="p1235" num="1235" class="description-paragraph style-scope patent-text">Genbank record update date: 2 months 2 afternoons in 2011 10:17</div>
      <div id="p1236" num="1236" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1237" num="1237" class="description-paragraph style-scope patent-text">Genbank accession number CCA49634</div>
      <div id="p1238" num="1238" class="description-paragraph style-scope patent-text">Genbank version number CCA49634.1 GI:36110</div>
      <div id="p1239" num="1239" class="description-paragraph style-scope patent-text">Genbank record update date: 2 months 2 afternoons in 2011 10:17</div>
      <div id="p1240" num="1240" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1241" num="1241" class="description-paragraph style-scope patent-text">Ronsin C. et al., Oncogene [oncogene] 8 (5), 1195-1202 (1993)</div>
      <div id="p1242" num="1242" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1243" num="1243" class="description-paragraph style-scope patent-text">Official signs: MST1R</div>
      <div id="p1244" num="1244" class="description-paragraph style-scope patent-text">Other alias: CD136, CDw136, PTK8, RON</div>
      <div id="p1245" num="1245" class="description-paragraph style-scope patent-text">Other titles: MSP receptorMST1R variant RON30MST1R variant RON62PTK8 protein tyrosine kinase 8
RON variant E2E3C-met related tyrosine kinasesMacrophage stimulating protein receptorp185-RonSoluble RON variant 1
Soluble RON variant 2Soluble RON variant 3Soluble RON variant 4</div>
      <div id="p1246" num="1246" class="description-paragraph style-scope patent-text">(79) EPHA2 (EPH receptor A2)</div>
      <div id="p1247" num="1247" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1248" num="1248" class="description-paragraph style-scope patent-text">Genbank accession number BC037166</div>
      <div id="p1249" num="1249" class="description-paragraph style-scope patent-text">Genbank version number BC037166.2 GI:33879863</div>
      <div id="p1250" num="1250" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 6th, 2012 01:59</div>
      <div id="p1251" num="1251" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1252" num="1252" class="description-paragraph style-scope patent-text">Genbank accession number AAH37166</div>
      <div id="p1253" num="1253" class="description-paragraph style-scope patent-text">Genbank version number AAH37166.1 GI:22713539</div>
      <div id="p1254" num="1254" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 6th, 2012 01:59</div>
      <div id="p1255" num="1255" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1256" num="1256" class="description-paragraph style-scope patent-text">Strausberg R.L. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 99
(26),16899-16903(2002)</div>
      <div id="p1257" num="1257" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1258" num="1258" class="description-paragraph style-scope patent-text">Official signs: EPHA2</div>
      <div id="p1259" num="1259" class="description-paragraph style-scope patent-text">Other alias: ARCC2, CTPA, CTPP1, ECK</div>
      <div id="p1260" num="1260" class="description-paragraph style-scope patent-text">Other titles: ephrin A receptor 2Epithelial receptor protein tyrosine kinaseSoluble E PHA2 variant 1
Receptor tyrosine kinases ECK</div>
      <div id="p1261" num="1261" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1262" num="1262" class="description-paragraph style-scope patent-text">Midi Miao Ni company: 1C1 (Lee JW. et al., Clin CancerRes. [Clinical Cancer Research] May 1 in 2010
Day16(9):2562-2570)</div>
      <div id="p1263" num="1263" class="description-paragraph style-scope patent-text">For example, with reference to US 20090304721A1 Fig. 7 and 8.</div>
      <div id="p1264" num="1264" class="description-paragraph style-scope patent-text">(80) CD20-MS4A1 (4 domain subfamily A member 1 of cross-film)</div>
      <div id="p1265" num="1265" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1266" num="1266" class="description-paragraph style-scope patent-text">Genbank accession number M27394</div>
      <div id="p1267" num="1267" class="description-paragraph style-scope patent-text">Genbank version number M27394.1 GI:179307</div>
      <div id="p1268" num="1268" class="description-paragraph style-scope patent-text">Genbank record update date: on November 30th, 2009 morning 11:16</div>
      <div id="p1269" num="1269" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1270" num="1270" class="description-paragraph style-scope patent-text">Genbank accession number AAA35581</div>
      <div id="p1271" num="1271" class="description-paragraph style-scope patent-text">Genbank version number AAA35581.1 GI:179308</div>
      <div id="p1272" num="1272" class="description-paragraph style-scope patent-text">Genbank record update date: on November 30th, 2009 morning 11:16</div>
      <div id="p1273" num="1273" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1274" num="1274" class="description-paragraph style-scope patent-text">Tedder T.F. et al., Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 85 (1),
208-212(1988)</div>
      <div id="p1275" num="1275" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1276" num="1276" class="description-paragraph style-scope patent-text">Official signs: MS4A1</div>
      <div id="p1277" num="1277" class="description-paragraph style-scope patent-text">Other alias: B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7</div>
      <div id="p1278" num="1278" class="description-paragraph style-scope patent-text">Other titles: bone-marrow-derived lymphocyte antigens c D20Bone-marrow-derived lymphocyte surface antigen B1CD20 antigenCD20 receptorIt is white thin
Cellular surface antigen Leu-16</div>
      <div id="p1279" num="1279" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1280" num="1280" class="description-paragraph style-scope patent-text">Genentech corp/Roche Holding Ag: Rituximab (Rituximab)-AbdullaNE. et al., BioDrugs.
[bio-pharmaceutical] on April 1st, 201226(2):71-82</div>
      <div id="p1281" num="1281" class="description-paragraph style-scope patent-text">For example, with reference to US 5736137, ATCC deposit number HB-69119.</div>
      <div id="p1282" num="1282" class="description-paragraph style-scope patent-text">GlaxoSmithKline PLC company (GSK)/Genmab: difficult to understand (Ofatumumab)-Nightingale G. et al.,
AnnPharmacother. [drug therapy annual] in October, 201145(10):1248-55</div>
      <div id="p1283" num="1283" class="description-paragraph style-scope patent-text">For example, with reference to US 20090169550A1 SEQ ID NO:2,4 and 5.</div>
      <div id="p1284" num="1284" class="description-paragraph style-scope patent-text">Immune medicine company: dimension trastuzumab (Veltuzumab)-Goldenberg DM. et al., Leuk Lymphoma.
[leukaemia and lymthoma] in May, 201051(5):747-55</div>
      <div id="p1285" num="1285" class="description-paragraph style-scope patent-text">For example, with reference to US 7919273B2 SEQ ID NO:1,2,3,4,5 and 6.</div>
      <div id="p1286" num="1286" class="description-paragraph style-scope patent-text">(81) tenascin C (Tenascin C)-TNC (tenascin C)</div>
      <div id="p1287" num="1287" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1288" num="1288" class="description-paragraph style-scope patent-text">Genbank accession number NM_002160</div>
      <div id="p1289" num="1289" class="description-paragraph style-scope patent-text">Genbank version number NM_002160.3 GI:340745336</div>
      <div id="p1290" num="1290" class="description-paragraph style-scope patent-text">Genbank records update date: 02:33 afternoon on the 23rd of September in 2012</div>
      <div id="p1291" num="1291" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1292" num="1292" class="description-paragraph style-scope patent-text">Genbank accession number NP_002151</div>
      <div id="p1293" num="1293" class="description-paragraph style-scope patent-text">Genbank version number NP_002151.2 GI:153946395</div>
      <div id="p1294" num="1294" class="description-paragraph style-scope patent-text">Genbank records update date: 02:33 afternoon on the 23rd of September in 2012</div>
      <div id="p1295" num="1295" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1296" num="1296" class="description-paragraph style-scope patent-text">Nies D.E. et al., J.Biol.Chem. [journal of biological chemistry] 266 (5), 2818-2823 (1991)Siri
A. et al., Nucleic Acids Res. [nucleic acids research] 19 (3), 525-531 (1991)</div>
      <div id="p1297" num="1297" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1298" num="1298" class="description-paragraph style-scope patent-text">Official signs: TNC</div>
      <div id="p1299" num="1299" class="description-paragraph style-scope patent-text">Other alias: 150-225, GMEM, GP, HXB, JI, TN, TN-C</div>
      <div id="p1300" num="1300" class="description-paragraph style-scope patent-text">Other titles: GP 150-225Myotendinous antigen (cytotactin)Glioma relevant extracellular matrix antigen
Six gasoline arm albumen (hexabrachion) (tenascin)Myotendinous antigenNeuronectinTenascinTenascin C is same
Kind type 14/AD1/16</div>
      <div id="p1301" num="1301" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1302" num="1302" class="description-paragraph style-scope patent-text">Fei Luogen company (Philogen): G11 (von Lukowicz T. et al., JNucl Med. [Journal of Nuclear Medicine]
In April, 200748 (4): 582-7) and F16 (Pedretti M. et al., Lung Cancer [lung cancer] in April, 200964(1):
28-33)</div>
      <div id="p1303" num="1303" class="description-paragraph style-scope patent-text">For example, with reference to US 7968685 SEQ ID NO:29,35,45 and 47.</div>
      <div id="p1304" num="1304" class="description-paragraph style-scope patent-text">(82) FAP (fibroblast activation protein alpha)</div>
      <div id="p1305" num="1305" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1306" num="1306" class="description-paragraph style-scope patent-text">Genbank accession number U09278</div>
      <div id="p1307" num="1307" class="description-paragraph style-scope patent-text">Genbank version number U09278.1 GI:1888315</div>
      <div id="p1308" num="1308" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 09:22</div>
      <div id="p1309" num="1309" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1310" num="1310" class="description-paragraph style-scope patent-text">Genbank accession number AAB49652</div>
      <div id="p1311" num="1311" class="description-paragraph style-scope patent-text">Genbank version number AAB49652.1 GI:1888316</div>
      <div id="p1312" num="1312" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 09:22</div>
      <div id="p1313" num="1313" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1314" num="1314" class="description-paragraph style-scope patent-text">Scanlan, M.J. et al. Proc.Natl.Acad.Sci.U.S.A. [National Academy of Sciences proceeding] 91 (12),
5657-5661(1994)</div>
      <div id="p1315" num="1315" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1316" num="1316" class="description-paragraph style-scope patent-text">Official signs: FAP</div>
      <div id="p1317" num="1317" class="description-paragraph style-scope patent-text">Other alias: DPPIV, FAPA</div>
      <div id="p1318" num="1318" class="description-paragraph style-scope patent-text">Other titles: 170kDa melanoma film combination gelatinaseConformity membrane serine proteaseseprase</div>
      <div id="p1319" num="1319" class="description-paragraph style-scope patent-text">(83) DKK-1 (1 homologue of Dickkopf (Africa xenopus (Xenopus laevis))</div>
      <div id="p1320" num="1320" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1321" num="1321" class="description-paragraph style-scope patent-text">Genbank accession number NM_012242</div>
      <div id="p1322" num="1322" class="description-paragraph style-scope patent-text">Genbank version number NM_012242.2 GI:61676924</div>
      <div id="p1323" num="1323" class="description-paragraph style-scope patent-text">Genbank records update date: 01:48 afternoon on the 30th of September in 2012</div>
      <div id="p1324" num="1324" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1325" num="1325" class="description-paragraph style-scope patent-text">Genbank accession number NP_036374</div>
      <div id="p1326" num="1326" class="description-paragraph style-scope patent-text">Genbank version number NP_036374.1 GI:7110719</div>
      <div id="p1327" num="1327" class="description-paragraph style-scope patent-text">Genbank records update date: 01:48 afternoon on the 30th of September in 2012</div>
      <div id="p1328" num="1328" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1329" num="1329" class="description-paragraph style-scope patent-text">Fedi P. et al., J.Biol.Chem. [journal of biological chemistry] 274 (27), 19465-19472 (1999)</div>
      <div id="p1330" num="1330" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1331" num="1331" class="description-paragraph style-scope patent-text">Official signs: DKK1</div>
      <div id="p1332" num="1332" class="description-paragraph style-scope patent-text">Other alias: UNQ492/PRO1008, DKK-1, SK</div>
      <div id="p1333" num="1333" class="description-paragraph style-scope patent-text">Other titles: dickkopf related protein-1Dickkopf-1 sampleDickkopf sample albumen 1Dickkopf is related
Albumen 1hDkk-1</div>
      <div id="p1334" num="1334" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1335" num="1335" class="description-paragraph style-scope patent-text">Novartis Co., Ltd: BHQ880 (Fulciniti M. et al., Blood [blood] .2009 July 9114(2):371-
379)</div>
      <div id="p1336" num="1336" class="description-paragraph style-scope patent-text">For example, with reference to US 20120052070A1 SEQ ID NO:100 and 108.</div>
      <div id="p1337" num="1337" class="description-paragraph style-scope patent-text">(84) CD52 (CD52 molecule)</div>
      <div id="p1338" num="1338" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1339" num="1339" class="description-paragraph style-scope patent-text">Genbank accession number NM_001803</div>
      <div id="p1340" num="1340" class="description-paragraph style-scope patent-text">Genbank version number NM_001803.2 GI:68342029</div>
      <div id="p1341" num="1341" class="description-paragraph style-scope patent-text">Genbank records update date: 01:48 afternoon on the 30th of September in 2012</div>
      <div id="p1342" num="1342" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1343" num="1343" class="description-paragraph style-scope patent-text">Genbank accession number NP_001794</div>
      <div id="p1344" num="1344" class="description-paragraph style-scope patent-text">Genbank version number NP_001794.2 GI:68342030</div>
      <div id="p1345" num="1345" class="description-paragraph style-scope patent-text">Genbank records update date: 01:48 afternoon on the 30th of September in 2012</div>
      <div id="p1346" num="1346" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1347" num="1347" class="description-paragraph style-scope patent-text">Xia M.Q. et al., Eur.J.Immunol. [European Journal of Immunology] 21 (7), 1677-1684 (1991)</div>
      <div id="p1348" num="1348" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1349" num="1349" class="description-paragraph style-scope patent-text">Official signs: CD52</div>
      <div id="p1350" num="1350" class="description-paragraph style-scope patent-text">Other alias: CDW52</div>
      <div id="p1351" num="1351" class="description-paragraph style-scope patent-text">Other titles: CAMPATH-1 antigenCD52 antigen (CAMPATH-1 antigen)(CAMPATH-1 is anti-for CDW52 antigen
It is former)1 antigen of Cambridge pathologyEpididymal secretory protein E5he5People's epididymis specific proteins 5</div>
      <div id="p1352" num="1352" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1353" num="1353" class="description-paragraph style-scope patent-text">Alemtuzumab (Alemtuzumab) (Campath)-Skoetz N. et al., Cochrane Database Syst
Rev. [comment of cock orchid Database Systems] on 2 15th, 20122:CD008078</div>
      <div id="p1354" num="1354" class="description-paragraph style-scope patent-text">For example, with reference to Drugbank accession number DB00087 (BIOD00109, BTD00109)</div>
      <div id="p1355" num="1355" class="description-paragraph style-scope patent-text">(85) CS1-SLAMF7 (SLAM family member 7)</div>
      <div id="p1356" num="1356" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1357" num="1357" class="description-paragraph style-scope patent-text">Genbank accession number NM_021181</div>
      <div id="p1358" num="1358" class="description-paragraph style-scope patent-text">Genbank version number NM_021181.3 GI:1993571</div>
      <div id="p1359" num="1359" class="description-paragraph style-scope patent-text">Genbank record update date: on June 29th, 2012 morning 11:24</div>
      <div id="p1360" num="1360" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1361" num="1361" class="description-paragraph style-scope patent-text">Genbank accession number NP_067004</div>
      <div id="p1362" num="1362" class="description-paragraph style-scope patent-text">Genbank version number NP_067004.3 GI:19923572</div>
      <div id="p1363" num="1363" class="description-paragraph style-scope patent-text">Genbank record update date: on June 29th, 2012 morning 11:24</div>
      <div id="p1364" num="1364" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1365" num="1365" class="description-paragraph style-scope patent-text">Boles K.S. et al., Immunogenetics [immunogenetics] 52 (3-4), 302-307 (2001)</div>
      <div id="p1366" num="1366" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1367" num="1367" class="description-paragraph style-scope patent-text">Official signs: SLAMF7</div>
      <div id="p1368" num="1368" class="description-paragraph style-scope patent-text">Other alias: UNQ576/PRO1138,19A, CD319, CRACC, CS1</div>
      <div id="p1369" num="1369" class="description-paragraph style-scope patent-text">Other titles: 19A24 albumenCD2 subgroup 1CD2 sample receptor activation cytotoxic cellCD2 sample receptor-activation
Cytotoxic cellMemebrane protein FOAP-12Novel LY9 (lymphocyte antigen 9) sample albumenProtein 19 A</div>
      <div id="p1370" num="1370" class="description-paragraph style-scope patent-text">Antibody:</div>
      <div id="p1371" num="1371" class="description-paragraph style-scope patent-text">BMS: (Benson DM. et al., J Clin Oncol. [face angstrom Lip river trastuzumab (elotuzumab)/HuLuc63
Bed oncology magazine] on June 1st, 201230(16):2013-2015)</div>
      <div id="p1372" num="1372" class="description-paragraph style-scope patent-text">For example, with reference to US 20110206701 SEQ ID NO:9,10,11,12,13,14,15 and 16.</div>
      <div id="p1373" num="1373" class="description-paragraph style-scope patent-text">(86) Endoglin (Endoglin)-ENG (Endoglin)</div>
      <div id="p1374" num="1374" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1375" num="1375" class="description-paragraph style-scope patent-text">Genbank accession number AF035753</div>
      <div id="p1376" num="1376" class="description-paragraph style-scope patent-text">Genbank version number AF035753.1 GI:3452260</div>
      <div id="p1377" num="1377" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 06:36</div>
      <div id="p1378" num="1378" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1379" num="1379" class="description-paragraph style-scope patent-text">Genbank accession number AAC32802</div>
      <div id="p1380" num="1380" class="description-paragraph style-scope patent-text">Genbank version number AAC32802.1 GI:3452261</div>
      <div id="p1381" num="1381" class="description-paragraph style-scope patent-text">Genbank record update date: afternoon on March 10th, 2010 06:36</div>
      <div id="p1382" num="1382" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1383" num="1383" class="description-paragraph style-scope patent-text">RiUSC. et al., Blood [blood] 92 (12), 4677-4690 (1998)</div>
      <div id="p1384" num="1384" class="description-paragraph style-scope patent-text">Official signs: ENG</div>
      <div id="p1385" num="1385" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1386" num="1386" class="description-paragraph style-scope patent-text">Other alias: RP11-228B15.2, CD105, END, HHT1, ORW, ORW1</div>
      <div id="p1387" num="1387" class="description-paragraph style-scope patent-text">Other titles: CD105 antigen</div>
      <div id="p1388" num="1388" class="description-paragraph style-scope patent-text">(87) Annexin A1-ANXA1 (Annexin A1)</div>
      <div id="p1389" num="1389" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1390" num="1390" class="description-paragraph style-scope patent-text">Genbank accession number X05908</div>
      <div id="p1391" num="1391" class="description-paragraph style-scope patent-text">Genbank version number X05908.1 GI:34387</div>
      <div id="p1392" num="1392" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:02</div>
      <div id="p1393" num="1393" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1394" num="1394" class="description-paragraph style-scope patent-text">Genbank accession number CCA29338</div>
      <div id="p1395" num="1395" class="description-paragraph style-scope patent-text">Genbank version number CCA29338.1 GI:34388</div>
      <div id="p1396" num="1396" class="description-paragraph style-scope patent-text">Genbank records update date: on 2 2nd, 2011 morning 10:02</div>
      <div id="p1397" num="1397" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1398" num="1398" class="description-paragraph style-scope patent-text">Et al. WallnerB.P. Nature [nature] 320 (6057), 77-81 (1986)</div>
      <div id="p1399" num="1399" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1400" num="1400" class="description-paragraph style-scope patent-text">Official signs: ANXA1</div>
      <div id="p1401" num="1401" class="description-paragraph style-scope patent-text">Other alias: RP11-71A24.1, ANX1, LPC1</div>
      <div id="p1402" num="1402" class="description-paragraph style-scope patent-text">Other titles: annexin I (lipocortin I)Annexin Calpactin IIAccording to calbindin
White -2Chromobindin -9Lipocortin Ip35Macrocortin</div>
      <div id="p1403" num="1403" class="description-paragraph style-scope patent-text">(88) V-CAM (CD106)-VCAM1 (Vcam1)</div>
      <div id="p1404" num="1404" class="description-paragraph style-scope patent-text">Nucleotide:</div>
      <div id="p1405" num="1405" class="description-paragraph style-scope patent-text">Genbank accession number M60335</div>
      <div id="p1406" num="1406" class="description-paragraph style-scope patent-text">Genbank version number M60335.1 GI:340193</div>
      <div id="p1407" num="1407" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:56</div>
      <div id="p1408" num="1408" class="description-paragraph style-scope patent-text">Polypeptide:</div>
      <div id="p1409" num="1409" class="description-paragraph style-scope patent-text">Genbank accession number AAA61269</div>
      <div id="p1410" num="1410" class="description-paragraph style-scope patent-text">Genbank version number AAA61269.1 GI:340194</div>
      <div id="p1411" num="1411" class="description-paragraph style-scope patent-text">Genbank record update date: on June 23rd, 2010 morning 08:56</div>
      <div id="p1412" num="1412" class="description-paragraph style-scope patent-text">Cross reference:</div>
      <div id="p1413" num="1413" class="description-paragraph style-scope patent-text">Hession C. et al., J.Biol.Chem. [journal of biological chemistry] 266 (11), 6682-6685 (1991)</div>
      <div id="p1414" num="1414" class="description-paragraph style-scope patent-text">Other information:</div>
      <div id="p1415" num="1415" class="description-paragraph style-scope patent-text">Formal symbol VCAM1</div>
      <div id="p1416" num="1416" class="description-paragraph style-scope patent-text">Other alias: CD106, INCAM-100</div>
      <div id="p1417" num="1417" class="description-paragraph style-scope patent-text">Other titles: CD106 antigenVascular cell adhesion albumen 1</div>
      <div id="p1418" num="1418" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined ADC includes to be used as anti-tumour antibody or its antigen knot herein
Close the antibody of segment.In another embodiment, which is selected from by anti-eph A2 antibody or its antigen-binding fragment, anti-Her2
Antibody or its antigen-binding fragment, resisting GPC 3 antibody or its antigen-binding fragment, anti-ASCT2 antibody or its antigen-binding fragment with
And the group of anti-B7H4 antibody or its antigen-binding fragment composition.</div>
      <div id="p1419" num="1419" class="description-paragraph style-scope patent-text">The present invention provides the pharmaceutical compositions comprising ADC of the invention.The present invention provides include IMT agent of the invention
Pharmaceutical composition.The present invention provides the pharmaceutical compositions comprising ADC and IMT agent of the invention.</div>
      <div id="p1420" num="1420" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined cancer includes but is not limited to neoplasm and tumour (example herein
Such as, histocytoma, glioma, astrocytoma, osteoma), cancer (such as lung cancer, Small Cell Lung Cancer, human primary gastrointestinal cancers, head
Neck cancer, gastric cancer, intestinal cancer, colon cancer, breast cancer, oophoroma, prostate cancer, carcinoma of testis, liver cancer, kidney, bladder cancer, cancer of pancreas,
The cancer of the brain, sarcoma, osteosarcoma, Kaposi sarcoma, melanoma) and leukaemia.Other cancers of interest include but is not limited to blood
Malignant tumour, such as leukaemia and lymthoma, such as non-Hodgkin lymphoma and hypotype (such as DLBCL, marginal zone lymphoma,
Cover area's lymthoma and follicular lymphoma), Hodgkin lymphoma, AML and other B or T cell source cancer.</div>
      <div id="p1421" num="1421" class="description-paragraph style-scope patent-text">Legend:</div>
      <div id="p1422" num="1422" class="description-paragraph style-scope patent-text">Fig. 1: vaccine inoculation model.(A): vaccine inoculation/challenge Experimental model of small mice schematic diagram.(B): molten with micro-pipe
Percentage without mice with tumor after the CT26 cell challenge of element, PBD or radiation treatment.Non-viable non-apoptotic cell is used as negative control (C): using
Quantity without mice with tumor after CT26 cell, tubulysin, PBD challenge after downright bad CT26 cell, irradiation.</div>
      <div id="p1423" num="1423" class="description-paragraph style-scope patent-text">Fig. 2: the repulsion in the mouse for realizing complete response by ADC to new tumour.(A): with EphA2-1508 or
The table of complete response in the mouse with CT26 tumour of EphA2-PBD processing.When gross tumor volume is 75mm<sup class="style-scope patent-text">3</sup>Or 150mm<sup class="style-scope patent-text">3</sup>When
Mouse is handled.B): in the mean tumour volume for the healing mouse that the 138th day is rechallenged with CT26 cell, and simultaneously
It is transplanted to the growth of the CT26 cell in initial Balb/C animal.C): carrying out EphA2PBD to the mouse with MCA205 tumour
Administration.All mouse realize complete response, and do not form tumour when rechallenging mouse at the 43rd day.It is shown in figure just
The growth of MCA205 tumour in initiating object.</div>
      <div id="p1424" num="1424" class="description-paragraph style-scope patent-text">Fig. 3: realize that the AH1 of the mouse of complete response stimulates measurement in vitro.After AH1 peptide stimulates in vitro, measurement from
EphA2-1508 and EphA2-PBD obtains the IFN- and TNF  production of the spleen t-cell of five mouse of complete response.</div>
      <div id="p1425" num="1425" class="description-paragraph style-scope patent-text">Fig. 4: ADC in immune competent mice than in immunodeficient mouse with bigger activity.It is (left in immune deficiency
Figure) it is molten to EphA2- micro-pipe with three kinds of syngeneic tumor models (CT26,4T1 and MCA205) of assessment in immune competent mice (right figure)
The antitumor response of plain (above) and EphA2-PBD (following figure).(A): CT26 tumor model.(B): 4T1 tumor model.(C):
MCA205 tumor model.When tumour is in 150-200mm<sup class="style-scope patent-text">3</sup>Between when carry out ADC administration.</div>
      <div id="p1426" num="1426" class="description-paragraph style-scope patent-text">Fig. 5: cd8 t cell is important the effect of ADC.It is carried out to the Balb/C mouse with CT26 tumour
The mixture or CD8 of EphA2-Tub and EphA2-PBD and Isotype control antibodies are administered while exhausting antibody.Also individually into
The administration of row isotype mixture.</div>
      <div id="p1427" num="1427" class="description-paragraph style-scope patent-text">Fig. 6: ADC acts synergistically in combination with IMT.To the Balb/C mouse with CT26 tumour carry out individually or with it is anti-
The administration of PD-L1 antibody or mouse GITRL fusion protein united EphA2-PBD ADC or EphA2- tubulysin ADC.A) not
The mouse of processing, B) EphA2-PBD, C) anti-PD-L1, D) EphA2-PBD+a-PD-L1, E) EphA2- tubulysin, F) GITRL
FP, G) EphA2- tubulysin+GITRL FP, H) EphA2-PBD+a-PD-L1 (after 15 days) and I) EphA2- tubulysin+
GITRL FP (after 15 days).</div>
      <div id="p1428" num="1428" class="description-paragraph style-scope patent-text">The joint study of Fig. 7: ADC and anti-PD-1, anti-PD-L1, OX40 ligand fusion protein and GITRL ligand fusion protein
Summarize.</div>
      <div id="p1429" num="1429" class="description-paragraph style-scope patent-text">Fig. 8: cd8 t cell PD-L1 joint activity anti-for ADC+ is important.It is small to the Balb/C with CT26 tumour
Mouse carries out the mixture of EphA2-Tub and EphA2-PBD and -PD-L1 and Isotype control antibodies or consumes with -PD-L1 and CD8
Administration while exhausting antibody.Also individually carry out the administration of isotype mixture.</div>
      <div id="p1430" num="1430" class="description-paragraph style-scope patent-text">The Immunophenotype analysis of T cell group after Fig. 9: ADC processing.By EphA2-PBD, EphA2- tubulysin individually or with
OX40 or PD-L1 is antibody combined to be administered to the mouse with CT26 tumour.5 days harvest spleens and tumour after medicament administration.A)
The percentage of CD45 cell in tumourB) in tumour CD45+CD8+ cell percentageC) CD45+CD8+CD69+ is thin in tumour
The percentage of born of the same parentsD) in tumour CD45+CD8+PD-1+ cell percentageE) in tumour CD45+CD8+Ki67+ cell hundred
Point ratio and F) percentage of CD45+CD4+Ki67+ cell in spleen.</div>
      <div id="p1431" num="1431" class="description-paragraph style-scope patent-text">The Immunophenotype analysis of myeloid cell group after Figure 10: ADC processing.EphA2-PBD, EphA2- tubulysin is independent
Or with OX40 or PD-L1 are antibody combined is administered to the mouse with CT26 tumour.It harvests within 5 days or 12 days after initial drug application
Spleen and tumour.A) in tumour CD45+CD86+ cell percentageB) in tumour CD45+CD80+ cell percentageC it) swells
The percentage of CD45+F480+CD86+ cell in tumorD) in the CD45+CD11c+ cell in tumour CD86 average fluorescent strength
(MFI)E) CD45+GR-1 in tumour<sup class="style-scope patent-text">hi</sup>+CD11b<sup class="style-scope patent-text">hi</sup>The percentage of+CD86+ cellF) CD86 in the CD45+ cell in spleen
MFIG) CD45+Gr-1 in spleen<sup class="style-scope patent-text">int</sup>+CD11b<sup class="style-scope patent-text">hi</sup>The percentage of+CD86+ cellH) CD45+GR-1 in spleen<sup class="style-scope patent-text">hi</sup>+
CD11b<sup class="style-scope patent-text">hi</sup>The percentage of CD86%I)</div>
      <div id="p1432" num="1432" class="description-paragraph style-scope patent-text">Figure 11: the joint of ADC+IMT and different ADC in different syngeneic tumor models.A) IGF1R-PBD in CT26 model
ADC (upper right), -PD-L1 (lower-left) or the activity for combining (bottom right).CR number comes from 12 mouse.B) in MCA205 model
The activity of EphA2- tubulysin ADC (upper right), OX40 ligand fusion protein (lower-left) or joint (bottom right).CR number comes from 12
Mouse.C) EphA2-PBD ADC (upper right) in Renca model, GITR ligand fusion protein (lower-left) or combine the work of (bottom right)
Property.CR number comes from 10 mouse.</div>
    </disclosure>
    <mode-for-invention class="style-scope patent-text">
      <div id="p1433" num="1433" class="description-paragraph style-scope patent-text">Specific embodiment</div>
      <div id="p1434" num="1434" class="description-paragraph style-scope patent-text">The present invention is based on following astonishing and be found surprisingly that: ADC payload can have an impact immunocyte, special
It is not inducing tumor specific immune memory.The present invention is also based on following astonishing and is found surprisingly that: the connection of ADC and IMT
Conjunction provides the effect of enhancing, to provide effective conjoint therapy.PBD and tubulysin class, which represent, has immunocyte
The two kinds of effective ADC payload classifications influenced.Therefore, the present invention provides targeting immune regulative tumour-specifics to treat
Method.</div>
      <div id="p1435" num="1435" class="description-paragraph style-scope patent-text">The present invention provides the new conjoint therapies based on ADC and IMT agent.</div>
      <div id="p1436" num="1436" class="description-paragraph style-scope patent-text">Antibody-drug conjugates (ADC)</div>
      <div id="p1437" num="1437" class="description-paragraph style-scope patent-text">ADC defined herein can be used for for cytotoxicity payload being provided to target position (for example, tumorigenic cell), promote
Into intracellular accumulation of the drug in tumour cell, then induce cell apoptosis.</div>
      <div id="p1438" num="1438" class="description-paragraph style-scope patent-text">In one embodiment of the invention, the drug for being conjugated to ADC is Pyrrolobenzodiazepines<span class="patent-image-not-available style-scope patent-text"></span>PBD.In this hair
In another bright embodiment, the drug for being conjugated to ADC is tubulysin.</div>
      <div id="p1439" num="1439" class="description-paragraph style-scope patent-text">One example of PBD dimer is SG2000 (SJG-136):</div>
      <div id="p1440" num="1440" class="description-paragraph style-scope patent-text">
        <span class="patent-image-not-available style-scope patent-text"></span>
      </div>
      <div id="p1441" num="1441" class="description-paragraph style-scope patent-text">(Gregson, S. et al., J.Med.Chem. [journal of biological chemistry], 44,737-748 (2001)Alley,M.C.
Et al., CancerResearch [cancer research], 64,6700-6706 (2004)Hartley, J.A. et al., Cancer
Research [cancer research], 64,6693-6699 (2004)).Other examples can learn from document, and for ability
The technical staff in domain will be apparent.</div>
      <div id="p1442" num="1442" class="description-paragraph style-scope patent-text">There is following general formula for tubulysin class of the invention:</div>
      <div id="p1443" num="1443" class="description-paragraph style-scope patent-text">
        <span class="patent-image-not-available style-scope patent-text"></span>
      </div>
      <div id="p1444" num="1444" class="description-paragraph style-scope patent-text">Further specific example is disclosed in WO 2015/157594, which is incorporated herein by quoting.</div>
      <div id="p1445" num="1445" class="description-paragraph style-scope patent-text">PBD is the naturally occurring antibiosis for combining to be formed interchain and the internally crosslinked adduct of chain in the ditch of DNA
Plain (Hartley, 2011), is incorporated herein by quoting).Tubulysin class is to act on the antimitotic agent for making microtubule depolymerization
(Li et al. people, 2016).These compounds have shown that as ADC payload be it is extremely effective (Saunders et al.,
2015Jeffrey et al., 2013, this two documents, which pass through to quote, to be incorporated herein).</div>
      <div id="p1446" num="1446" class="description-paragraph style-scope patent-text">The synthesis of PBD compound has carried out extensive discussions in below with reference to document, these, which pass through discussion to quote, is incorporated to this
Text:</div>
      <div id="p1447" num="1447" class="description-paragraph style-scope patent-text">A) WO 00/12508 (page 14 to 30)</div>
      <div id="p1448" num="1448" class="description-paragraph style-scope patent-text">B) WO 2005/023814 (page 3 to 10)</div>
      <div id="p1449" num="1449" class="description-paragraph style-scope patent-text">C) WO 2004/043963 (page 28 to 29)With</div>
      <div id="p1450" num="1450" class="description-paragraph style-scope patent-text">D) WO 2005/085251 (page 30 to 39).</div>
      <div id="p1451" num="1451" class="description-paragraph style-scope patent-text">Synthesis for tubulysin molecule of the invention is discussed in WO 2015/157594, which passes through
It quotes and is incorporated herein.</div>
      <div id="p1452" num="1452" class="description-paragraph style-scope patent-text">In one embodiment of the invention, the antibody of ADC is anti-tumour antibody or its antigen-binding fragment.It is potential anti-
Tumor targets include but is not limited to tumor associated antigen illustrated above.This advantageouslys allow for ADC target tumor of the invention thin
Born of the same parents.This be located in tumour provides relatively high drug concentration.In order to identify that the suitable tumour correlation that ADC is targeted is anti-
Original, using two kinds of universal methods.Then indication dependence method carries out leading to target from concern particular cancers type
Selection is to obtain the research of the ADC of the disease.Alternatively, non-adaptive disease dependence screening can be used for based on functional character
(such as be internalized by) rather than target is identified based on the specific type of cancer.Once identifying potential target, table can be screened
Up to the kinds cancer of those targets, to select leading indication.</div>
      <div id="p1453" num="1453" class="description-paragraph style-scope patent-text">In yet another embodiment of the present invention, antibody is anti-eph A2 antibody or its antigen-binding fragment.Of the invention
In another embodiment, antibody be 1C1 anti-eph A2 antibody (Jackson et al., 2008US 2011/028092(SEQ ID
NO:3)).EphA2 great expression in several tumours.</div>
      <div id="p1454" num="1454" class="description-paragraph style-scope patent-text">In yet another embodiment of the present invention, antibody is resisting GPC 3 antibody or its antigen-binding fragment.</div>
      <div id="p1455" num="1455" class="description-paragraph style-scope patent-text">In yet another embodiment of the present invention, antibody is anti-B7H4 antibody or its antigen-binding fragment.</div>
      <div id="p1456" num="1456" class="description-paragraph style-scope patent-text">In yet another embodiment of the present invention, antibody is anti-ASCT2 antibody or its antigen-binding fragment.</div>
      <div id="p1457" num="1457" class="description-paragraph style-scope patent-text">In yet another embodiment of the present invention, antibody is anti-Her2 antibody or its antigen-binding fragment.</div>
      <div id="p1458" num="1458" class="description-paragraph style-scope patent-text">In one embodiment of the invention, antibody or its antigen-binding fragment are monoclonal antibodies.Of the invention another
In one embodiment, antibody or its antigen-binding fragment are humanized antibodies.In yet another embodiment of the present invention, antibody or
Its antigen-binding fragment is human antibody.</div>
      <div id="p1459" num="1459" class="description-paragraph style-scope patent-text">In one embodiment of the invention, antibody or its antigen-binding fragment are IgA, IgD, IgE, IgG, IgM, IgG1
Or IgG2 antibody or its antigen-binding fragment.</div>
      <div id="p1460" num="1460" class="description-paragraph style-scope patent-text">Antibody or its antigen-binding fragment are not limited to specifically generation or preparation method.Antibody or its antigen-binding fragment can
To use multiple technologies known in the art (including hybridoma technology, recombinant technique, display technique of bacteriophage, transgenic animals
(for example,<span class="patent-image-not-available style-scope patent-text"></span>) or their certain combinations) prepare.</div>
      <div id="p1461" num="1461" class="description-paragraph style-scope patent-text">Antigen-binding fragment includes Fab, Fv, scFv, dAb, Fd, Fab ', F (ab ')<sub class="style-scope patent-text">2</sub>Or with the frame for being enough to combine
The isolated complementary determining region (CDR) of frame.Fab segment can be the monovalent fragment being made of the domain VLC, VHC, CL and CHl.F
(ab')<sub class="style-scope patent-text">2</sub>Segment can be the bivalent fragment comprising two Fab segments, the two Fab segments are connected in hinge area by disulphide bridges.
Fc segment can be made of the domain VHC and CHl.Fv segment can be made of the domain VLC and VHC of the single arm of antibody.By quoting
The dAb segment (Ward et al., 1989) being incorporated herein can be made of the domain VHC.Separation with the frame for being enough to combine
CDR can be the antigen-binding portion thereof of variable region.</div>
      <div id="p1462" num="1462" class="description-paragraph style-scope patent-text">Antigen-binding portion thereof (such as two domains of Fv segment of the antigen-binding portion thereof of light chain variable region and heavy chain variable region
VLC can be used recombination method with VHC) and be connected by synthetic linker, which allows them to become single protein chain,
It matches to form monovalent molecule (referred to as scFv (scFv) in the middle area VLC and VHCReferring to (Huston et al., 1988Bird et al.,
1988), this two documents are incorporated herein by quoting).These parts use routine techniques known to those skilled in the art
It obtains, and screens these parts for practicability in a manner of identical with complete antibody.</div>
      <div id="p1463" num="1463" class="description-paragraph style-scope patent-text">As known to those skilled in the art, segment can be by molecular engineering or via complete or complete antibody or anti-
The chemistry or enzymatic treatment (such as papain or pepsin) of body chain are obtained by recombination form.Referring to (Paul,
1999) about the more detailed description of antibody fragment.</div>
      <div id="p1464" num="1464" class="description-paragraph style-scope patent-text">In one embodiment of the invention, antibody or its antigen-binding fragment combine its target with high-affinity.At this
In one embodiment of invention, as measured by BIAcore, antibody or its antigen-binding fragment combine the K of its target<sub class="style-scope patent-text">D</sub>&lt;
50nM.In order to play a role, ADC not only needs to be effectively combined with the target on cell surface, but also combination needs cause
The internalization of ADC- antigenic compound.After internalization, ADC needs to be metabolized to discharge bullet (warhead) and to cause cell toxicant
Property.In one embodiment of the invention, antibody or antigen-binding fragment are internalized by after being bound to its target antigen.</div>
      <div id="p1465" num="1465" class="description-paragraph style-scope patent-text">Immunization therapy (IMT) agent</div>
      <div id="p1466" num="1466" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined IMT agent is checkpoint inhibitor herein.In another implementation
Example in, such as herein Anywhere defined in IMT agent be tumor necrosis factor (TNF) receptor superfamily agonist.At one
In embodiment, such as herein Anywhere defined in IMT agent be selected from the group that is made up of: PD1 inhibitor, PD-L1 inhibitor,
OX40 agonist and GITRL agonist.In yet another embodiment, as herein Anywhere defined in IMT agent be selected from by with
The group of lower composition: anti-PD1 antibody, anti-PD-L1 antibody and OX40 antibody, OX40 ligand fusion protein and GITRL fusion protein.</div>
      <div id="p1467" num="1467" class="description-paragraph style-scope patent-text">Pharmaceutical preparations</div>
      <div id="p1468" num="1468" class="description-paragraph style-scope patent-text">The present invention provides the pharmaceutical compositions comprising ADC of the invention.The present invention also provides include IMT of the invention
The pharmaceutical composition of agent.The present invention also provides the pharmaceutical compositions comprising ADC and IMT agent of the invention.In one embodiment
In, pharmaceutical composition includes pharmaceutically acceptable excipient.</div>
      <div id="p1469" num="1469" class="description-paragraph style-scope patent-text">A variety of pharmaceutically acceptable excipient (including medium, adjuvant and diluent) can be easy from many commercial sources
Ground obtains.Certain non-restrictive illustrative excipient include salt water, buffered saline, dextrose, water, glycerol, ethyl alcohol and they
Combination.In addition, pharmaceutically acceptable auxiliary substances (such as pH adjusting agent and buffer, tension regulator, stabilizer,
Wetting agent etc.) collocation be also available.Pharmaceutical composition can the solubility containing suitable stabilizer or increase compound
To allow to prepare the reagent of highly concentrated solution.Suitable pharmaceutically acceptable excipient can promote ADC application or
Promote ADC to be processed into pharmaceutically to optimize to be delivered to the prepared product of site of action.</div>
      <div id="p1470" num="1470" class="description-paragraph style-scope patent-text">Pharmaceutical composition can be in the form of aqueous solution, and may include the buffer of physical compatibility, such as Hunk
This (Hank) liquid, woods grignard (Ringer) liquid or physiological buffered saline.Pharmaceutical composition can be additionally or alternatively containing increasing
Add the substance of the viscosity of suspension, such as sodium carboxymethylcellulose, D-sorbite or glucan.Pharmaceutical composition can be prepared as
Oily injection suspension appropriate.Suitable lipophilic solvent or medium include fat oil such as sesame oil or synthetic fat
Fat acid esters such as ethyl oleate or glyceryl ester or liposome.</div>
      <div id="p1471" num="1471" class="description-paragraph style-scope patent-text">Pharmaceutical composition of the invention (can including but not limited to take orally, intravenous, intra-arterial, skin through a variety of ways
Under, parenteral, intranasal, intramuscular, encephalic, intracardiac, intra-ventricle, in intratracheal, cheek, rectum, peritonaeum, it is intradermal, local, transdermal and
It is intrathecal) or by being implanted into or sucking it is applied to patient.Pharmaceutical composition can be configured to solid, semisolid, liquid or gas
The prepared product of formIncluding but not limited to tablet, capsule, pulvis, granule, ointment, solution, suppository, enema, injection
Agent, inhalant and aerosol.Preparation appropriate and administration method can be selected according to intended application and therapeutic scheme.</div>
      <div id="p1472" num="1472" class="description-paragraph style-scope patent-text">In one embodiment, pharmaceutical composition of the invention is intravenously applied.In one embodiment, application in peritonaeum
Pharmaceutical composition of the invention.In one embodiment, application pharmaceutical composition of the invention in tumour.</div>
      <div id="p1473" num="1473" class="description-paragraph style-scope patent-text">Conjoint therapy</div>
      <div id="p1474" num="1474" class="description-paragraph style-scope patent-text">The present invention provides the ADC defined herein used in cancer immunotherapy is used for, wherein the use includes inciting somebody to action
ADC and IMT agent are administered in combination in patient.The present invention also provides for used in the cancer immunotherapy as this paper is any
IMT agent defined in side, wherein the use includes that IMT and ADC is administered in combination in patient.The present invention also provides in cancer
ADC and IMT defined herein used in disease immunization therapy, wherein the use includes that ADC and IMT agent are administered in combination in trouble
Person.</div>
      <div id="p1475" num="1475" class="description-paragraph style-scope patent-text">The present invention provides for used in the cancer immunotherapy as herein Anywhere defined in ADC, wherein
The use includes combining ADC with IMT agent simultaneously, individually or sequential application is in patient.The present invention also provides in cancer
Such as Anywhere defined IMT agent herein used in immunization therapy, wherein the use includes combining IMT agent together with ADC
When, individually or sequential application in patient.The present invention also provides be used for the ADC defined herein used in cancer immunotherapy
With IMT agent, wherein the use includes combining ADC with IMT agent simultaneously, individually or sequential application is in patient.</div>
      <div id="p1476" num="1476" class="description-paragraph style-scope patent-text">The present invention provides cancer immunotherapy method, this method includes that ADC and IMT agent defined herein is applied to trouble
Person.The present invention also provides cancer immunotherapy method, this method include by ADC and IMT agent defined herein simultaneously, individually or
Sequential application is in patient.</div>
      <div id="p1477" num="1477" class="description-paragraph style-scope patent-text">In use, ADC and IMT therapy defined herein combines the effect for providing enhancing (for example, phase in nature
Add or cooperate with).United result can be the effect observed when every kind for the treatment of (for example, ADC and IMT therapy) individually carries out
It is added.Although being at least added, effect is typically desired, and the effect of any enhancing is beneficial.</div>
      <div id="p1478" num="1478" class="description-paragraph style-scope patent-text">In a preferred embodiment of the present invention, in use, the joint of ADC and IMT therapy defined herein has association
Same-action.In particular, the effect of cancer immunotherapy, increases.In addition, the antitumor response of the treatment increases.</div>
      <div id="p1479" num="1479" class="description-paragraph style-scope patent-text">Combination therapy can by those skilled in the art think it is necessary or it is convenient it is any in a manner of carry out, and for this
The purpose of specification, it is contemplated that there is no limit to the sequence of component used in the joint, amount, repetition or relative quantity.</div>
      <div id="p1480" num="1480" class="description-paragraph style-scope patent-text">ADC and IMT therapy defined herein can be in single composition or in the identical or different administration method of use
It is administered simultaneously in single formulation in patient.</div>
      <div id="p1481" num="1481" class="description-paragraph style-scope patent-text">Alternatively, ADC and IMT can be in individual composition and sequential application.</div>
      <div id="p1482" num="1482" class="description-paragraph style-scope patent-text">Preferably, the application of ADC carries out simultaneously before therapy or with IMT therapy.The application of ADC can be treated in IMT
It carries out at least 6 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours or at least 96 hours before method.
Preferably, the application of ADC carries out between 6 hours and 48 hours before therapy.It is highly preferred that the application of ADC is being treated
It is carried out between 12 hours and 24 hours before method.</div>
      <div id="p1483" num="1483" class="description-paragraph style-scope patent-text">Therefore, conjoint therapy considers discontinuously to apply or be divided into the daily dosage of repeatedly part application.Every time between delivering
Period enable IMT therapy and ADC to play synergy to tumour.Application can be applied by the repetition in long period
For carry out.Application can be parallel or successive, and can carry out in any order.</div>
      <div id="p1484" num="1484" class="description-paragraph style-scope patent-text">By ADC and IMT agent combined administration cover as described above while and sequential application.</div>
      <div id="p1485" num="1485" class="description-paragraph style-scope patent-text">The applied dose range of ADC and/or IMT therapy defined herein is that effect is treated or prevented needed for generating
A little dosage ranges.It should be appreciated that required dosage range depends on precise nature, administration method, the system of ADC and/or IMT therapy
The property of agent, the age of patient, property, degree or the seriousness of patient condition, contraindication (if any) and attending physician
Judgement.Standard empirical routines can be used and adjust the variation of these dosage levels to optimize.Optimal dose is measured usually will
It is related to treating the balance of benefit level and any risk or harmful side effect.The sustained continuous of theme pharmaceutical composition discharges
Preparation may be appropriate.</div>
      <div id="p1486" num="1486" class="description-paragraph style-scope patent-text">ADC defined herein and/or IMT therapy defined herein can through a variety of ways (it is including but not limited to oral,
Intravenously, intra-arterial, subcutaneous, parenteral, intranasal, intramuscular, encephalic, intracardiac, intra-ventricle, intratracheal, cheek, rectum, peritonaeum
It is in interior, intradermal, local, transdermal, tumor and intrathecal) or by being implanted into or sucking it is applied to patient.In an implementation of the invention
In example, ADC defined herein is intravenously applied.In one embodiment of the invention, application ADC defined herein in tumour.
In one embodiment of the invention, IMT therapy defined herein is intravenously applied.In one embodiment of the invention, abdomen
Application IMT therapy defined herein in film.In one embodiment of the invention, application IMT therapy defined herein in tumour.</div>
      <div id="p1487" num="1487" class="description-paragraph style-scope patent-text">The suitable dosage of ADC defined herein and IMT therapy defined herein can be about in clinical treatment
Dosage those of is used, wherein the IMT therapy individually or with other IMT therapies is administered in combination.Advantageously, in one embodiment
In, reach needed for treatment validity compared with dosage when single therapy, such as herein Anywhere defined in ADC with lower
Dosage application.Advantageously, in another embodiment, compared with dosage needed for treatment validity is reached when single therapy, such as
Anywhere defined IMT agent is applied with lower dosage herein.Reach when In yet another embodiment, with single therapy and controls
The corresponding dosage of IMT agent or ADC needed for treating validity are compared, such as herein Anywhere defined in ADC and as any herein
IMT agent defined in place is with the application of lower dosage.Such Asia effective dose (sub-efficacious dose) reduces
Toxicity, and therefore improve safety.</div>
      <div id="p1488" num="1488" class="description-paragraph style-scope patent-text">In one embodiment, as herein Anywhere defined in ADC than reaching treatment validity when single therapy
Required dosage is low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, extremely
Few 20%, at least 10%, at least 5%, at least 1% dosage application.In another embodiment, as Anywhere determined herein
The IMT agent of justice with it is lower at least 90% than dosage needed for reaching treatment validity when single therapy, at least 80%, at least 70%,
At least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1% dosage is applied
With.In yet another embodiment, as herein Anywhere defined in ADC and as herein Anywhere defined in IMT agent it is equal
It is low at least 90% with corresponding dosage than IMT agent or ADC needed for reaching treatment validity when single therapy, at least 80%, extremely
Few 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1%
Dosage application.Appropriate model for observing tumour growth is well-known to those having ordinary skill in the art, and can be according to institute
The indication of research and change.</div>
      <div id="p1489" num="1489" class="description-paragraph style-scope patent-text">In one embodiment of the invention, patient is immune deficiency.In yet another embodiment of the present invention, patient
It is immune sound.Immune response facilitates the anti-tumor activity that ADC as defined herein is observed in application, therefore is exempting from
Bigger clinical response is observed in the sound patient of epidemic disease.</div>
      <div id="p1490" num="1490" class="description-paragraph style-scope patent-text">In one embodiment, cancer immunotherapy includes inducing tumor specific immune memory.In one embodiment,
Cancer immunotherapy includes induced cancer specific immunity memory.This immunological memory can valuably enhance for then exposure
In any response of tumour antigen, and prevent or reduce the recurrence of patient tumors.</div>
      <div id="p1491" num="1491" class="description-paragraph style-scope patent-text">In one embodiment, cancer immunotherapy includes reducing tumour growth.</div>
      <div id="p1492" num="1492" class="description-paragraph style-scope patent-text">In one embodiment, ADC or cancer immunotherapy include inducing immunogenic cell death.</div>
      <div id="p1493" num="1493" class="description-paragraph style-scope patent-text">In one embodiment, as Anywhere defined cancer includes but is not limited to neoplasm and tumour (example herein
Such as, histocytoma, glioma, astrocytoma, osteoma), cancer (such as lung cancer, Small Cell Lung Cancer, human primary gastrointestinal cancers, head
Neck cancer, gastric cancer, intestinal cancer, colon cancer, breast cancer, oophoroma, prostate cancer, carcinoma of testis, liver cancer, kidney, bladder cancer, cancer of pancreas,
The cancer of the brain, sarcoma, osteosarcoma, Kaposi sarcoma, melanoma) and leukaemia.Other cancers of interest include but is not limited to blood
Malignant tumour, such as leukaemia and lymthoma, such as non-Hodgkin lymphoma and hypotype (such as DLBCL, marginal zone lymphoma,
Cover area's lymthoma and follicular lymphoma), Hodgkin lymphoma, AML and other B or T cell source cancer.</div>
      <div id="p1494" num="1494" class="description-paragraph style-scope patent-text">In one embodiment, cancer is colon cancer.In one embodiment, cancer is lung cancer.In one embodiment,
Cancer is breast cancer.In one embodiment, cancer is kidney.Preferred cancer indication includes the antigen for expressing ADC targeting
Those of indication.</div>
      <div id="p1495" num="1495" class="description-paragraph style-scope patent-text">The therapeutical uses of new A DC</div>
      <div id="p1496" num="1496" class="description-paragraph style-scope patent-text">The present invention provides the purposes that ADC of the invention is used for drug.The present invention also provides ADC of the invention to be used for cancer
The purposes of disease immunization therapy, wherein the cancer immunotherapy includes that ADC is applied to patient.</div>
      <div id="p1497" num="1497" class="description-paragraph style-scope patent-text">The present invention also provides the methods prevented or treat disease, and this method includes that ADC of the invention is applied to patient.
The present invention also provides cancer immunotherapy method, this method includes that ADC of the invention is applied to patient.</div>
      <div id="p1498" num="1498" class="description-paragraph style-scope patent-text">In one embodiment, the method for the treatment disease includes applying the ADC of the invention of therapeutically effective amount.Another
In one embodiment, the method for the prevention disease includes applying the ADC of the invention of prevention effective dose.</div>
      <div id="p1499" num="1499" class="description-paragraph style-scope patent-text">ADC can be used as single therapy application, or in addition to ADC defined herein, can also relate to the application of IMT.IMT
Application can combine with ADC defined herein or as its auxiliary or in connection, and can be component be used individually
Simultaneously, in succession or the mode that is administered alone carries out.</div>
      <div id="p1500" num="1500" class="description-paragraph style-scope patent-text">In use, ADC defined herein can reduce tumour growth.</div>
      <div id="p1501" num="1501" class="description-paragraph style-scope patent-text">In use, ADC defined herein can be with inducing immunogenic cell death.</div>
      <div id="p1502" num="1502" class="description-paragraph style-scope patent-text">Definition</div>
      <div id="p1503" num="1503" class="description-paragraph style-scope patent-text">" therapeutically effective amount ", which refers to, is faced when ADC is applied to patient alone or in combination at least one for treating disease or disease
When bed symptom, it is sufficient to influence the amount of this treatment of disease or symptom.Therapeutically effective amount can according to the ADC of such as disease and/
Or symptom, the age of patient to be treated, weight and/or health status and prescriber judgement and change.It is given any
Determine in situation, therapeutically effective amount appropriate can be determined by those skilled in the art or can be determined by routine experiment.It controls
It is more than any toxicity of ADC or the amount of illeffects that treatment effective quantity, which is also beneficial effect,.</div>
      <div id="p1504" num="1504" class="description-paragraph style-scope patent-text">Cancer immunotherapy stimulates the activity of the specific composition part of immune system or offsets the cancer by inhibition immune response
The signal that disease cell generates.</div>
      <div id="p1505" num="1505" class="description-paragraph style-scope patent-text">Example</div>
      <div id="p1506" num="1506" class="description-paragraph style-scope patent-text">
        <u class="style-scope patent-text">Example 1: materials and methods</u>
      </div>
      <div id="p1507" num="1507" class="description-paragraph style-scope patent-text">Example 1.1: antibody, reagent and cell line</div>
      <div id="p1508" num="1508" class="description-paragraph style-scope patent-text">CT26,4T1 and Renca cell are obtained from ATCC (Virginia Manassas (Manassas, VA)).By CT26
It maintains and is supplemented in the RPMI culture medium of 10% fetal calf serum with 4T1.Renca is maintained and is supplemented with 10% fetal calf serum
In EMEM.The western company in the Argonne of MCA205 cell from Portland, Oregon (Agonox (Portland, OR)) obtains, and is mending
It is grown in RPMI filled with 10% fetal calf serum.Using based on STR DNA typing and multiplex PCR (Columbia, MD
IDEXX biological study (IDEXX Bioresearch, Columbia, MO)) cell line is verified again.Anti- PD-1 (RMP1-
14), (state of New Hampshire is western from BioXCell company by anti-PD-L1 (10F.9G2), anti-CD4 (GK1.5) and anti-CD8 (53-6.7)
Lebanon (West Lebanon, NH)) it obtains.Mouse OX40 ligand fusion protein (OX40L FP), mouse GITR ligand fused
Albumen (GITRL FP) and Isotype control antibodies are produced by Midi Miao Ni company.In order to generate OX86 mIgG2a antibody, from west
Ge Ma company (Sigma) buys OX86 hybridoma.Then by Midi Miao Ni company that the domain Fc is again engineered for mouse IgG 2a
Form.</div>
      <div id="p1509" num="1509" class="description-paragraph style-scope patent-text">Example 1.2: zooscopy</div>
      <div id="p1510" num="1510" class="description-paragraph style-scope patent-text">It grows cell in monolayer culturess, is harvested by trypsin digestion, then subcutaneous transplantation is into mouse.
For CT26 and Renca tumor model, using No. 26 needles by 5  10<sup class="style-scope patent-text">5</sup>A cell is transplanted to 6-8 week old female BAl BIc/c mouse
In the right abdomen of (the Ha Lan company (Harlan, Indianapolis, IN) of Indiana State Indianapolis).For
MCA205 tumor model, using No. 26 needles by 2.5  10<sup class="style-scope patent-text">5</sup>A cell is transplanted to 6-8 week old female C57BL/6 mouse (Yin Dian
The Ha Lan company of the Indianapolis Na Zhou) right abdomen in.For 4T1 tumor model, using No. 26 needles by 1  10<sup class="style-scope patent-text">5</sup>
Cell is transplanted in 6-8 week old female BAl BIc/c mouse right abdomen.</div>
      <div id="p1511" num="1511" class="description-paragraph style-scope patent-text">All antibody and fusion protein are administered by intraperitoneal injection.Immunotherapeutic agent administration in CT26 model is such as
Under: anti-PD-L1 (30mg/kg, 2 times/week  4)Anti- PD-1 (20mg/kg2 times/week  4)Mouse OX40 ligand fusion protein
(5mg/kg2 times/week  2)Mouse GITR ligand fusion protein (5mg/kg  6).Administration in MCA205 model is as follows:
EphA2- tubulysin (3mg/kg, single dose) and mouse OX40L FP (20mg/kg, 2 times/week  2).In Renca model
It is administered as follows: EphA2-PBD (0.33mg/kg, once a week  3) and mouse GITRL FP (1mg/kg2 times/week  6).It is logical
It crosses and intravenous injection progress ADC administration is carried out with 10mL/kg mouse weight.Treat start when, according to gross tumor volume by mouse
Random grouping, reaches 100-200mm in tumour<sup class="style-scope patent-text">3</sup>When be administered, but in CT26 model GITRL FP exception, reach about in tumour
300mm<sup class="style-scope patent-text">3</sup>When be administered.For delay administration experiment, start to treat within 15 days after applying ADC using dosage same as described above
Method.</div>
      <div id="p1512" num="1512" class="description-paragraph style-scope patent-text">As determined by being calculated based on the sample size for using nQuery software to carry out, every group of size of animal is in every group of 10-
In the range of 12 animals.Tumour and body weight measurements are acquired twice a week, and use equation (L  W<sup class="style-scope patent-text">2</sup>)/2 calculate tumour body
Product, wherein L and W respectively refers to length and width size.Error bars are calculated as the standard error of average value.The one of monitoring mouse daily
As health status, and it is all experiment according to the AAALAC and Midi Buddhist nun Miao for treating and nursing about experimental animal humanity
IACUC guide carries out.The statistical analysis (Rios-Doria et al., 2015) to act synergistically as described above.</div>
      <div id="p1513" num="1513" class="description-paragraph style-scope patent-text">It is studied for exhausting, the 6th day, the 10th day, the 14th day and the 18th day application CD8 exhausts anti-after tumor cell transplantation
Body (8mg/kg).The administration of EphA2- tubulysin is carried out with 5mg/kg at the 11st day, EphA2-PBD is carried out with 0.3mg/kg and is given
Medicine.Anti- PD-L1 is applied with 30mg/kg at the 11st day, the 14th day, the 17th day and the 21st day.</div>
      <div id="p1514" num="1514" class="description-paragraph style-scope patent-text">Example 1.3:AH-1 stimulation measurement</div>
      <div id="p1515" num="1515" class="description-paragraph style-scope patent-text">The spleen for the mouse that complete response is realized in treating from ADC is handled, by cell with 2  10<sup class="style-scope patent-text">6</sup>A cells/well
It is inoculated in 96 orifice plates.By the AH1 peptide (Anaspec#64798) and protein transport inhibitor of cell and 10  g/mL
(Ebioscience#00-4980-93) it incubates four hours, is then assessed by flow cytometry together.Then it analyzes
CD45<sup class="style-scope patent-text">+</sup>/CD8<sup class="style-scope patent-text">+</sup>Or CD45<sup class="style-scope patent-text">+</sup>/CD4<sup class="style-scope patent-text">+</sup>(and TNF <sup class="style-scope patent-text">+</sup>And/or IFN <sup class="style-scope patent-text">+</sup>) percentage.</div>
      <div id="p1516" num="1516" class="description-paragraph style-scope patent-text">Example 1.4: pharmacodynamic studies</div>
      <div id="p1517" num="1517" class="description-paragraph style-scope patent-text">By CT26 cell (5  10<sup class="style-scope patent-text">5</sup>A cell/mouse) it is transplanted in the right abdomen of 6-8 week old BALB/c female mice.
When tumour is about 300mm<sup class="style-scope patent-text">3</sup>When, EphA2-PBD (0.3mg/kg) is carried out to mouse, EphA2- tubulysin (5mg/kg), is resisted
PDL1 (10F.9G2,20mg/kg) or OX40 monoclonal antibody (OX86,5mg/kg) administration.At the 0th day with an intravenous agent
Amount application ADC.It is anti-in the 0th day and the 4th day application OX40 in the 0th day, the 4th day, the 7th day and the 11st day application PD-L1 antibody
Body.The 5th day and the 12nd day upon administration, spleen and tumour, processing and dyeing are collected, to be used for flow cytometry.For Renca
Model, when tumour is about 150mm<sup class="style-scope patent-text">3</sup>When start the administration of EphA2-PBD, GITRL FP or combinations thereof.In the 0th day progress EphA2-
PBD administration, in progress GITRL FP administration in the 0th day and the 4th day, and in the 5th day harvest tumour.With ACK solution (California
Life Technologies Corporation (Life Tech, Carlsbad, CA) of state Carlsbad) splitting erythrocyte.Tumour is cut into 2mm<sup class="style-scope patent-text">3</sup>Block
And mankind's kit (Mei Tian Ni Bioisystech Co., Ltd of San Diego, CA is dissociated using Miltenyi tumour
(Miltenyi Biotec, San Diego, CA)) digestion 40 minutes.Vigor count is carried out to tissue, it is then thin with 1,000,000
Born of the same parents/hole inoculation.With dead blue (Live Dead Blue) (Life Technologies Corporation of Carlsbad, CA) living with 1:
1000 dye 20 minutes at room temperature, are washed out and are blocked at room temperature 15 minutes using 4% mice serum.Add extracellular dye
Then material incubates 20 minutes in FACS buffer solution (PBS+2%FBS) at 4 deg. celsius.Then FOXP3 transcript reagent is used
Box (the Ebioscience company (Ebioscience, San Diego, CA) of San Diego, CA) washing is fixed
With permeabilization cell.Apply dyestuff intracellular at room temperature to be kept for 30 minutes.It is washed out cell and in LSRII or Fortessa streaming
It is run on cell instrument (Santiago BD company (BD, San Diego)).Antibody for flow cytometry dyeing includes CD8 (BD
5H10 clones in company), CD11b (BD company, clone M1/70), (RM4- clones to CD4 in life legend company (Biolegend)
5), CD11c (n418 clones in life legend company), CD86 (GL-1 clones in life legend company), GR-1 (life legend public affairs
RB6-8C5 clones in department), MHC-II (life legend company, clone M5/114.15.2), F4/80 (life legend company, clone
BM8), CD69 (H1.2F3 clones in life legend company), KI-67 (SolA15 clones in Ebioscience company), PD-1
(J43 clones in Ebioscience company), FOXP3 (FJK-16S clones in Ebioscience company), CD45 (Ebioscience
30-F11 clones in company) and IFN- (clone XMG1.2).Use FlowJo software (the Shu Xing company of Oregon ashland
(Treestar, Ashland, OR)) analyze data.</div>
      <div id="p1518" num="1518" class="description-paragraph style-scope patent-text">Example 1.5: internal vaccine inoculation research</div>
      <div id="p1519" num="1519" class="description-paragraph style-scope patent-text">It is handled CT26 cell 24 hours with 400nM AZD9185 (tubulysin) or 8nM SG3199 (PBD), so that carefully
Born of the same parents be intended to cell death (such as by renewed vaccination test in shortage growth assess) but still have &gt; 95% survival.By this
It is inoculated in the left abdomen of BALB/c mouse through 500,000 in processing cell a bit, to test their vaccine inoculation ability,
To be used for subsequent right abdomen challenge.Control includes with 75Gy radiation treatment or has passed through the thin of 3 Frozen-thawed cycleds (necrosis)
Born of the same parents.3  10 are utilized after 7 days<sup class="style-scope patent-text">6</sup>A untreated CT26 cell throws down the gauntlet on right abdomen.</div>
      <div id="p1520" num="1520" class="description-paragraph style-scope patent-text">Example 1.6:ADC preparation</div>
      <div id="p1521" num="1521" class="description-paragraph style-scope patent-text">The antibody of EphA2 is as previously described (Jackson et al., 2008).By PBD and tubulysin payload site-specific
Property is conjugated to by the cysteine in the engineered domain Fc for antibody.Initially, molten by the way that the antibody of 5-10mg/mL concentration to be added to
In three (2- carboxyethyl) phosphines (TCEP) of the PBS edta buffer liquid adjusted through pH, so that resulting antibody/TCEP solution
TCEP/mAb molar ratio be 40 to carry out partial reduction antibody.By antibody/TCEP solution incubation 2.5-3 hours at 37 DEG C.It uses
NAP column by the antibody after reduction through in buffer-exchanged to conjugation reaction buffer (PBS, 1mM EDTA, pH 7.2), to be used for
Milligram grade conjugation.By add hydroascorbic acid (dHAA) DMSO solution with realize 20 dHAA/mAb molar ratio, and
3-4 hours are incubated at 20 DEG C to cause reoxidizing for antibody interchain disulfide bond.</div>
      <div id="p1522" num="1522" class="description-paragraph style-scope patent-text">PBD or tubulysin payload are prepared and they being dissolved in DMSO to realize the ultimate density of 10mM.
For conjugation reaction, DMSO is slowly added into the antibody after reduction, reaches the ultimate density of 10%v/v, then will effectively bear
It carries and is added in antibody, to realize 12 payload/mAb molar ratio.It is at 20 DEG C that payload/mAb solution incubation 1 is small
When, and conjugation reaction is quenched by addition N-acetylcystein (NAC) solution, to realize 48 NAC/mAb molar ratio, with
It is incubated 15 minutes at 20 DEG C afterwards.Then by final ADC product buffer-exchanged to PBS or 25mM histidine monohydrochloride, 200mM sugarcane
In sugar and 0.02%w/v PS80 (pH 6).In the following manner come characterize gained ADC biochemical property: arranged using size
Chromatography high pressure liquid chromatography (SEC-HPLC) is hindered to measure purity and aggregation content, and uses hydrophobic interaction chromatograph HPLC
(HIC-HPLC) confirm drugloading rate.Carry out reduction glycosylation reversed-phase HPLC (RP-HPLC) and liquid chromatography-mass spectrography (LC-MS)
To measure drug: the specificity of antibody ratio (DAR) and locus specificity conjugation.Typically, these conjugation reactions, which generate, has &gt;
The ADC of 98% monomer, wherein coupling efficiency &gt; 90%, related to DAR &gt; 1.82.</div>
      <div id="p1523" num="1523" class="description-paragraph style-scope patent-text">
        <u class="style-scope patent-text">Example 2: vaccine inoculation/challenge measurement</u>
      </div>
      <div id="p1524" num="1524" class="description-paragraph style-scope patent-text">Different nti-neoplastic compounds command the ability from the dying cell of targeting release immunogenic molecules at them
Aspect is different.Induction that immunogenicity cell death is related to cell surface calreticulin and ATP and HMGB1 are from dying
The release of cell, they are respectively in connection with CD91, P2RX7 and TLR4 on dendritic cells, so as to cause adaptive immune response
Enhancing.</div>
      <div id="p1525" num="1525" class="description-paragraph style-scope patent-text">Since tubulysin and PBD inhibit to induce with DNA cross-linking mechanism carefully by fundamentally different micro-pipe respectively
Born of the same parents are dead, it is therefore to be understood that they are in terms of the ability of booster immunization in activation dendritic cells or by other means
Different.</div>
      <div id="p1526" num="1526" class="description-paragraph style-scope patent-text">The internal vaccine inoculation ability of example 2.1:PBD and tubulysin</div>
      <div id="p1527" num="1527" class="description-paragraph style-scope patent-text">In order to test this point, tubulysin and PBD are used for vaccine inoculation/challenge mouse model.With tubulysin (1 
M) or PBD (10nM) handles the period (Figure 1A) that CT26 mouse colonic cell continues 24 hours.At this point, cell is still deposited
It is living, but consequently tend to cell death.</div>
      <div id="p1528" num="1528" class="description-paragraph style-scope patent-text">By these dying but not dead cell subcutaneous transplantations into the left abdomen of BALB/c mouse, to test their energy
It is no carry out vaccine inoculation with resist after 1 week in opposite side abdomen with tumour formed the untreated CT26 cell of dosage into
Capable subsequent challenge.Cell via radiation is included as positive control, have passed through the non-viable non-apoptotic cell of Frozen-thawed cycled as yin
Property control be included.</div>
      <div id="p1529" num="1529" class="description-paragraph style-scope patent-text">Vaccine inoculation is not implemented in provided non-viable non-apoptotic cell, because there is no tumor free the 32nd day after CT26 challenge
Mouse (Figure 1B and Fig. 1 C).As was expected, and CT26 cell via radiation has high degree of immunogenicity, and prevents all small
There is tumour in mouse.In assessment in the 65th day, the cell of tubulysin and PBD processing prevented 40% and 70% mouse from being formed respectively
Tumour.These are the results show that the cell of tubulysin processing and the cell of PBD processing provide significant vaccine inoculation.</div>
      <div id="p1530" num="1530" class="description-paragraph style-scope patent-text">Example 2.2: the internal vaccine inoculation ability of the ADC comprising PBD or tubulysin</div>
      <div id="p1531" num="1531" class="description-paragraph style-scope patent-text">According in example 2.1 as a result, having studied has with the ADC processing with tubulysin or PBD payload conjugation
Whether the mouse of tumour may also lead to the vaccine inoculation of mouse.</div>
      <div id="p1532" num="1532" class="description-paragraph style-scope patent-text">For these researchs, using the antibody of targeting EphA2, and the antibody and tubulysin (AZ1508) or PBD
(SG3315) payload is conjugated.It is molten with EphA2- micro-pipe with the expected dosage level and frequency that will generate high proportion complete response
Element or EphA2-PBD processing have the BALB/c mouse of CT26 tumour.When gross tumor volume is 75mm<sup class="style-scope patent-text">3</sup>Or 150mm<sup class="style-scope patent-text">3</sup>When, to having
The processing of the mouse of CT26 tumour produces a high proportion of complete response (Fig. 2A).After treating and observing for 90 days, about 57%
The mouse for receiving 5mg/kg EphA2- tubulysin has complete response.In contrast, largely receive 1mg/kg EphA2-
The mouse (82%) of PBD all has complete response.</div>
      <div id="p1533" num="1533" class="description-paragraph style-scope patent-text">Then, these subgroups without mice with tumor are challenged again with CT26 cell, treated with EphA2- tubulysin small
Mouse has 86% to repel tumour cell challenge, and has 76% to repel tumour cell challenge (figure with the mouse that EphA2-PBD is treated
2B).CT26 cell is easily grown in the initial BALB/c mouse that same time is inoculated with.These are the results show that these ADC are lured
The cell killing led produces tumor-specific immunity memory.Then ADC is assessed in another syngeneic tumor model MCA205
The ability of inducing memory.In the model, when with the EphA2-PBD of 1mg/kg application single dose, 10/10 animal has been realized
Full response.After being rechallenged at the 43rd day with MCA205 cell (Fig. 2 C), all mouse are still without tumour, and in initial cell
Tumour growth was not observed up to 160 days after transplanting.In contrast, MCA205 tumour when rechallenging while being transplanted initial
It is easily grown in C57Bl/6 animal.These data show that EphA-Tub and EphA2-PBD are to rechallenge to provide in vivo
Significant vaccine inoculation.</div>
      <div id="p1534" num="1534" class="description-paragraph style-scope patent-text">The ability of example 2.3:ADC inducing tumor specific immune memory</div>
      <div id="p1535" num="1535" class="description-paragraph style-scope patent-text">In order to measure the T cell from the mouse for realizing complete response after being treated with ADC with the presence or absence of any function
Variation determines after with AH1 peptide (it is the immunodominant antigen of CT26 cell) in vitro stimulation, from EphA2- tubulysin or
EphA2-PBD obtains the IFN- and TNF  production of the spleen t-cell of five mouse of complete response.</div>
      <div id="p1536" num="1536" class="description-paragraph style-scope patent-text">In the measurement, the CD4 of the mouse of Lai Ziyong EphA2- tubulysin processing<sup class="style-scope patent-text">+</sup>T cell is produced when being stimulated with AH1 peptide
It has given birth to TNF  (Fig. 3 A), and has been generated come the CD4+T cell of the animal for both EphA2- tubulysin and EphA2-PBD processing of using by oneself
IFN- (Fig. 3 B).Similar expression pattern is found in CD8<sup class="style-scope patent-text">+</sup>T cell (Fig. 3 C-D).</div>
      <div id="p1537" num="1537" class="description-paragraph style-scope patent-text">In short, these data are shown, these ADC remember induction of tumor-specific immunity, and these cells with come from
The T cell of initial mouse is functionally different.In addition, due to only having EphA2- tubulysin thin induction of TNF- secretion T
Born of the same parents, therefore seem that there are payload specificity responses.</div>
      <div id="p1538" num="1538" class="description-paragraph style-scope patent-text">
        <u class="style-scope patent-text">Example 3: effect of the immune system in the anti-tumor activity that ADC is induced</u>
      </div>
      <div id="p1539" num="1539" class="description-paragraph style-scope patent-text">The antitumor research of most of assessment ADC has been carried out in immunodeficient mouse.Because of the tables of data in example 2
Bright T cell may play a role in anti-tumor activity, so having evaluated these EphA2ADC compared with immune competent mice and existing
Anti-tumor activity in T cell defect (naked) mouse.</div>
      <div id="p1540" num="1540" class="description-paragraph style-scope patent-text">Example 3.1: the immune sound anti-tumor activity with immunodeficient mouse</div>
      <div id="p1541" num="1541" class="description-paragraph style-scope patent-text">ADC is had evaluated to three kinds of syngeneic tumor models (CT26, the 4T1 grown in immune sound or immunodeficient mouse
And MCA205) anti-tumor activity (Fig. 4).In each tumor model, compared with immunodeficient mouse (left figure), EphA2- is micro-
Both pipe lysin (above) and EphA2-PBD (following figure) all have bigger antitumor work in immune competent mice (right figure)
Property.</div>
      <div id="p1542" num="1542" class="description-paragraph style-scope patent-text">These are the results show that function immune system is important the fully active of these ADC, and shows T cell pair
ADC is important in immune effect perfected in model.</div>
      <div id="p1543" num="1543" class="description-paragraph style-scope patent-text">Example 3.2:T cell the ADC the effect of in effect</div>
      <div id="p1544" num="1544" class="description-paragraph style-scope patent-text">Whether it is important to test T cell to ADC in immune effect perfected in model, with EphA2- tubulysin
Or EphA2-PBD ADC and CD8 exhaust mouse of the Antybody therapy with CT26 tumour.</div>
      <div id="p1545" num="1545" class="description-paragraph style-scope patent-text">Strikingly, CD8<sup class="style-scope patent-text">+</sup>The exhaustion of T cell keeps individual ADC invalid (Fig. 5).When progress Isotype control antibodies
When administration, on ADC activity without influence.These are the results show that T cell is important ADC in immune effect perfected in model.</div>
      <div id="p1546" num="1546" class="description-paragraph style-scope patent-text">The above results show that the anti-tumor activity that immune response may be responsible for ADC induction increases.</div>
      <div id="p1547" num="1547" class="description-paragraph style-scope patent-text">The synergistic effect of example 4:ADC and cancer immunotherapy</div>
      <div id="p1548" num="1548" class="description-paragraph style-scope patent-text">The cell that tubulysin or PBD are killed can be with vaccinated mice to resist the fact that CT26 tumour rechallenges table
Bright, these bullets can be with inducing immunogenic cell death.Combine if had studied with cancer immunotherapy, carries these bullets
ADC whether can generate summation action or potential synergistic effect.</div>
      <div id="p1549" num="1549" class="description-paragraph style-scope patent-text">It is individually or antibody combined to the BALB/c mouse progress EphA2-ADC administration (figure with CT26 tumour with anti-PD-L1
6)</div>
      <div id="p1550" num="1550" class="description-paragraph style-scope patent-text">Modest antitumor activity is produced with the anti-PD-L1 treatment of 0.1mg/kg EphA2-PBD or 30mg/kg, wherein every
In ten mouse of group, there are two complete responses (CR), i.e., subside (Fig. 6 B and Fig. 6 C) completely.However anti-PD-L1 and EphA2-PBD
Combine the collaboration response (Fig. 6 D) produced with 7/10CR.It should be noted that the EphA2-PBD of 0.1mg/kg is that ADC exists
Suboptimum dosage (Fig. 4 A) in CT26 model.</div>
      <div id="p1551" num="1551" class="description-paragraph style-scope patent-text">Tumor growth delay is resulted in EphA2- tubulysin ADC processing mouse, but without CR (Fig. 6 E).With mouse GITR
Ligand fusion protein processing mouse has caused effective antitumour activity, wherein 8/12 animal realizes CR (Fig. 6 F).However,
The combining to produce of EphA2- tubulysin ADC and GITRL FP response is cooperateed with, wherein observing in all (12/12) mouse
To CR (Fig. 6 G).</div>
      <div id="p1552" num="1552" class="description-paragraph style-scope patent-text">The studies above has been carried out by being administered while ADC and immunization therapy.When postponing the administration of immunization therapy, observation
To the result to differ widely.It carried out not observing joint when anti-PD-L1 administration (Fig. 6 H) at 15 days after EphA2-PBD ADC
Effect.The progress GITRL FP administration in 15 days after EphA2- tubulysin ADC observes that joint effect substantially reduces (figure
6I).These data show that the dosage regimen of ADC and IMT are important activity.</div>
      <div id="p1553" num="1553" class="description-paragraph style-scope patent-text">These ADC and anti-PD-1 antibody or the united joint study of OX40 ligand fusion protein are also carried out.From these connection
It is as shown in Figure 6 to close the result obtained in research.These are the results show that compared with single agent activity, these ADC and these cancers
Combining for immunization therapy produces synergistic antitumor response.</div>
      <div id="p1554" num="1554" class="description-paragraph style-scope patent-text">These are the results show that ADC is combined with the agonist of checkpoint inhibitor or TNFR superfamily to be had in vivo
Effect, the antitumor action enhanced.</div>
      <div id="p1555" num="1555" class="description-paragraph style-scope patent-text">CD8 exhaustion also eliminates the united activity of ADC and anti-PD-L1 (Fig. 7 and referring to example 3.2).These data show,
CD8<sup class="style-scope patent-text">+</sup>T cell plays a role in ADC in immune perfect in the activity in animal.</div>
      <div id="p1556" num="1556" class="description-paragraph style-scope patent-text">The pharmacodynamic studies of example 5:ADC</div>
      <div id="p1557" num="1557" class="description-paragraph style-scope patent-text">In order to measure these ADC in vivo to the effect of immunocyte, pharmacodynamics has been carried out in CT26 model and has been ground
Study carefully.</div>
      <div id="p1558" num="1558" class="description-paragraph style-scope patent-text">By EphA2-PBD or EphA2- tubulysin individually or with PD-L1 or OX40 are antibody combined is applied to CT26
The mouse of tumour.5 days or 12 days harvest spleens and tumour after medicament administration, and study the variation of immunocyte group.</div>
      <div id="p1559" num="1559" class="description-paragraph style-scope patent-text">EphA2- tubulysin is induction of CD45<sup class="style-scope patent-text">+</sup>Lymphocyte and CD45<sup class="style-scope patent-text">+</sup>CD8<sup class="style-scope patent-text">+</sup>Both cytotoxic T lymphocytes (CTL)
Tumor-infiltrated (Fig. 9, A-B).Although EphA2-PBD does not induce the tumor-infiltrated of these cell types, it really with
EphA2- tubulysin is together induction of CD8 pre-existing in tumour<sup class="style-scope patent-text">+</sup>The activation of cell, such as passes through CD8<sup class="style-scope patent-text">+</sup>CD69<sup class="style-scope patent-text">+</sup>Group is reflected
Fixed (Fig. 9 C).Both anti-OX40 treatment and EphA2-PBD and EphA2- tubulysin is also observed to combine with anti-PD-L1 pair
The activation of CD8+ cell.EphA2- tubulysin, OX40 antibody combine individually and with two kinds of ADC and reduce total CD4 in tumour<sup class="style-scope patent-text">+</sup>
The quantity (Fig. 9 D) of T cell.In the subgroup, after EphA2- tubulysin is individually or with anti-PD-L1 combination therapy, tumour
Middle FOXP3<sup class="style-scope patent-text">+</sup>Cell (regulatory T cells (T<sub class="style-scope patent-text">reg</sub>) marker) quantity slightly increase (Fig. 9 E).In contrast, with OX40
Antibody individually or with after ADC combination therapy, T in tumour<sub class="style-scope patent-text">reg</sub>Quantity substantially reduce (Fig. 9 E).However, although EphA2- micro-pipe
Lysin makes T<sub class="style-scope patent-text">reg</sub>Slightly increase, but the CD8:T in the group<sub class="style-scope patent-text">reg</sub>Ratio and untreated tumour and with individually and with two kinds of ADC join
The OX40 antibody of conjunction is compared and generally increases (Fig. 9 F).Two kinds of ADC induction of PD-1 expression and greater percentage be in Ki67
Positive CD8<sup class="style-scope patent-text">+</sup>Cell shows CD8<sup class="style-scope patent-text">+</sup>T cell proliferation increases (Fig. 9, G-H).EphA- tubulysin with OX40 is antibody combined controls
After treatment, CD8<sup class="style-scope patent-text">+</sup>PD-1 and Ki67 expression on cell also increase.Two kinds of ADC can also induce CD4 in spleen<sup class="style-scope patent-text">+</sup>The proliferation of cell,
Such as CD45<sup class="style-scope patent-text">+</sup>CD4<sup class="style-scope patent-text">+</sup>Ki67<sup class="style-scope patent-text">+</sup>(Fig. 9 I) shown in the quantity increase of cell.However, observing compared with individual medicament, EphA2-PBD
Combine with anti-PD-L1 and OX40 and EphA2- tubulysin combines with anti-PD-L1 and causes spleen CD4<sup class="style-scope patent-text">+</sup>T cell proliferation is shown
Write bigger increase (Fig. 9 I).The discovery highlights compared with single agent treatment, and ADC+IMT conjoint therapy causes significant bigger
Antitumor action a kind of potential mechanism.</div>
      <div id="p1560" num="1560" class="description-paragraph style-scope patent-text">When checking the variation of myeloid cell, discovery ADC increases the level of CD86 in multiple cell masses.These results
It is illustrated in fig. 10 shown below.EphA2- tubulysin individually and with anti-PD-L1 or OX40 combined induction CD45<sup class="style-scope patent-text">+</sup>CD86<sup class="style-scope patent-text">+</sup>The tumour of cell
Infiltration.These identical group also increases F480<sup class="style-scope patent-text">+</sup>The expression of CD86 on macrophage.Since CD86 is the increased mark of antigen presentation
Will object, therefore these be the results show that EphA2- tubulysin can directly induce the cell that may have this enhancing ability
It is tumor-infiltrated.Although EphA2-PBD does not induce CD45<sup class="style-scope patent-text">+</sup>CD86<sup class="style-scope patent-text">+</sup>Cell it is tumor-infiltrated, but EphA2-PBD individually or with it is anti-
PD-L1 and OX40 joint is really induction of CD45<sup class="style-scope patent-text">+</sup>CD11c<sup class="style-scope patent-text">+</sup>MHCII<sup class="style-scope patent-text">hi</sup>CD86 expression on mature dendritic cell.In fact, removing
Except individual anti-PD-L1, all processing groups increase the expression of the CD86 on mature dendritic cell.It is interesting that EphA2-
Tubulysin is combined individually and with anti-PD-L1 and EphA2-PBD combines with anti-OX40 and increases CD86 in tumour<sup class="style-scope patent-text">+</sup>Graininess
The percentage of MDSC shows that the antigen presentation phenotype on these cells increases.</div>
      <div id="p1561" num="1561" class="description-paragraph style-scope patent-text">The master between joint and single medication is observed on the myeloid cell in the spleen of the animal with CT26 tumour
Want phenotypic difference.Compared with individual anti-PD-L1, EphA2- tubulysin or EphA2-PBD combine with anti-PD-L1 increases spleen
Dirty middle CD45<sup class="style-scope patent-text">+</sup>CD11c<sup class="style-scope patent-text">+</sup>MHCII<sup class="style-scope patent-text">hi</sup>The percentage of mature dendritic cell.EphA2- tubulysin is combined with anti-OX40 with class
As effect, but EphA2-PBD combine with OX40 then do not have the effect.Compared with individual anti-PD-L1, EphA2-PBD and
EphA2- tubulysin is combined with anti-PD-L1 increases CD45<sup class="style-scope patent-text">+</sup>CD86 expression on lymphocyte.It is interesting that EphA2-
Tubulysin combines the CD86 expression also increased on these cells with anti-OX40, but EphA2-PBD combines then with anti-OX40
Do not increase.The phenotype represents the differentiation effect when OX40 antibody is with tubulysin joint compared with the ADC based on PBD.It is right
Other inspections of spleen Zhong Sui sample group disclose the adjusting expressed CD86 on MDSC.Compared with single medication, EphA2-PBD
Combine with EphA2- tubulysin with anti-PD-L1 and increases CD86<sup class="style-scope patent-text">+</sup>The percentage of monokaryon MDSC.EphA2- tubulysin and anti-
OX40, which combines, also increases CD86<sup class="style-scope patent-text">+</sup>Monokaryon MDSC, but EphA2-PBD combines with anti-OX40, does not increase.With individual anti-PD-
L1 is compared, EphA2-PBD and EphA2- tubulysin also increases the percentage that CD86 is expressed on graininess MDSC.EphA2- micro-pipe
Lysin and anti-OX40 combine the percentage for increasing CD86+ graininess MDSC in spleen, but EphA2-PBD and anti-OX40 joint is then
Do not increase.Strikingly, compared with EphA2-PBD combines, EphA2- tubulysin is combined with anti-PD-L1 and anti-OX40 to be lured
The significant higher infiltration of these cells is led.These are the results show that the ADC induction with PBD or tubulysin payload
Immunophenotype variation in tumour and spleen.</div>
      <div id="p1562" num="1562" class="description-paragraph style-scope patent-text">The results show that two different ADC payloads, induction of immunoregulation effect, this effect does not have report previously
Road.Although PBD and tubulysin have different cytotoxic effect mechanism, perfect in background immune, two kinds effectively
Load can induce the immunogenicity cell shown when being administered in combination with the ADC of these payloads conjugation and immunization therapy
It is dead.This point is also supported in the discovery that two kinds of payloads are capable of inducing antigen-specific immunological memory.In particular, result
It has been shown that, these ADC payloads disclose effect of these payloads in dendritic cells activation to the effect of immunocyte,
Combine to generate with the potent of immunization therapy, which depends on CD8<sup class="style-scope patent-text">+</sup>T cell.</div>
      <div id="p1563" num="1563" class="description-paragraph style-scope patent-text">In short, these statistics indicate that, the combination therapy of the ADC and immunization therapy that are discussed herein can provide increased clinical anti-
It answers.</div>
      <div id="p1564" num="1564" class="description-paragraph style-scope patent-text">All data provided so far are using always the CT26 model sensitive to many immunization therapies, and use targeting
The ADC of single tumor associated antigen EphA2.In order to confirm with the effect of the ADC of the targeting EphA2 ADC payload observed
Independent of model, and it can be applied to the ADC for other targets, we start to measure in different syngeneic tumor models
Whether ADC can combine with immunization therapy, and using whether targeting the ADC of different tumor associated antigens to observe that collaboration is made
With.CT26 cell is overexpressed IGF1R receptor, therefore makes to identify that mouse IGF1R antibody and PBD payload are conjugated.It is having been established
CT26 tumour in give IGF1R-PBD with the single administration of 1mg/kg and obtain an example CR (Figure 11 A, upper right).Anti- PD-L1 treatment
Generate 4 CR (Figure 11 A, lower-left).However, the joint generates synergistic effect, wherein observed CR in 11/12 mouse.
These are the results show that ADC and the synergistic effect of immunization therapy can be observed with different ADC.</div>
      <div id="p1565" num="1565" class="description-paragraph style-scope patent-text">Then EphA2ADC is had evaluated in MCA205 tumor model, because the model is also overexpressed EphA2 receptor.To tool
There is the mouse of MCA205 tumour to carry out EphA2- tubulysin (Figure 11 B, upper right), OX40 ligand fusion protein (Fig. 9 B, lower-left)
With the administration of joint (Fig. 9 B, bottom right).The treatment of EphA2- tubulysin causes 2 CR, OX40FP to lead to 0 CR, but combines
Treatment leads to 6/12 CR.These the results show that ADC and immunization therapy combine caused by synergistic antitumor effect can also be
It represents and is observed in the different tumor models of different patient tumors phenotypes.</div>
      <div id="p1566" num="1566" class="description-paragraph style-scope patent-text">Then EphA2-PBD is had evaluated in Renca tumor model.Since the agonist antibody of GITR has shown that exhaustion
T in mouse model<sub class="style-scope patent-text">reg</sub>, and Renca model shows that growth will depend on T before this<sub class="style-scope patent-text">reg</sub>(25), therefore we have checked T<sub class="style-scope patent-text">reg</sub>
Depletion mouse GITR ligand fusion protein (mGITRL FP) acts in combination with EphA2-PBD ADC.With EphA2-PBD (figure
11C, upper right), mGITRL FP (Figure 12 C, lower-left) or joint (Figure 12 C, bottom right) treatment have Renca tumour mouse.With
EphA2-PBD treatment mouse does not result in CR, and mGITRL FP is induction of 3 CR.Strikingly, EphA2-PBD and
Combining for mGITRL FP produces CR in 8/10 mouse.ADC of these data confirm thats with PBD payload is shown
Out with the third tumor model of the synergistic effect of immunization therapy.</div>
      <div id="p1567" num="1567" class="description-paragraph style-scope patent-text">Difference between example 6:ADC payload</div>
      <div id="p1568" num="1568" class="description-paragraph style-scope patent-text">Although the ADC with tubulysin or PBD payload can act synergistically with immunization therapy, ought with this
When checking immune microenvironment after a little ADC treatment mouse, most of difference between these payloads is observed.</div>
      <div id="p1569" num="1569" class="description-paragraph style-scope patent-text">(it is included in dendritic cells, macrophage in many marrow sample compartments with the EphA2 ADC of tubulysin payload conjugation
On cell and MDSC) successive induction CD86 expression.EphA2-PBD only observes identical effect in some cases.</div>
      <div id="p1570" num="1570" class="description-paragraph style-scope patent-text">In short, following viewpoint: these payload inducing immunogenic cell deaths is supported in these discoveries, and at least right
For dendritic cells, CD86 up-regulation can indicate the increase of the antigen presentation of these cells.</div>
      <div id="p1571" num="1571" class="description-paragraph style-scope patent-text">Bibliography</div>
      <div id="p1572" num="1572" class="description-paragraph style-scope patent-text">Bird,R.E.,K.D.Hardman,J.W.Jacobson,S.Johnson,B.M.Kaufman,S.M.Lee,
T.Lee,S.H.Pope,G.S.Riordan,and M.Whitlow.1988.Single-chain antigen-binding
proteins.Science.242:423-426.</div>
      <div id="p1573" num="1573" class="description-paragraph style-scope patent-text">Callahan,M.K.,and J.D.Wolchok.2013.At the bedside:CTLA-4-and PD-1-
blocking antibodies in cancer immunotherapy.J.Leukoc.Biol.94:41-53.</div>
      <div id="p1574" num="1574" class="description-paragraph style-scope patent-text">Galluzzi,L.,L.Senovilla,L.Zitvogel,and G.Kroemer.2012.The secret
ally:immunostimulationby anticancer drugs.Nat.Rev.DrugDiscov.11:215-233.</div>
      <div id="p1575" num="1575" class="description-paragraph style-scope patent-text">Gerber,H.P.,P.Sapra,F.Loganzo,and C.May.2016.Combining antibody-drug
Conjugates and immune-mediated cancer therapy:What to expect?
Biochem.Pharmacol.102:1-6.</div>
      <div id="p1576" num="1576" class="description-paragraph style-scope patent-text">Hartley,J.A.2011.The development of pyrrolobenzodiazepines as
antitumour agents.Expert Opin.Investig.Drugs.20:733-744.</div>
      <div id="p1577" num="1577" class="description-paragraph style-scope patent-text">Hu-Lieskovan,S.,S.Mok,B.Homet Moreno,J.Tsoi,L.Robert,L.Goedert,
E.M.Pinheiro,R.C.Koya,T.G.Graeber,B.Comin-Anduix,and A.Ribas.2015.Improved
antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF
(V600E)melanoma.Sci.Transl.Med.7:279ra41.</div>
      <div id="p1578" num="1578" class="description-paragraph style-scope patent-text">Huston,J.S.,D.Levinson,M.Mudgett-Hunter,M.S.Tai,J.Novotny,
M.N.Margolies,R.J.Ridge,R.E.Bruccoleri,E.Haber,and R.Crea.1988.Protein
engineering of antibody binding sites:recovery of specific activity in an
anti-digoxin single-chain Fv analogue produced in Escherichia coli.Proc.Natl
.Acad.Sci.U.S.A.85:5879-5883.</div>
      <div id="p1579" num="1579" class="description-paragraph style-scope patent-text">Jackson,D.,J.Gooya,S.Mao,K.Kinneer,L.Xu,M.Camara,C.Fazenbaker,
R.Fleming,S.Swamynathan,D.Meyer,P.D.Senter,C.Gao,H.Wu,M.Kinch,S.Coats,
P.A.Kiener,and D.A.Tice.2008.A human antibody-drug conjugate targeting
EphA2inhibits tumor growth in vivo.CancerRes.68:9367-9374.</div>
      <div id="p1580" num="1580" class="description-paragraph style-scope patent-text">Jeffrey,S.C.,P.J.Burke,R.P.Lyon,D.W.Meyer,D.Sussman,M.Anderson,
J.H.Hunter,C.I.Leiske,J.B.Miyamoto,N.D.Nicholas,N.M.Okeley,R.J.Sanderson,
I.J.Stone,W.Zeng,S.J.Gregson,L.Masterson,A.C.Tiberghien,P.W.Howard,
D.E.Thurston,C.L.Law,and P.D.Senter.2013.A potent anti-CD70antibody-drug
conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific
conjugation technology.Bioconjug.Chem.24:1256-1263.</div>
      <div id="p1581" num="1581" class="description-paragraph style-scope patent-text">Khalil,D.N.,E.L.Smith,R.J.Brentjens,and J.D.Wolchok.2016.The future
of cancer treatment:immunomodulation,CARs and combination immunotherapy.Nat.
Rev.Clin.Oncol.</div>
      <div id="p1582" num="1582" class="description-paragraph style-scope patent-text">Kroemer,G.,L.Galluzzi,O.Kepp,and L.Zitvogel.2013.Immunogenic cell
death in cancer therapy.Annu.Rev.Immunol.31:51-72.</div>
      <div id="p1583" num="1583" class="description-paragraph style-scope patent-text">Larkin,J.,V.Chiarion-Sileni,R.Gonzalez,J.J.Grob,C.L.Cowey,C.D.Lao,
D.Schadendorf,R.Dummer,M.Smylie,P.Rutkowski,P.F.Ferrucci,A.Hill,J.Wagstaff,
M.S.Carlino,J.B.Haanen,M.Maio,I.Marquez-Rodas,G.A.McArthur,P.A.Ascierto,
G.V.Long,M.K.Callahan,M.A.Postow,K.Grossmann,M.Sznol,B.Dreno,L.Bastholt,
A.Yang,L.M.Rollin,C.Horak,F.S.Hodi,and J.D.Wolchok.2015.Combined Nivolumab
and Ipilimumab or Monotherapy in Untreated Melanoma.N.Engl.J.Med.373:23-34.</div>
      <div id="p1584" num="1584" class="description-paragraph style-scope patent-text">Li,J.Y.,S.R.Perry,V.Muniz-Medina,X.Wang,L.K.Wetzel,M.C.Rebelatto,
M.J.Hinrichs,B.Z.Bezabeh,R.L.Fleming,N.Dimasi,H.Feng,D.Toader,A.Q.Yuan,L.Xu,
J.Lin,C.Gao,H.Wu,R.Dixit,J.K.Osbourn,and S.R.Coats.2016.A Biparatopic HER2-
Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models
Refractory to or Ineligible for HER2-Targeted Therapy.Cancer.Cell.29:117-129.</div>
      <div id="p1585" num="1585" class="description-paragraph style-scope patent-text">Liu,L.,P.A.Mayes,S.Eastman,H.Shi,S.Yadavilli,T.Zhang,J.Yang,
L.Seestaller-Wehr,S.Y.Zhang,C.Hopson,L.Tsvetkov,J.Jing,S.Zhang,J.Smothers,and
A.Hoos.2015.The BRAF and MEK Inhibitors Dabrafenib and Trametinib:Effects on
Immune Function and in Combination with Immunomodulatory Antibodies Targeting
PD-1,PD-L1,and CTLA-4.Clin.CancerRes.21:1639-1651.</div>
      <div id="p1586" num="1586" class="description-paragraph style-scope patent-text">Martin,K.,P.Muller,J.Schreiner,S.S.Prince,D.Lardinois,
V.A.Heinzelmann-Schwarz,D.S.Thommen,and A.Zippelius.2014.The microtubule-
depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced
anti-tumor immunity.CancerImmunol.Immunother.63:925-938.</div>
      <div id="p1587" num="1587" class="description-paragraph style-scope patent-text">Muller,P.,M.Kreuzaler,T.Khan,D.S.Thommen,K.Martin,K.Glatz,S.Savic,
N.Harbeck,U.Nitz,O.Gluz,M.von Bergwelt-Baildon,H.Kreipe,S.Reddy,M.Christgen,
and A.Zippelius.2015.Trastuzumab emtansine(T-DM1)renders HER2+breast cancer
highly susceptible to CTLA-4/PD-1 blockade.Sci.Transl.Med.7:315ra188.</div>
      <div id="p1588" num="1588" class="description-paragraph style-scope patent-text">Muller,P.,K.Martin,S.Theurich,J.Schreiner,S.Savic,G.Terszowski,
D.Lardinois,V.A.Heinzelmann-Schwarz,M.Schlaak,H.M.Kvasnicka,G.Spagnoli,
S.Dirnhofer,D.E.Speiser,M.von Bergwelt-Baildon,and
A.Zippelius.2014a.Microtubule-depolymerizing agents used in antibody-drug
conjugates induce antitumor immunity by stimulation of dendritic
cells.Cancer.Immunol.Res.2:741-755.</div>
      <div id="p1589" num="1589" class="description-paragraph style-scope patent-text">Muller,P.,K.Martin,S.Theurich,M.von Bergwelt-Baildon,and
A.Zippelius.2014b.Cancer chemotherapy agents target intratumoral dendritic
cells to potentiate antitumor immunity.Oncoimmunology.3:e954460.</div>
      <div id="p1590" num="1590" class="description-paragraph style-scope patent-text">Obeid,M.,A.Tesniere,F.Ghiringhelli,G.M.Fimia,L.Apetoh,J.L.Perfettini,
M.Castedo,G.Mignot,T.Panaretakis,N.Casares,D.Metivier,N.Larochette,P.van
Endert,F.Ciccosanti,M.Piacentini,L.Zitvogel,and G.Kroemer.2007.Calreticulin
exposure dictates the immunogenicity ofcancer cell death.Nat.Med.13:54-61.</div>
      <div id="p1591" num="1591" class="description-paragraph style-scope patent-text">Paul,W.,E.1999.Fundamental Immunology,Fourth Edition..1589 pp.</div>
      <div id="p1592" num="1592" class="description-paragraph style-scope patent-text">Rios-Doria,J.,N.Durham,L.Wetzel,R.Rothstein,J.Chesebrough,
N.Holoweckyj,W.Zhao,C.C.Leow,and R.Hollingsworth.2015.Doxil synergizes with
cancer immunotherapies to enhance antitumor responses in syngeneic mouse
models.Neoplasia.17:661-670.</div>
      <div id="p1593" num="1593" class="description-paragraph style-scope patent-text">Saunders,L.R.,A.J.Bankovich,W.C.Anderson,M.A.Aujay,S.Bheddah,K.Black,
R.Desai,P.A.Escarpe,J.Hampl,A.Laysang,D.Liu,J.Lopez-Molina,M.Milton,A.Park,
M.A.Pysz,H.Shao,B.Slingerland,M.Torgov,S.A.Williams,O.Foord,P.Howard,
J.Jassem,A.Badzio,P.Czapiewski,D.H.Harpole,A.Dowlati,P.P.Massion,W.D.Travis,
M.C.Pietanza,J.T.Poirier,C.M.Rudin,R.A.Stull,and S.J.Dylla.2015.A DLL3-
targeted antibody-drug conjugate eradicates high-grade pulmonary
neuroendocrine tumor-initiating cells in vivo.Sci.Transl.Med.7:302ra136.</div>
      <div id="p1594" num="1594" class="description-paragraph style-scope patent-text">Sievers,E.L.,and P.D.Senter.2013.Antibody-drug conjugates in cancer
therapy.Annu.Rev.Med.64:15-29.</div>
      <div id="p1595" num="1595" class="description-paragraph style-scope patent-text">Smyth,M.J.,S.F.Ngiow,A.Ribas,and M.W.Teng.2016.Combination cancer
immunotherapies tailored to the tumour microenvironment.Nat.Rev.Clin.Oncol.
13:143-158.</div>
      <div id="p1596" num="1596" class="description-paragraph style-scope patent-text">Tesniere,A.,F.Schlemmer,V.Boige,O.Kepp,I.Martins,F.Ghiringhelli,
L.Aymeric,M.Michaud,L.Apetoh,L.Barault,J.Mendiboure,J.P.Pignon,V.Jooste,P.van
Endert,M.Ducreux,L.Zitvogel,F.Piard,and G.Kroemer.2010.Immunogenic death
ofcolon cancer cells treated with oxaliplatin.Oncogene.29:482-491.</div>
      <div id="p1597" num="1597" class="description-paragraph style-scope patent-text">Vanneman,M.,and G.Dranoff.2012.Combining immunotherapy and targeted
therapies in cancer treatment.Nat.Rev.Cancer.12:237-251.</div>
      <div id="p1598" num="1598" class="description-paragraph style-scope patent-text">Ward,E.S.,D.Gussow,A.D.Griffiths,P.T.Jones,and G.Winter.1989.Binding
activities of a repertoire of single immunoglobulin variable domains secreted
from Escherichia coli.Nature.341:544-546.</div>
      <div id="p1599" num="1599" class="description-paragraph style-scope patent-text">Wolchok,J.D.,H.Kluger,M.K.Callahan,M.A.Postow,N.A.Rizvi,A.M.Lesokhin,
N.H.Segal,C.E.Ariyan,R.A.Gordon,K.Reed,M.M.Burke,A.Caldwell,S.A.Kronenberg,
B.U.Agunwamba,X.Zhang,I.Lowy,H.D.Inzunza,W.Feely,C.E.Horak,Q.Hong,A.J.Korman,
J.M.Wigginton,A.Gupta,and M.Sznol.2013.Nivolumab plus ipilimumab in advanced
melanoma.N.Engl.J.Med.369:122-133.</div>
    </mode-for-invention>
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(29)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM186702830" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <div class="claim style-scope patent-text"> <div id="en-cl0001" num="0001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. one kind be used for the antibody-drug conjugates used in cancer immunotherapy (ADC), wherein this using include should
ADC and immunization therapy (IMT) agent are administered in combination in patient, and with single therapy when reach treatment validity needed for the ADC
And/or the corresponding dosage of the IMT agent is compared, the ADC and/or the IMT agent are applied with lower dosage.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="en-cl0002" num="0002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. a kind of for immune-mediated treatment (IMT) agent used in the cancer immunotherapy, wherein this using include should
IMT agent and antibody-drug conjugates (ADC) are administered in combination in patient, and with single therapy when reaches needed for treatment validity
The IMT agent and/or the corresponding dosage of the ADC compare, the IMT agent and/or the ADC are applied with lower dosage.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="en-cl0003" num="0003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. one kind is used for the antibody-drug conjugates used in cancer immunotherapy (ADC) and immune-mediated treatment (IMT)
Agent, it includes by the ADC and IMT agent combined administration in patient that wherein this, which is used, and</div>
      <div class="claim-text style-scope patent-text">A. compared with dosage needed for reaching treatment validity when single therapy, which is applied with lower dosageOr</div>
      <div class="claim-text style-scope patent-text">B. compared with dosage needed for reaching treatment validity when single therapy, which is applied with lower dosageOr</div>
      <div class="claim-text style-scope patent-text">C. compared with the corresponding dosage of the IMT agent needed for reaching treatment validity when single therapy or the ADC, with lower dose
Amount application both the IMT agent and the ADC.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0004" num="0004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">4. antibody-drug conjugates (ADC) according to any one of claim 1 to 3, wherein the ADC than single medicine to control
Dosage needed for reaching treatment validity when treatment is low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, extremely
Few 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1% dosage application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0005" num="0005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">5. immune-mediated treatment (IMT) agent according to any one of claim 1 to 4, wherein the IMT agent is than single medicine
Dosage needed for reaching treatment validity when treating is low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%,
At least 40%, at least 30%, at least 20%, at least 10%, at least 5%, at least 1% dosage application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0006" num="0006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">6. it includes by the ADC and being somebody's turn to do that wherein this, which is used, according to claim 1 to ADC the and IMT agent used described in any one of 5
IMT agent is combined simultaneously, individually or sequential application is in patient.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0007" num="0007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">7. according to claim 1 to ADC the and IMT agent used described in any one of 6, wherein being conjugated to the drug of the ADC is
PBD or tubulysin.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0008" num="0008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">8. wherein the ADC is through in intravenous or tumour according to claim 1 to ADC the and IMT agent used described in any one of 7
Application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0009" num="0009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0008" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">9. wherein the IMT agent is through in intravenous, peritonaeum according to claim 1 to ADC the and IMT agent used described in any one of 8
Or application in tumour.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0010" num="0010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0008" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0009" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">10. wherein the IMT agent is that checkpoint inhibits according to claim 1 to ADC the and IMT agent used described in any one of 9
Agent.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0011" num="0011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0008" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0009" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0010" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">11. wherein the IMT agent is tumor necrosis factor according to claim 1 to ADC the and IMT agent used described in any one of 10
The agonist of sub (TNF) receptor superfamily.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0012" num="0012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0008" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0009" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0010" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0011" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">12. wherein the IMT agent is selected from by with the following group according to claim 1 to ADC the and IMT agent used described in any one of 11
At group: PD1 inhibitor, PD-L1 inhibitor, OX40 agonist and GITRL agonist.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0013" num="0013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0012" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">13. ADC the and IMT agent used according to claim 12, wherein the IMT agent is selected from the group being made up of: anti-PD1
Antibody, anti-PD-L1 antibody and anti-OX40 antibody, OX40 ligand fusion protein and GITRL fusion protein.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0014" num="0014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0001" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0002" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0003" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0004" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0005" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0006" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0007" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0008" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0009" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0010" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0011" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0012" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0013" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">14. ADC the and IMT agent according to any one of claims 1 to 13 used, wherein the ADC includes as antitumor
The antibody of antibody or its antigen-binding fragment.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0015" num="0015" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0014" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">15. the 4 ADC and IMT agent used according to claim 1, wherein the antibody is selected from the group being made up of: anti-
EphA2 antibody or its antigen-binding fragment, anti-Her2 antibody or its antigen-binding fragment, resisting GPC 3 antibody or its antigen binding fragment
Section, anti-ASCT2 antibody or its antigen-binding fragment and anti-B7H4 antibody or its antigen-binding fragment.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="en-cl0016" num="0016" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. a kind of cancer immunotherapy method, this method includes administration of antibodies-drug conjugate (ADC) and immune-mediated controls
(IMT) agent is treated, wherein this method includes by the ADC and IMT agent combined administration in patient, and</div>
      <div class="claim-text style-scope patent-text">A. compared with dosage needed for reaching treatment validity when single therapy, which is applied with lower dosageOr</div>
      <div class="claim-text style-scope patent-text">B. compared with dosage needed for reaching treatment validity when single therapy, which is applied with lower dosageOr</div>
      <div class="claim-text style-scope patent-text">C. compared with the corresponding dosage of the IMT agent needed for reaching treatment validity when single therapy or the ADC, with lower dose
Amount application both the IMT agent and the ADC.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0017" num="0017" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">17. the method according to claim 11, wherein the ADC is than agent needed for reaching treatment validity when single therapy
Measure low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%,
At least 10%, at least 5%, at least 1% dosage application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0018" num="0018" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">18. method according to claim 16 or 17, wherein the IMT agent is than reaching treatment validity institute when single therapy
The dosage needed is low at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least
20%, at least 10%, at least 5%, at least 1% dosage application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0019" num="0019" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">19. method described in any one of 6 to 18 according to claim 1, this method include by ADC and IMT agent simultaneously, individually or
Sequential application is in patient.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0020" num="0020" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">20. method described in any one of 6 to 19 according to claim 1, wherein the drug for being conjugated to the ADC is PBD or micro-
Pipe lysin.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0021" num="0021" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">21. method described in any one of 6 to 20 according to claim 1, wherein ADC application in intravenous or tumour.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0022" num="0022" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0021" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">22. method described in any one of 6 to 21 according to claim 1, wherein IMT agent warp is intravenous, peritonaeum is interior or tumour
Interior application.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0023" num="0023" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0021" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0022" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">23. method described in any one of 6 to 22 according to claim 1, wherein the IMT agent is checkpoint inhibitor.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0024" num="0024" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0021" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0022" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0023" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">24. method described in any one of 6 to 23 according to claim 1, wherein the IMT agent be tumor necrosis factor (TNF) by
The agonist of body superfamily.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0025" num="0025" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0021" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0022" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0023" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0024" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">25. method described in any one of 6 to 24 according to claim 1, wherein the IMT agent is selected from the group being made up of: PD1
Inhibitor, PD-L1 inhibitor, OX40 agonist and GITRL agonist.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0026" num="0026" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0025" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">26. according to the method for claim 25, wherein the IMT agent is selected from the group being made up of: anti-PD1 antibody, anti-PD-
L1 antibody and anti-OX40 antibody, OX40 ligand fusion protein and GITRL fusion protein.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0027" num="0027" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0016" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0017" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0018" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0019" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0020" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0021" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0022" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0023" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0024" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0025" class="style-scope patent-text"> </claim-ref>
        <claim-ref idref="en-cl0026" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">27. method described in any one of 6 to 26 according to claim 1, wherein the ADC includes as anti-tumour antibody or it is anti-
The antibody of former binding fragment.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0028" num="0028" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">
        <claim-ref idref="en-cl0027" class="style-scope patent-text"> </claim-ref>
      </div>
      <div class="claim-text style-scope patent-text">28. according to the method for claim 27, wherein the antibody is selected from the group that is made up of: anti-eph A2 antibody or its
Antigen-binding fragment, anti-Her2 antibody or its antigen-binding fragment, resisting GPC 3 antibody or its antigen-binding fragment, anti-ASCT2 are anti-
Body or its antigen-binding fragment and anti-B7H4 antibody or its antigen-binding fragment.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="en-cl0029" num="0029" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">29. a kind of pharmaceutical composition, it includes the ADC according to defined in claim 7 or 10 to any one of 15 and/or IMT
Agent.</div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (113)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2301570A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2301570A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-31</span>
                    <span class="td style-scope patent-result">2011-03-30</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated and conjugated antibodies, antibody combinations and fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN108136015A/en"><a id="link" href="#" class="style-scope state-modifier">CN108136015A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-08-20</span>
                    <span class="td style-scope patent-result">2018-06-08</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Anti- DLL3 antibody drug conjugates and application method 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN108884161A/en"><a id="link" href="#" class="style-scope state-modifier">CN108884161A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-12-01</span>
                    <span class="td style-scope patent-result">2018-11-23</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Combination therapy and application thereof and method 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CU22545A1/en"><a id="link" href="#" class="style-scope state-modifier">CU22545A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-11-18</span>
                    <span class="td style-scope patent-result">1999-03-31</span>
                    <span class="td style-scope patent-result">Centro Inmunologia Molecular</span>
                    <span class="td style-scope patent-result">
  OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6013772A/en"><a id="link" href="#" class="style-scope state-modifier">US6013772A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-08-13</span>
                    <span class="td style-scope patent-result">2000-01-11</span>
                    <span class="td style-scope patent-result">Bayer Corporation</span>
                    <span class="td style-scope patent-result">Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8800078D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8800078D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-01-05</span>
                    <span class="td style-scope patent-result">1988-02-10</span>
                    <span class="td style-scope patent-result">Ciba Geigy Ag</span>
                    <span class="td style-scope patent-result">Novel antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5162504A/en"><a id="link" href="#" class="style-scope state-modifier">US5162504A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-06-03</span>
                    <span class="td style-scope patent-result">1992-11-10</span>
                    <span class="td style-scope patent-result">Cytogen Corporation</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU4128089A/en"><a id="link" href="#" class="style-scope state-modifier">AU4128089A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-09-15</span>
                    <span class="td style-scope patent-result">1990-03-22</span>
                    <span class="td style-scope patent-result">Rorer International (Overseas) Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HUT60768A/en"><a id="link" href="#" class="style-scope state-modifier">HUT60768A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-03-16</span>
                    <span class="td style-scope patent-result">1992-10-28</span>
                    <span class="td style-scope patent-result">Sandoz Ag</span>
                    <span class="td style-scope patent-result">Process for producing cd25 fixing molecules 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB9014932D0/en"><a id="link" href="#" class="style-scope state-modifier">GB9014932D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-07-05</span>
                    <span class="td style-scope patent-result">1990-08-22</span>
                    <span class="td style-scope patent-result">Celltech Ltd</span>
                    <span class="td style-scope patent-result">Recombinant dna product and method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994004679A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994004679A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-06-14</span>
                    <span class="td style-scope patent-result">1994-03-03</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Method for making humanized antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5955075A/en"><a id="link" href="#" class="style-scope state-modifier">US5955075A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-09-21</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">Method of inhibiting tumor growth using antibodies to MN protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5736137A/en"><a id="link" href="#" class="style-scope state-modifier">US5736137A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-13</span>
                    <span class="td style-scope patent-result">1998-04-07</span>
                    <span class="td style-scope patent-result">Idec Pharmaceuticals Corporation</span>
                    <span class="td style-scope patent-result">Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5472693A/en"><a id="link" href="#" class="style-scope state-modifier">US5472693A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-02-16</span>
                    <span class="td style-scope patent-result">1995-12-05</span>
                    <span class="td style-scope patent-result">The Dow Chemical Company</span>
                    <span class="td style-scope patent-result">Family of anti-carcinoembryonic antigen chimeric antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5686292A/en"><a id="link" href="#" class="style-scope state-modifier">US5686292A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-02</span>
                    <span class="td style-scope patent-result">1997-11-11</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Hepatocyte growth factor receptor antagonist antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6824993B2/en"><a id="link" href="#" class="style-scope state-modifier">US6824993B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-06</span>
                    <span class="td style-scope patent-result">2004-11-30</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">Antibodies that bind human prostate specific G-protein receptor HPRAJ70 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2342897A/en"><a id="link" href="#" class="style-scope state-modifier">AU2342897A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-20</span>
                    <span class="td style-scope patent-result">1997-10-10</span>
                    <span class="td style-scope patent-result">Immunomedics Inc.</span>
                    <span class="td style-scope patent-result">Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6150508A/en"><a id="link" href="#" class="style-scope state-modifier">US6150508A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-25</span>
                    <span class="td style-scope patent-result">2000-11-21</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7011812B1/en"><a id="link" href="#" class="style-scope state-modifier">US7011812B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-03</span>
                    <span class="td style-scope patent-result">2006-03-14</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Targeted combination immunotherapy of cancer and infectious diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ331978A/en"><a id="link" href="#" class="style-scope state-modifier">NZ331978A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-04</span>
                    <span class="td style-scope patent-result">2000-05-26</span>
                    <span class="td style-scope patent-result">Zeneca Ltd</span>
                    <span class="td style-scope patent-result">Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6107090A/en"><a id="link" href="#" class="style-scope state-modifier">US6107090A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-06</span>
                    <span class="td style-scope patent-result">2000-08-22</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6590088B1/en"><a id="link" href="#" class="style-scope state-modifier">US6590088B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-07-19</span>
                    <span class="td style-scope patent-result">2003-07-08</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">CD33-like protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6653104B2/en"><a id="link" href="#" class="style-scope state-modifier">US6653104B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-10-17</span>
                    <span class="td style-scope patent-result">2003-11-25</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6417337B1/en"><a id="link" href="#" class="style-scope state-modifier">US6417337B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-10-31</span>
                    <span class="td style-scope patent-result">2002-07-09</span>
                    <span class="td style-scope patent-result">The Dow Chemical Company</span>
                    <span class="td style-scope patent-result">High affinity humanized anti-CEA monoclonal antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5989604A/en"><a id="link" href="#" class="style-scope state-modifier">US5989604A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-12-19</span>
                    <span class="td style-scope patent-result">1999-11-23</span>
                    <span class="td style-scope patent-result">Adore-A-Pet, Ltd.</span>
                    <span class="td style-scope patent-result">Xylitol-containing non-human foodstuff and method 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5942602A/en"><a id="link" href="#" class="style-scope state-modifier">US5942602A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-13</span>
                    <span class="td style-scope patent-result">1999-08-24</span>
                    <span class="td style-scope patent-result">Schering Aktiengessellschaft</span>
                    <span class="td style-scope patent-result">Growth factor receptor antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6235883B1/en"><a id="link" href="#" class="style-scope state-modifier">US6235883B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-05-05</span>
                    <span class="td style-scope patent-result">2001-05-22</span>
                    <span class="td style-scope patent-result">Abgenix, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to epidermal growth factor receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ATE473242T1/en"><a id="link" href="#" class="style-scope state-modifier">ATE473242T1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-20</span>
                    <span class="td style-scope patent-result">2010-07-15</span>
                    <span class="td style-scope patent-result">Immunomedics Inc</span>
                    <span class="td style-scope patent-result">
  THERAPEUTIC AGENTS CONTAINING A BISPECIFIC ANTI-HLA CLASS II INVARIANT CHAIN X ANTI-PATHOGEN ANTIBODIES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1193270B1/en"><a id="link" href="#" class="style-scope state-modifier">EP1193270B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2003-05-14</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL147638A0/en"><a id="link" href="#" class="style-scope state-modifier">IL147638A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-29</span>
                    <span class="td style-scope patent-result">2002-08-14</span>
                    <span class="td style-scope patent-result">Medarex Inc</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to prostate specific membrane antigen 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7147850B2/en"><a id="link" href="#" class="style-scope state-modifier">US7147850B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-18</span>
                    <span class="td style-scope patent-result">2006-12-12</span>
                    <span class="td style-scope patent-result">Altarex Medical Corp.</span>
                    <span class="td style-scope patent-result">Therapeutic binding agents against MUC-1 antigen and methods for their use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6716966B1/en"><a id="link" href="#" class="style-scope state-modifier">US6716966B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-18</span>
                    <span class="td style-scope patent-result">2004-04-06</span>
                    <span class="td style-scope patent-result">Altarex Corp.</span>
                    <span class="td style-scope patent-result">Therapeutic binding agents against MUC-1 antigen and methods for their use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7129332B2/en"><a id="link" href="#" class="style-scope state-modifier">US7129332B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-25</span>
                    <span class="td style-scope patent-result">2006-10-31</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7163681B2/en"><a id="link" href="#" class="style-scope state-modifier">US7163681B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-07</span>
                    <span class="td style-scope patent-result">2007-01-16</span>
                    <span class="td style-scope patent-result">Centocor, Inc.</span>
                    <span class="td style-scope patent-result">Anti-integrin antibodies, compositions, methods and uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6759045B2/en"><a id="link" href="#" class="style-scope state-modifier">US6759045B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-08</span>
                    <span class="td style-scope patent-result">2004-07-06</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotherapy for chronic myelocytic leukemia 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20050019324A1/en"><a id="link" href="#" class="style-scope state-modifier">US20050019324A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-29</span>
                    <span class="td style-scope patent-result">2005-01-27</span>
                    <span class="td style-scope patent-result">Wreschner Daniel H.</span>
                    <span class="td style-scope patent-result">Peptides and antibodies to muc 1 proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7183388B2/en"><a id="link" href="#" class="style-scope state-modifier">US7183388B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-30</span>
                    <span class="td style-scope patent-result">2007-02-27</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Anti-MUC-1 single chain antibodies for tumor targeting 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2443138A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2443138A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-30</span>
                    <span class="td style-scope patent-result">2002-10-10</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Anti-muc-1 single chain antibodies for tumor targeting 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MXPA03010804A/en"><a id="link" href="#" class="style-scope state-modifier">MXPA03010804A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-01</span>
                    <span class="td style-scope patent-result">2004-11-22</span>
                    <span class="td style-scope patent-result">Cornell Res Foundation Inc</span>
                    <span class="td style-scope patent-result">Modified antibodies to prostate-specific membrane antigen and uses thereof. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003000117A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003000117A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-21</span>
                    <span class="td style-scope patent-result">2003-01-03</span>
                    <span class="td style-scope patent-result">Glycotech Corporation</span>
                    <span class="td style-scope patent-result">Detection and treatment of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2002339845B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2002339845B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-03</span>
                    <span class="td style-scope patent-result">2009-03-26</span>
                    <span class="td style-scope patent-result">Roche Glycart Ag</span>
                    <span class="td style-scope patent-result">Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AR036833A1/en"><a id="link" href="#" class="style-scope state-modifier">AR036833A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-18</span>
                    <span class="td style-scope patent-result">2004-10-06</span>
                    <span class="td style-scope patent-result">Bayer Corp</span>
                    <span class="td style-scope patent-result">
  HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELLULAR ADHESION.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3184539A3/en"><a id="link" href="#" class="style-scope state-modifier">EP3184539A3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">2017-09-13</span>
                    <span class="td style-scope patent-result">PSMA Development Company L.L.C.</span>
                    <span class="td style-scope patent-result">Psma antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2005538682A/en"><a id="link" href="#" class="style-scope state-modifier">JP2005538682A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-03</span>
                    <span class="td style-scope patent-result">2005-12-22</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Antibody against carboxic anhydrase IX (CAIX) tumor antigen
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR0307216A/en"><a id="link" href="#" class="style-scope state-modifier">BR0307216A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-28</span>
                    <span class="td style-scope patent-result">2005-12-20</span>
                    <span class="td style-scope patent-result">Medarex Inc</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibodies to prostate specific membrane antigen (psma)
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2477163C/en"><a id="link" href="#" class="style-scope state-modifier">CA2477163C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">2010-07-27</span>
                    <span class="td style-scope patent-result">Institute Of Virology</span>
                    <span class="td style-scope patent-result">Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090162382A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090162382A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2009-06-25</span>
                    <span class="td style-scope patent-result">Bernett Matthew J</span>
                    <span class="td style-scope patent-result">Optimized ca9 antibodies and methods of using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN1649902B/en"><a id="link" href="#" class="style-scope state-modifier">CN1649902B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2011-04-13</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Internalizing anti-CD74 antibodies and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ535425A/en"><a id="link" href="#" class="style-scope state-modifier">NZ535425A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-13</span>
                    <span class="td style-scope patent-result">2008-05-30</span>
                    <span class="td style-scope patent-result">Biogen Idec Inc</span>
                    <span class="td style-scope patent-result">Anti-alphavbeta6 antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2429112T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2429112T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-10</span>
                    <span class="td style-scope patent-result">2013-11-13</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">
  Anti-HER2 antibody variants
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7202346B2/en"><a id="link" href="#" class="style-scope state-modifier">US7202346B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-03</span>
                    <span class="td style-scope patent-result">2007-04-10</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Antibodies to non-shed Muc1 and Muc16, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090252738A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090252738A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-23</span>
                    <span class="td style-scope patent-result">2009-10-08</span>
                    <span class="td style-scope patent-result">Novartis Vaccines And Diagnostics, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7541440B2/en"><a id="link" href="#" class="style-scope state-modifier">US7541440B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-30</span>
                    <span class="td style-scope patent-result">2009-06-02</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Chimeric, human and humanized anti-granulocyte antibodies and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4790413B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4790413B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-08</span>
                    <span class="td style-scope patent-result">2011-10-12</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Antibody therapy
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5354835B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5354835B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-07</span>
                    <span class="td style-scope patent-result">2013-11-27</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Anti-CD33 antibody and method for treating acute myeloid leukemia using the same
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0226593D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0226593D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-14</span>
                    <span class="td style-scope patent-result">2002-12-24</span>
                    <span class="td style-scope patent-result">Consultants Ltd</span>
                    <span class="td style-scope patent-result">Compounds 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2514419A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2514419A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-28</span>
                    <span class="td style-scope patent-result">2004-08-12</span>
                    <span class="td style-scope patent-result">Proscan Rx Pharma Inc.</span>
                    <span class="td style-scope patent-result">Prostate cancer diagnosis and treatment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7534431B2/en"><a id="link" href="#" class="style-scope state-modifier">US7534431B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-31</span>
                    <span class="td style-scope patent-result">2009-05-19</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for administering therapeutic and diagnostic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI0407446A/en"><a id="link" href="#" class="style-scope state-modifier">BRPI0407446A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-13</span>
                    <span class="td style-scope patent-result">2006-01-31</span>
                    <span class="td style-scope patent-result">Pharmacia Corp</span>
                    <span class="td style-scope patent-result">
  C-met Antibodies for cancer treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PL1636593T3/en"><a id="link" href="#" class="style-scope state-modifier">PL1636593T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-06-06</span>
                    <span class="td style-scope patent-result">2009-08-31</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Modulating the interaction between hgf beta chain and c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102675462A/en"><a id="link" href="#" class="style-scope state-modifier">CN102675462A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-06-27</span>
                    <span class="td style-scope patent-result">2012-09-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1648512A4/en"><a id="link" href="#" class="style-scope state-modifier">EP1648512A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-07-31</span>
                    <span class="td style-scope patent-result">2009-01-21</span>
                    <span class="td style-scope patent-result">Immunomedics Inc</span>
                    <span class="td style-scope patent-result">Anti-cd19 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7902338B2/en"><a id="link" href="#" class="style-scope state-modifier">US7902338B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-07-31</span>
                    <span class="td style-scope patent-result">2011-03-08</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-CD19 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HN2004000285A/en"><a id="link" href="#" class="style-scope state-modifier">HN2004000285A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-04</span>
                    <span class="td style-scope patent-result">2006-04-27</span>
                    <span class="td style-scope patent-result">Pfizer Prod Inc</span>
                    <span class="td style-scope patent-result">
  ANTIBODIES DIRECTED TO c-MET
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0321295D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0321295D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-09-11</span>
                    <span class="td style-scope patent-result">2003-10-15</span>
                    <span class="td style-scope patent-result">Spirogen Ltd</span>
                    <span class="td style-scope patent-result">Synthesis of protected pyrrolobenzodiazepines 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2004298483A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2004298483A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-11</span>
                    <span class="td style-scope patent-result">2005-06-30</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for inhibiting c-met dimerization and activation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MXPA06009547A/en"><a id="link" href="#" class="style-scope state-modifier">MXPA06009547A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-23</span>
                    <span class="td style-scope patent-result">2007-01-26</span>
                    <span class="td style-scope patent-result">Dana Farber Cancer Inst Inc</span>
                    <span class="td style-scope patent-result">Method of treating abnormal cell growth using c-met and-tor inhibitors. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085251A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085251A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-01</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1763367A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1763367A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-02</span>
                    <span class="td style-scope patent-result">2007-03-21</span>
                    <span class="td style-scope patent-result">Wilex AG</span>
                    <span class="td style-scope patent-result">Improved adjuvant therapy of g250-expressing tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20150140417A/en"><a id="link" href="#" class="style-scope state-modifier">KR20150140417A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-22</span>
                    <span class="td style-scope patent-result">2015-12-15</span>
                    <span class="td style-scope patent-result">, .</span>
                    <span class="td style-scope patent-result">Her2 antibody composition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ552485A/en"><a id="link" href="#" class="style-scope state-modifier">NZ552485A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-08-05</span>
                    <span class="td style-scope patent-result">2009-11-27</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Humanized anti-cmet antagonists 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2583208C/en"><a id="link" href="#" class="style-scope state-modifier">CA2583208C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-10-15</span>
                    <span class="td style-scope patent-result">2015-08-25</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JO3000B1/en"><a id="link" href="#" class="style-scope state-modifier">JO3000B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-10-20</span>
                    <span class="td style-scope patent-result">2016-09-05</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Antibody Formulations. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006050834A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006050834A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-09</span>
                    <span class="td style-scope patent-result">2006-05-18</span>
                    <span class="td style-scope patent-result">Philogen Spa</span>
                    <span class="td style-scope patent-result">Antibodies against tenascin-c 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2589374C/en"><a id="link" href="#" class="style-scope state-modifier">CA2589374C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-30</span>
                    <span class="td style-scope patent-result">2016-05-03</span>
                    <span class="td style-scope patent-result">Curagen Corporation</span>
                    <span class="td style-scope patent-result">Antibodies directed to gpnmb and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5249587B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5249587B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-18</span>
                    <span class="td style-scope patent-result">2013-07-31</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">
  Monoclonal antibody against prostate specific membrane antigen (PSMA) lacking fucosyl residues
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7615529B2/en"><a id="link" href="#" class="style-scope state-modifier">US7615529B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-03-25</span>
                    <span class="td style-scope patent-result">2009-11-10</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for modulating hyperstabilized c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102875681A/en"><a id="link" href="#" class="style-scope state-modifier">CN102875681A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-08</span>
                    <span class="td style-scope patent-result">2013-01-16</span>
                    <span class="td style-scope patent-result">Idec</span>
                    <span class="td style-scope patent-result">Anti-alpha v beta 6 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2009506790A/en"><a id="link" href="#" class="style-scope state-modifier">JP2009506790A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-09-07</span>
                    <span class="td style-scope patent-result">2009-02-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  EPH receptor antibody conjugated to toxin
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007126799A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007126799A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-30</span>
                    <span class="td style-scope patent-result">2007-11-08</span>
                    <span class="td style-scope patent-result">Novartis Ag</span>
                    <span class="td style-scope patent-result">Compositions and methods of use for antibodies of c-met 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2163563A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2163563A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-31</span>
                    <span class="td style-scope patent-result">2010-03-17</span>
                    <span class="td style-scope patent-result">Massachusetts Institute of Technology</span>
                    <span class="td style-scope patent-result">Treatment of tumors expressing mutant EGF receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI429658B/en"><a id="link" href="#" class="style-scope state-modifier">TWI429658B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-06-07</span>
                    <span class="td style-scope patent-result">2014-03-11</span>
                    <span class="td style-scope patent-result">Bioalliance Cv</span>
                    <span class="td style-scope patent-result">Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2009107277A/en"><a id="link" href="#" class="style-scope state-modifier">RU2009107277A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-08-03</span>
                    <span class="td style-scope patent-result">2010-09-10</span>
                    <span class="td style-scope patent-result">  (Se)</span>
                    <span class="td style-scope patent-result">
  ANTIBODIES AIMED AT V6 AND THEIR APPLICATION
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2457072T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2457072T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-08-14</span>
                    <span class="td style-scope patent-result">2014-04-24</span>
                    <span class="td style-scope patent-result">Xencor, Inc.</span>
                    <span class="td style-scope patent-result">
  Optimized antibodies that select as target CD19
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN101535332A/en"><a id="link" href="#" class="style-scope state-modifier">CN101535332A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-31</span>
                    <span class="td style-scope patent-result">2009-09-16</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Methods for improving antibody production 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2014681A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2014681A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-07-12</span>
                    <span class="td style-scope patent-result">2009-01-14</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Novel antibodies inhibiting c-met dimerization, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PT2211904T/en"><a id="link" href="#" class="style-scope state-modifier">PT2211904T</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-10-19</span>
                    <span class="td style-scope patent-result">2016-11-02</span>
                    <span class="td style-scope patent-result">Seattle Genetics Inc</span>
                    <span class="td style-scope patent-result">Cd19 binding agents and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009056342A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009056342A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-11-02</span>
                    <span class="td style-scope patent-result">2009-05-07</span>
                    <span class="td style-scope patent-result">Wilex Ag</span>
                    <span class="td style-scope patent-result">Binding epitopes for g250 antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2008338313B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2008338313B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-18</span>
                    <span class="td style-scope patent-result">2014-01-16</span>
                    <span class="td style-scope patent-result">Bioalliance C.V.</span>
                    <span class="td style-scope patent-result">Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090169550A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090169550A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-21</span>
                    <span class="td style-scope patent-result">2009-07-02</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Therapy of rituximab-refractory rheumatoid arthritis patients 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PT2242772E/en"><a id="link" href="#" class="style-scope state-modifier">PT2242772E</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-26</span>
                    <span class="td style-scope patent-result">2015-02-09</span>
                    <span class="td style-scope patent-result">Biotest Ag</span>
                    <span class="td style-scope patent-result">Immunoconjugates targeting cd138 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2238168B8/en"><a id="link" href="#" class="style-scope state-modifier">EP2238168B8</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-26</span>
                    <span class="td style-scope patent-result">2014-07-23</span>
                    <span class="td style-scope patent-result">Biotest AG</span>
                    <span class="td style-scope patent-result">Agents targeting cd138 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI472339B/en"><a id="link" href="#" class="style-scope state-modifier">TWI472339B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-01-30</span>
                    <span class="td style-scope patent-result">2015-02-11</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102099377A/en"><a id="link" href="#" class="style-scope state-modifier">CN102099377A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-04-11</span>
                    <span class="td style-scope patent-result">2011-06-15</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ590330A/en"><a id="link" href="#" class="style-scope state-modifier">NZ590330A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-21</span>
                    <span class="td style-scope patent-result">2012-08-31</span>
                    <span class="td style-scope patent-result">Immunomedics Inc</span>
                    <span class="td style-scope patent-result">Structural variants of anti-cd20 antibodies for improved therapeutic characteristics 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8734795B2/en"><a id="link" href="#" class="style-scope state-modifier">US8734795B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-31</span>
                    <span class="td style-scope patent-result">2014-05-27</span>
                    <span class="td style-scope patent-result">Biogen Idec Ma Inc.</span>
                    <span class="td style-scope patent-result">Light targeting molecules and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010051391A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010051391A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-31</span>
                    <span class="td style-scope patent-result">2010-05-06</span>
                    <span class="td style-scope patent-result">Facet Biotech Corporation</span>
                    <span class="td style-scope patent-result">Use of anti-cs1 antibodies for treatment of rare lymphomas 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PA8849001A1/en"><a id="link" href="#" class="style-scope state-modifier">PA8849001A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-11-21</span>
                    <span class="td style-scope patent-result">2010-06-28</span>
                    <span class="td style-scope patent-result">Lilly Co Eli</span>
                    <span class="td style-scope patent-result">
  C-MET ANTIBODIES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8545839B2/en"><a id="link" href="#" class="style-scope state-modifier">US8545839B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2013-10-01</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Anti-c-Met antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AR074439A1/en"><a id="link" href="#" class="style-scope state-modifier">AR074439A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-02</span>
                    <span class="td style-scope patent-result">2011-01-19</span>
                    <span class="td style-scope patent-result">Pf Medicament</span>
                    <span class="td style-scope patent-result">
  ANTI-CMET ANTIBODY (C-MET RECEIVER)
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ596807A/en"><a id="link" href="#" class="style-scope state-modifier">NZ596807A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-05-06</span>
                    <span class="td style-scope patent-result">2013-09-27</span>
                    <span class="td style-scope patent-result">Biotest Ag</span>
                    <span class="td style-scope patent-result">Uses of immunoconjugates targeting cd138 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2427490A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2427490A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-05-07</span>
                    <span class="td style-scope patent-result">2012-03-14</span>
                    <span class="td style-scope patent-result">Novartis AG</span>
                    <span class="td style-scope patent-result">Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5347813B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5347813B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-03</span>
                    <span class="td style-scope patent-result">2013-11-20</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Communication apparatus and communication method
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2774260C/en"><a id="link" href="#" class="style-scope state-modifier">CA2774260C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-16</span>
                    <span class="td style-scope patent-result">2018-10-09</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Class i anti-cea antibodies and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110028129A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110028129A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-10-13</span>
                    <span class="td style-scope patent-result">2011-02-03</span>
                    <span class="td style-scope patent-result">Hutchison James W</span>
                    <span class="td style-scope patent-result">Proximity Triggered Profile-Based Wireless Matching 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101671378B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101671378B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-10-30</span>
                    <span class="td style-scope patent-result">2016-11-01</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">c-Met specific antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101748707B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101748707B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-11-27</span>
                    <span class="td style-scope patent-result">2017-06-20</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">c-Met specific antibodies and diagnosis kit for cancer using thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2594893T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2594893T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-12-16</span>
                    <span class="td style-scope patent-result">2016-12-23</span>
                    <span class="td style-scope patent-result">Abbvie Biotherapeutics Inc.</span>
                    <span class="td style-scope patent-result">
  Anti HER2 antibodies and their uses
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8609095B2/en"><a id="link" href="#" class="style-scope state-modifier">US8609095B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-03-04</span>
                    <span class="td style-scope patent-result">2013-12-17</span>
                    <span class="td style-scope patent-result">Symphogen A/S</span>
                    <span class="td style-scope patent-result">Anti-HER2 antibodies and compositions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015155345A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015155345A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-04-11</span>
                    <span class="td style-scope patent-result">2015-10-15</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Antibodies and antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20160142392A/en"><a id="link" href="#" class="style-scope state-modifier">KR20160142392A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-04-11</span>
                    <span class="td style-scope patent-result">2016-12-12</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">Tubulysin derivatives 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201406767D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201406767D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-04-15</span>
                    <span class="td style-scope patent-result">2014-05-28</span>
                    <span class="td style-scope patent-result">Cancer Rec Tech Ltd</span>
                    <span class="td style-scope patent-result">Humanized anti-Tn-MUC1 antibodies anf their conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016075174A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016075174A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-11</span>
                    <span class="td style-scope patent-result">2016-05-19</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Therapeutic combinations for treating neoplasia 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      CATHERINE S. DIEFENBACH ET AL.: ""Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)"", BLOOD, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 585, XP086650487, DOI: 10.1182/blood.V126.23.585.585
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      DAVID M GOLDENBERG ET AL.: ""Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb"", BLOOD, vol. 116, no. 21, 19 November 2010 (2010-11-19), pages 3941, XP086608310, DOI: 10.1182/blood.V116.21.3941.3941
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      PHILIPP MLLER ET AL.: ""Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade"", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 315, 25 November 2015 (2015-11-25), pages 1 - 14, XP055437353, DOI: 10.1126/scitranslmed.aac4925
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2020012418A/en"><a id="link" href="#" class="style-scope state-modifier">MX2020012418A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-23</span>
                    <span class="td style-scope patent-result">2021-04-28</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sa</span>
                    <span class="td style-scope patent-result">Molecular adjuvant. 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10543279B2/en"><a id="link" href="#" class="style-scope state-modifier">US10543279B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-01-28</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN109843335B/en"><a id="link" href="#" class="style-scope state-modifier">CN109843335B</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-07-30</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230143309A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230143309A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-05-11</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine antibody conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10695439B2/en"><a id="link" href="#" class="style-scope state-modifier">US10695439B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-30</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20190307890A1/en"><a id="link" href="#" class="style-scope state-modifier">US20190307890A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-10-10</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20220211864A1/en"><a id="link" href="#" class="style-scope state-modifier">US20220211864A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-07-07</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates with immune-mediated therapy agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20190055254A1/en"><a id="link" href="#" class="style-scope state-modifier">US20190055254A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-02-21</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US201662406630P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2016-10-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US62/406630<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2016-10-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018069289A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2017/075766</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-10-10</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates with immune-mediated therapy agents 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-06-07</span>
                    <span class="td nowrap style-scope patent-result">PB01</span>
                    <span class="td nowrap style-scope patent-result">Publication</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-06-07</span>
                    <span class="td nowrap style-scope patent-result">PB01</span>
                    <span class="td nowrap style-scope patent-result">Publication</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-11-12</span>
                    <span class="td nowrap style-scope patent-result">SE01</span>
                    <span class="td nowrap style-scope patent-result">Entry into force of request for substantive examination</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-11-12</span>
                    <span class="td nowrap style-scope patent-result">SE01</span>
                    <span class="td nowrap style-scope patent-result">Entry into force of request for substantive examination</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2023-03-10</span>
                    <span class="td nowrap style-scope patent-result">WD01</span>
                    <span class="td nowrap style-scope patent-result">Invention patent application deemed withdrawn after publication</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2023-03-10</span>
                    <span class="td nowrap style-scope patent-result">WD01</span>
                    <span class="td nowrap style-scope patent-result">Invention patent application deemed withdrawn after publication</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Application publication date</strong>: 20190607</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1352265007" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1352265007" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=362007543" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>